OSCE Study Master

Exam format (per [[L0 Introduction and Project]]): 2-hour OSCE with 8 cases — 5 Oral Medicine + 3 Orofacial Pain & Sleep Medicine. Each station may include clinical photo, histopathology, and/or lab results.

Each per-lecture cram sheet now carries Clinical features, Differential diagnosis, and Relevant investigations for each condition (or “Key features / when to use”, “Alternatives / considerations”, “Companion investigations / adjuncts” for procedural lectures).

§0 added 2026-05-15 after reading the 8 new mock OSCE cases in [[Tutorials/Mock OSCEs]] (5 Oral Med + 3 OFP). HY LOs now aligned per lecture, with explicit ▶ MOCK case-test markers.

§0 — High-Yield LOs Per Lecture (ordered most → least likely tested)

Updated 2026-05-16. Each lecture’s LOs are now ordered by likelihood of being tested. Ordering signals: (a) explicit High-yield tags in OFP LOs, (b) direct mock-OSCE case testing (5 OM + 3 OFP cases), (c) tutorial emphasis (16 integrated tutorial files), (d) past-year 2024/2025 stems, (e) clinical breadth + OSCE-friendliness.

Markers: ▶ OM # = Oral Med Mock Q1 Case # · ▶ OFP Q# = OFP Mock Formative · ▷ TUTORIAL ONLY = condition discussed in tutorial but not in source LO file (added 2026-05-16).

L1 — Oral Soft Tissue and Lesion Evaluations

1. ▶ OM 1, 4, 5: “Identify and record risk factors—such as tobacco and alcohol use—relevant to the presentation of oral lesions.” — tested in 3 mock cases
2. ▶ OM 1: “Describe the pathophysiological basis for clinical signs like induration, ulceration, and fixation during lesion evaluation.” — SCC induration
3. ▶ OM 4: “Discuss the application of structured clinical workflows as adjuncts to obtaining an accurate history and differential diagnosis.” — pigmented lesion DDx workflow
4. “Describe the anatomical basis for clinical signs found during systematic extraoral and intraoral examinations.” — foundational

L2 — Surgery in Oral Medicine (Biopsy)

1. ▶ OM 1, 2, 4, 5: “Explain the different surgical investigations used within oral medicine, specifically punch, incisional, and excisional biopsies.” — 4 mock cases
2. ▶ OM 1: “Describe best procedures to maximize information yield and minimize tissue artifacts during specimen collection and handling.” — specimen handling
3. “Explain the meaning of histopathology investigation results to direct subsequent patient care and staging.”
4. “Identify risk factors and contraindications, such as anticoagulation or vascularity, relevant to surgical intervention.”

L3 — Investigations (Blood, Microbiological & Skin)

1. ▶ OM 1, 2: “Explain the meaning of hematology, biochemistry, and microbiology investigation results used to identify systemic links to oral disease.”
2. ▶ OM 2 (HbA1c + diabetes): “Describe and relate the relevance of blood investigation results (e.g., FBC, Iron, B12, HbA1c) to health and disease manifestations like glossitis or candidosis.”
3. “Explain how laboratory investigation results for autoimmune or inflammatory conditions direct subsequent patient care.” — DIF + serology rationale
4. “Describe best procedures for collecting swabs and blood samples to maximize information yield and avoid false results.”

L4 — Imaging of Hard and Soft Tissues

1. ▶ OM 1, 3, 4: “Explain the meaning of imaging investigation results ranging from 2D radiographs to advanced 3D and functional modalities.”
2. ▶ OM 3: “Describe and relate the relevance of imaging results (e.g., CBCT for bone, MRI for soft tissue) to maxillofacial health and disease.”
3. “Discuss the application of specific imaging modalities as adjuncts to clinical examination based on suspected pathology.”
4. “Describe procedures to maximize information yield, such as using correct windowing in CT scans or specific sequences in MRI.”

L5 — Viral, Bacterial, and Fungal Infections

1. ▶ OM 2 (candidiasis 2°): “Discuss the clinical features, histopathology, investigation, and management of primary candidal infections (Pseudomembranous, Erythematous, and Hyperplastic).” ◇ Tut 3: acute pseudomembranous presentation details.
2. “Describe the clinical features of secondary oral candidosis, such as Chronic Mucocutaneous Candidosis, in immunocompromised patients.”
3. “Explain the investigation of fungal infections and the appropriate antifungal protocols, including denture hygiene measures to prevent reinfection.” ◇ Tut 3: systemic workup panel (FBC + iron + B12 + folate + glucose/HbA1c). ◇ Tut 3: antifungal hierarchy (amphotericin lozenges > nystatin > miconazole — warfarin/statin interactions).
4. “Discuss the clinical features, histopathology, and stages (Primary, Secondary, Tertiary, Congenital) of Syphilis manifesting in the oral cavity.”
5. “Explain the serological investigation (Nontreponemal and Treponemal tests) and penicillin-based management of Syphilis.”
6. “Describe appropriate measures to reduce infection spread, including partner notification and deferring elective dental care.”
7. “Discuss the clinical features, etiology (Coxsackievirus), and supportive management of HFMD oral and cutaneous lesions.”
8. “Identify the histopathology and diagnostic investigations, such as PCR or viral culture, for atypical HFMD presentations.”
9. “Describe the transmission routes (fecal-oral, respiratory) and measures to reduce the risk of infection spread in community settings.”
10. “Discuss the clinical features, investigation, and management of primary Varicella (Chickenpox) and reactivated Herpes Zoster (Shingles) affecting orofacial dermatomes.”
11. “Describe the clinical features and complications of Varicella Zoster, such as Post-herpetic neuralgia, in immunocompromised individuals.”
12. “Describe preventive measures, including vaccination and isolation, to reduce the risk of Varicella Zoster spread.”
13. “Discuss the clinical features, histopathology, investigation, and management of primary and reactivated (secondary) oral Herpes Simplex infections.” ◇ Tut 4: cervical lymphadenopathy as systemic sign in primary herpetic gingivostomatitis.
14. “Describe the clinical features and increased severity of Herpes Simplex infections in immunocompromised patients.”
15. “Explain appropriate measures to reduce the risk of Herpes Simplex transmission through avoiding direct contact.” ◇ Tut 4: chlorhexidine (Difflam) × 2 wk for 2° bacterial prevention.
16. “Discuss the clinical features and non-specific oropharyngeal manifestations of Gonorrhoea, including its ability to mimic other stomatitides.”
17. “Explain the investigation using Gram stain or molecular testing and the dual antimicrobial management of gonococcal infections.”
18. “Describe the risks of antimicrobial resistance and measures to reduce infection spread through contact tracing and co-infection screening.”
19. “Discuss the clinical features, Ziehl–Neelsen histopathology, and management of primary and secondary oral Tuberculosis.”
20. “Describe the oral manifestations of Tuberculosis in immunocompromised patients, particularly those with HIV co-infection.”
21. “Describe occupational infection control measures, including ventilation and BCG vaccination, to reduce the risk of Tuberculosis spread.”

L5 — Tutorial-only (unmapped): None — all 5 pearls mapped to existing LOs.

L6 — Physical and Chemical Injuries

1. ▶ OM 4: “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of amalgam tattoos and other localized exogenous pigmentations.” — MOCK Case 4 primary
2. ▶ OM 5 (DDx): “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of traumatic ulceration.” ◇ Tut 5+6: secondary candidal infection complicating chronic non-healing ulcer; select antifungal by patient context (avoid lozenges if xerostomic).
3. ▶ OM 4 (DDx): “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of smoker’s melanosis.” — pigmented lesion DDx anchor
4. “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of morsicatio buccarum.”
5. “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of frictional keratosis.”
6. “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of burns.”
7. “Explain oral complication of radiation therapy.” — links to L13
8. “Discuss exfoliative cheilitis.”
9. “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of linea alba.”
10. “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of drug related discoloration of oral mucosa.”
11. “Describe the repertoire of responses of oral soft tissues to trauma.” ◇ Tut 6: acute vs chronic ulcer distinction — chronic shows hyperkeratosis + induration at margins + reduced inflammation; acute lacks these.
12. “Describe the repertoire of physical and chemical injuries that can affect the oral hard and soft tissues.”
13. “Knowledge of physical and chemical injuries of oral hard and soft tissues.” — overarching

L6 — Tutorial-only (unmapped): None — both pearls mapped to existing LOs.

L7 — Allergies and Immune-Mediated Disease I — OLP

1. ▶ OM 2 (primary diagnosis): “Explain the aetiology, pathogenesis, clinical and histopathologic features, and the diagnosis and treatment of Lichen planus.” ◇ Tut 15: beclomethasone spray 2 × 3/day until resolution + 2-3 days extra (preferred over Kenalog/ointments on wet mucosa). ◇ Tut 15/16: non-response ≥6 weeks = transformation red flag → urgent rebiopsy. ◇ Tut 15: superimposed candidiasis = steroid failure clue → concurrent amphotericin B lozenges.
2. ▶ OM 2: “Describe the mechanisms involved in immunologically-mediated oral mucosal diseases, specifically the Type 1 (Th1) cell-mediated immune response.” ◇ Tut 16: dysplasia on OLP biopsy EXCLUDES OLP diagnosis → reclassify as oral epithelial dysplasia (OED); biopsy mandatory even if classic.
3. ▶ OM 2: “Discuss the differential diagnosis of allergic contact stomatitis (contact lichenoid reactions) and allergic mucosal reactions to systemic drug administration (lichenoid drug reactions).” ◇ Tut 15: patch testing “Dental Series” via dermatology; negative ≠ 100% exclude amalgam allergy (delayed reactions >5 days possible).
4. “Explain the clinical and histopathologic features of dermatologic diseases that mimic OLP, including Pemphigus, Pemphigoid, Chronic ulcerative stomatitis, and Lupus erythematosus.” ◇ Tut 16: field cancerisation — if ONE OLP area transforms, biopsy ALL other lichenoid/erythematous areas immediately.

L7 — Tutorial-only (unmapped):

• ▷ Solitary red lesion ≠ OLP (must be bilateral + symmetric); solitary red = erythroplakia until proven otherwise — Tut 15/16 (distinct DDx principle; sits outside the 4 LOs)

L8 — Allergies and Immune-Mediated Disease II

1. ▶ OM 2 (DDx): “Discuss the aetiology, clinical features, and management of Recurrent aphthous stomatitis.” ◇ Tut 15/16: “inflammation balance” — chronic inflammation ↑ malignancy risk but inflammation may also defend against dysplasia; topical > systemic CS preferred.
2. “Evaluate the diagnosis and treatment of Pemphigus vulgaris.” ◇ Tut 16: close monitoring ≤3-monthly mandatory if dysplasia present in immune-mediated lesions; photographic tracking.
3. “Evaluate the diagnosis and treatment of Mucous membrane pemphigoid.” — blistering; linear IgG; ocular risk
4. “Evaluate the diagnosis and treatment of Erythema multiforme.” — target lesions + HSV/drug trigger
5. “Evaluate the diagnosis and treatment of Chronic ulcerative stomatitis.” ◇ Tut 16: PVL (Proliferative Verrucous Leukoplakia) as differential — can mimic OLP/CUS clinically.
6. “Evaluate the diagnosis and treatment of Lupus erythematosus.” ◇ Tut 15: dexamethasone mouthwash effective but ↑ candidiasis risk in diabetics — targeted spray preferred.
7. “Discuss the aetiology, clinical features, and management of Allergic contact stomatitis.”
8. “Evaluate the diagnosis and treatment of Linear IgA disease.”
9. “Explain the clinical and histopathologic features used to diagnose and treat Orofacial granulomatosis.”
10. “Discuss the aetiology, clinical features, and management of Perioral dermatitis.”
11. “Explain the clinical and histopathologic features used to diagnose and treat Wegener’s granulomatosis.”
12. “Describe the mechanisms and pathogenesis involved in hypersensitivity and immunologically-mediated oral mucosal diseases, including cell-mediated responses and autoantibody-driven epithelial damage.”
13. “Evaluate the diagnosis and treatment of Systemic sclerosis.”
14. “Discuss the aetiology, clinical features, and management of Transient lingual papillitis.”
15. “Evaluate the diagnosis and treatment of CREST syndrome.”
16. “Discuss the aetiology, clinical features, and management of Angioedema.”
17. “Discuss the aetiology, clinical features, and management of Erythema migrans.”

L8 — Tutorial-only (unmapped): None — all 4 pearls mapped to existing LOs.

L9 — Benign Epithelial Pathosis [LOs synthesised from L9 lecture note — added 2026-05-15]

1. ▶ OM 1 + 2 + 5 (linked): “Discuss the aetiology, pathogenesis, clinical and histopathologic features, differential diagnosis, and management of SCC of the oral cavity, including its association with chronic irritation, tobacco/alcohol, and immunosuppressive medications (e.g., doxorubicin).” ◇ Tut 1: leukoplakia detailed (white patch not rubbed off; biopsy for dysplasia). ◇ Tut 10: unknown primary metastatic SCC (1-4% of H&N cancers — immune clearance or prior skin cancer spread).
2. ▶ OM 2 (linked): “Discuss the aetiology, clinical presentation, histopathologic features, differential diagnosis, and management of OLP, including malignant transformation risk to SCC, steroid response, and distinction from traumatic ulcers and lichenoid drug reactions.” ◇ Tut 9: lichenoid drug reaction — antihypertensives (esp. ramipril/ACE-I) implicated. ◇ Tut 9: traumatic ulcer mgmt — antiseptic mouthwash NOT corticosteroids. ◇ Tut 9: desquamative gingivitis as descriptive term (OLP, Linear IgA, autoimmune mimics).
3. “Discuss the aetiology, clinical presentation, histopathologic features, differential diagnosis, and management of nicotinic stomatitis (smoker’s palate), including reversibility upon smoking cessation and distinction from malignant lesions.” ◇ Tut 1/2: smoking cessation reversibility within ~6 months.
4. “Describe the clinical presentation, aetiology, and differential diagnosis of pigmented oral lesions — physiologic pigmentation, oral melanotic macules, drug-induced melanosis (Doxorubicin/Caelyx), smoker’s melanosis, and melanoma — including biopsy indications.” ◇ Tut 1: drug-induced melanosis (Doxorubicin/Caelyx); melanoma biopsy thresholds.
5. “Discuss the aetiology, clinical presentation, histopathologic features, differential diagnosis, and management of benign epithelial hyperplasias and keratoses, including leukoedema, white sponge nevus, frictional keratosis, and leukoplakia, with emphasis on the blanching/stretching test and biopsy criteria for dysplasia.” ◇ Tut 1: leukoplakia dysplasia biopsy criteria. ◇ Tut 9: erythroleukoplakia (mixed red/white, isolated, inflammatory excluded — high malignancy risk).
6. “Discuss the aetiology, clinical presentation, histopathologic features, and management of HPV-related oral lesions, including squamous papilloma, verruca vulgaris, and condyloma acuminatum, with emphasis on mandatory reporting of condylomata in children.” ◇ Tut 9: mandatory child-protection reporting.
7. “Describe the clinical presentation, aetiology, histopathologic features, differential diagnosis, and management of melanocytic lesions (melanotic macules, melanocytic nevi, rare oral melanoma) with biopsy indications + palate as most common melanoma site.” ◇ Tut 1: pigmented-lesion biopsy threshold algorithm.
8. “Discuss the aetiology, clinical presentation, histopathologic features, and management of hairy tongue, including predisposing factors (antibiotics, CS, mouthwashes, radiation, transplant) and treatment principles.”

L9 — Tutorial-only (unmapped):

• ▷ Erythroplakia (red patch, high malignancy risk, diagnosis of exclusion) — Tut 1 (distinct OPMD entity → see L10/L11 LOs for full coverage)
• ▷ Smear vs swab distinction (smear = active hyphae = active infection; swab = organism presence; 50% population carriers) — Tut 1/2 (diagnostic technique principle, not condition-specific)
• ▷ Pyogenic granuloma as gingival swelling/ulceration differential — Tut 9 (soft tissue tumour → L14 covers in detail)

L10 — OPMDs and Oral Cancer I

1. ▶ OM 1, 5: “Identify clinical features of OPMDs and squamous cell carcinoma, such as non-healing ulcers, induration, and color changes (leukoplakia/erythroplakia).” ◇ Tut 8: erythroplakia higher intrinsic malignancy risk than leukoplakia (90% severe dysplasia/CIS on biopsy).
2. ▶ OM 1, 3: “Describe the histopathologic progression from normal mucosal variations to epithelial dysplasia and invasive squamous cell carcinoma.” — dysplasia → invasion pathway
3. ▶ OM 5: “Explain the diagnosis and treatment framework for oral cancer, prioritizing early detection through thorough examination, palpation, and biopsy.” ◇ Tut 7: biopsy site selection — margin not necrotic centre; multifocal sampling for heterogeneous lesions.
4. ▶ OM 1, 5: “Discuss the aetiology and pathogenesis of oral cancer, including traditional risks like tobacco and heat, and emerging trends in non-traditional cohorts.” ◇ Tut 7/8: female + non-smoker = paradoxically higher relative malignant transformation risk (non-traditional cohort exemplar).

L11 — OPMDs and Oral Cancer II

1. ▶ OM 5: “Describe the clinical and histopathologic features of key OPMDs, such as the morphological variants of leukoplakia, the bilateral presentation of oral lichen planus, and the ‘honeycomb’ appearance of oral lupus erythematosus.” ◇ Tut 8: Oral Lichenoid Lesion (solitary/non-symmetric) — clinically + histologically distinct from bilateral classic OLP.
2. “Define and classify OPMDs according to the WHO 2020/2021 standards, distinguishing between established entities like leukoplakia and newly included conditions such as oral lichenoid lesions and graft versus host disease.” ◇ Tut 8: oral lichenoid lesions as WHO 2021 entity; desquamative gingivitis as descriptive clinical term (encompasses OLP, Linear IgA, other autoimmune).
3. “Explain the diagnosis and management framework for OPMDs, focusing on the diagnosis of exclusion for white lesions and the appropriate use of adjunctive diagnostic tools and biopsies.” ◇ Tut 7/8: repeat biopsy cadence — 3-mo initial → 6-12 mo stable → 1-yearly after 5-y stability → lifelong recall.
4. “Discuss the aetiology and pathogenesis of OPMDs by identifying major carcinogenic risk factors, including the synergistic effects of tobacco and alcohol, the role of areca nut in fibrosis, and the impact of high-risk HPV.”

L12 — OPMDs and Oral Cancer III

1. ▶ OM 1: “Identify the clinical and histopathologic features of oral squamous cell carcinoma (OSCC) and epithelial dysplasia, including high-risk anatomical sites and microscopic indicators of invasion.” ◇ Tut 8: field cancerisation — 2° primary within 5 y in different anatomical area; multifocal mapping + biopsy of all at-risk areas.
2. ▶ OM 1: “Explain the treatment and management of oral cancer based on TNM staging, including surgical and radiotherapy protocols and long-term post-treatment surveillance.” ◇ Tut 7/8: 1 cm surgical margin standard; lifelong post-treatment surveillance schedules.
3. ▶ OM 1: “Describe the diagnosis of suspicious oral lesions through a systematic clinical assessment, differential diagnosis of white/red patches, and the ‘gold standard’ biopsy protocol.” ◇ Tut 7: biopsy margin not necrotic centre; multifocal sampling; worst-looking heterogeneous area.
4. “Discuss the aetiology and pathogenesis of oral cancer, focusing on the genetic mutations and lifestyle risk factors like tobacco, alcohol, and UV exposure that drive malignant transformation.”

L10–L12 — Tutorial-only (unmapped):

• ▷ Actinic cheilitis as L10/L11 OPMD (Mock Case 5 anchor) — distinct lip-specific OPMD requiring separate didactic emphasis (covered in §3 L11 cram sheet)

L13 — Dental Management of Oral Cancer Patients

1. ▶ OM 1 (primary): “Describe the dental diagnosis and management protocols required for a pre-radiation therapy work-up, including the specific criteria for pre-treatment extractions.” ◇ Tut 11/12: pre-RT extraction timing 2-3 wk healing + 6-wk tumour-to-RT window. ◇ Tut 12: atraumatic extraction + post-extraction alveolectomy mandatory (smooth ridge to prevent ORN). ◇ Tut 12: backscatter radiation consideration for metallic dental materials. ◇ Tut 11: pre-RT recalls every 3 months first year.
2. “Identify the clinical features of acute and chronic radiation-induced adverse effects, such as radiation mucositis, salivary gland dysfunction, and osteoradionecrosis.” ◇ Tut 11/12: ORN dose thresholds — 50 Gy baseline risk / 60 Gy significantly elevated / lifelong risk never decreases. ◇ Tut 11: ORN risk pre-RT extraction ~5% vs post-RT extraction 5-15%.
3. “Explain the long-term treatment and preventive strategies for managing post-radiation complications, focusing on radiation caries, trismus exercises, and salivary stimulants.” ◇ Tut 11/12: Neutrafill 5000 ppm fluoride for life (standard toothpaste insufficient). ◇ Tut 12: post-RT denture timing minimum 6 months (some 12); immediate dentures contraindicated. ◇ Tut 12: post-denture follow-up monthly first year then annual.
4. “Discuss the epidemiology and treatment modalities of oral cancer, including surgery and radiation therapy, and their significant psychosocial impact on the patient’s quality of life.” ◇ Tut 12: full clearance strategy in poor-compliance/smoking/alcohol/depression patients (avoid future ORN from radiation caries).

L13 — Tutorial-only (unmapped): None — all 10 pearls mapped to existing LOs.

L14 — Soft Tissue Tumours

1. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of pyogenic granulomas…” — common reactive; pregnancy/trauma link
2. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of Kaposi’s sarcoma, an angioproliferative malignancy driven by HHV8 that is highly aggressive in immunosuppressed or AIDS patients.” — HHV8 + AIDS/immunosuppression
3. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of neurilemomas (Schwannomas), focusing on their encapsulated Antoni A/B histologic patterns and their specific association with Neurofibromatosis Type 2 (NF-2).” — Antoni A/B + Verocay bodies
4. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of neurofibromas, including Schwann cell proliferation and systemic manifestations like axillary freckling and Lisch nodules in NF-1.” — NF-1 + MPNST surveillance
5. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of hemangiomas, true endothelial neoplasms that proliferate during infancy and subsequently self-involute over several years.” — blanching test + AVOID biopsy
6. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of fibro-epithelial polyps…” — reactive proliferation, bite trauma
7. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of fibrous epulides…”
8. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of denture hyperplasia (epulis fissuratum)…”
9. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of inflammatory papillary hyperplasia…” — cobblestone + Candida
10. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of vascular malformations…” — high vs low flow
11. “Demonstrate knowledge of the broad spectrum of soft tissue (mesenchymal) tumours, including the differentiation between developmental, reactive, and neoplastic lesions.”
12. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of rhabdomyosarcomas, the most common childhood soft tissue sarcoma derived from skeletal striated muscle cells.”
13. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of fibrosarcomas, noting their highly cellular ‘herringbone’ microscopic pattern.”
14. “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of lipomas…” — rare intraoral, well-circumscribed

L15 — Salivary Gland Diseases

1. “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of mucoepidermoid carcinoma.” — Tut 14 case; minor gland palate; cystic + epithelial + mucin
2. “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of pleomorphic adenoma.” — most common benign; benign vs malignant surgical planning
3. “Describe the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of necrotizing sialometaplasia.” — SCC mimic; high pitfall
4. “Describe the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of Sjogren syndrome.” — ACR-EULAR criteria + focus score + serology
5. “Describe the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of mucoceles.” ◇ Tut 13: mucous extravasation phenomenon (no epithelial lining + foamy histiocytes/muciphages — most common form). ◇ Tut 13: mucous retention cyst (epithelial-lined cavity, no CT spillage — distinct entity).
6. “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of Warthin’s tumour.” — bilateral/multifocal, male smokers
7. “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of adenoid cystic carcinoma.” — perineural invasion; cribriform pattern
8. “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of acinic cell carcinoma.”
9. “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of oncocytoma.”
10. “Describe the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of sialadenitis.” — acute infection; Sjögren’s complication
11. “Describe the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of sialolithiasis.” — occlusal radiograph/CT sialogram
12. “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of polymorphous low grade adenocarcinoma.”
13. “Describe the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of sialadenosis.” — non-inflammatory acinar enlargement
14. “Discuss the clinical features, diagnosis and treatment of salivary gland aplasia.” — rare developmental anomaly

L15 — Tutorial-only (unmapped):

• ▷ Sialolith as a causal mechanism for mucocele obstruction (vs standalone sialolithiasis LO #11); occlusal radiograph + CT sialogram imaging — Tut 13 (cross-references LOs #5 and #11)

L16 — Dry Mouth

1. “Differentiate xerostomia, salivary gland hypofunction, and hyposalivation using subjective symptoms, objective flow-rate thresholds, and their clinical overlap.” — foundational + OM 2 link
2. “Apply a structured diagnostic approach to dry mouth using medical and dental history, clinical examination, subjective screening tools, sialometry, the Challacombe Scale, laboratory investigations, and Sjögren’s syndrome classification criteria.” — ACR-EULAR + Challacombe
3. “Identify the major causes and risk factors for dry mouth, including medications, polypharmacy, systemic diseases, radiation therapy, menopause, aging-related changes, and genetic conditions.”
4. “Describe the clinical features and complications of dry mouth, including functional impairment, mucosal disease, candidosis, sialadenitis, caries, tooth wear, periodontal effects, GORD, nutritional changes, and reduced quality of life.”
5. “Summarize management of dry mouth by addressing underlying causes, providing symptomatic treatments and saliva substitutes, stimulating residual salivary function, managing oral complications, and applying preventive strategies for high-risk patients.”
6. “Describe the physiology, composition, glandular sources, autonomic regulation, and key functions of saliva relevant to oral comfort and tissue protection.” — foundational

L17–L19 — Bone Disease (combined)

1. ▶ OM 3 (primary): “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of metastatic disease.” — MOCK Case 3
2. “Explain the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of osteonecrosis, including bisphosphonate-induced osteonecrosis.” — MRONJ key differential for Case 3
3. “Explain the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of osteomyelitis.” — Case 3 differential
4. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of osteosarcoma.” — malignant primary; sunburst
5. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of ameloblastoma.” — multilocular soap-bubble
6. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of odontogenic keratocyst / keratocystic odontogenic tumour.” — high recurrence + Gorlin-Goltz
7. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of dentigerous cyst.” — classic unerupted tooth
8. “Explain the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of central giant cell granuloma.” — anterior mandible + PTH check
9. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of fibrous dysplasia.” — ground-glass + AVOID RT
10. “Explain the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of tori and exostosis.”
11. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of nasopalatine canal cyst.”
12. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of traumatic simple bone cyst.”
13. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of cemento-osseous dysplasia.”
14. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of adenomatoid odontogenic tumour.”
15. “Explain the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of sclerotic bone island.”
16. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of aneurysmal bone cyst.”
17. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of Stafne’s bone defect.”
18. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of focal osteoporotic bone marrow defect.”
19. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of glandular odontogenic cyst.”
20. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of calcifying odontogenic cyst.”
21. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of globulomaxillary lesions.”
22. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of calcifying odontogenic tumour.”
23. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of squamous odontogenic tumour.”
24. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of osteoma.”
25. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of osteoblastoma.”
26. “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of cementoblastoma.”

L27 — Defining Orofacial Pain

1. “Define and classify orofacial pain according to the 2020 IASP definition, distinguishing nociceptive, neuropathic, and nociplastic mechanisms. High-yield: 2020 IASP definition, nociception vs pain perception, three pain types, mind-body connection.”
2. “Distinguish physiological (acute, protective) from pathophysiological (chronic, non-protective) pain presentations + biopsychosocial model. High-yield: acute vs chronic paradigm shift, psychosocial dominance in chronic pain, biopsychosocial axes (I and II).”
3. “Describe the sensory-discriminative and motivational-affective components of the pain experience, including emotional, psychological, and contextual factors influencing perception. High-yield: emotional response, catastrophising, empathy-centred approach, prior experience + expectations.”
4. “Explain the enhanced neurobiological basis for facial pain — heightened amygdala activation + craniofacial nociceptive processing. High-yield: facial pain greater emotional weight, lateral parabrachial nucleus activation, lack of habituation.”
5. “Define TMD as musculoskeletal + neuromuscular conditions of TMJs + masticatory muscles + Axis I/II framework. High-yield: DC/TMD criteria, Axis I + Axis II co-diagnosis, prevalence, biopsychosocial diagnostic approach.”

L28 — History and Examination including DC/TMD

1. ▶ OFP Q2 (primary): “Apply the DC/TMD framework to diagnose pain-related disorders (myalgia, arthralgia, headache attributed to TMD) + joint disorders (disc displacements, DJD, subluxation). High-yield: Axis I via history (SQ) + examination (E), pain provocation, familiar pain reproduction, click vs crepitus.”
2. ▶ OFP Q1, Q2: “Perform a comprehensive OFP history using structured pain-characterization prompts (temporal behaviour, pain quality, functional modification, parafunctional triggers). High-yield: OPQRST framework, onset triggers, pain modifiers with jaw function, clenching/grinding, locking/catching, TMJ noises.”
3. ▶ OFP Q2: “Perform systematic clinical examination using DC/TMD protocol including palpation of masticatory muscles + TMJ with correct force thresholds + jaw movement + noises/locking. High-yield: palpation force (0.5 kg pole, 1.0 kg muscles), pain/familiar pain/referred pain distinction, deviation vs deflection, click identification.”
4. “Explain TMJ anatomy — disc, compartments, retrodiscal tissue innervation, inherent joint instability — and relate to clinical findings. High-yield: condyle-fossa incongruency, disc position + vascularity, retrodiscal innervation, loose capsule.”
5. ▶ OFP Q1: “Administer + interpret Axis II psychosocial screening tools (pain drawing, GCPS, PHQ-4) to assess distress + disability. High-yield: PHQ-4 anxiety/depression screening, pain manikin for diffuse vs localised, disability impact.”
6. “Understand the contemporary biopsychosocial model + multifactorial risk factors for TMD onset + chronicity (genetic, environmental, psychological). High-yield: genetic predisposition, physical trauma, psychological distress, sensory processing dysfunction, pain amplification states.”
7. “Recognise limitations of clinical examination for disc displacement + when advanced imaging (MRI, CT/CBCT) is indicated versus bDC/TMD for general practice. High-yield: bDC/TMD efficiency <10 min, low specificity of clinical exam for disc position, imaging adjunct only when findings alter care.”

L29 — Intracapsular Disorders of TMD

1. ▶ OFP Q2 (primary): “Differentiate the four DC/TMD disc displacement categories (with reduction, with reduction + intermittent locking, without reduction with limited opening, without reduction without limited opening) by clinical signs + imaging. High-yield: DDwR vs DDw/oR, clicking mechanics, closed-lock concept, MRI confirmation.”
2. “Understand TMJ anatomy, biomechanics, role of disc morphology + retrodiscal tissues. High-yield: biconcave disc shape, disc-condyle coordination, bilaminar zone innervation + vascularisation.”
3. ▶ OFP Q2: “Explain pathophysiology of intracapsular pain — arthralgia, arthritis, retrodiscitis, synovitis, soft vs hard end-feel. High-yield: retrodiscal tissue as pain source, synovitis + capsulitis, soft/hard end-feel differential.”
4. ▶ OFP Q2: “Apply conservative management principles (education, soft diet, physio, oral appliances, pharmacotherapy) + identify specialist-referral indications. High-yield: conservative first-line, NSAIDs + muscle relaxants, splint offloading, specialist triggers (arthrocentesis, arthroscopy).”
5. “Discuss degenerative joint disease (osteoarthrosis/osteoarthritis) — crepitus, radiographic findings (sclerosis, erosion, osteophytes, bird’s-beak), chronic overload pathophysiology. High-yield: crepitus as cardinal sign, CT/OPG findings, osteophyte morphology.”
6. “Describe subluxation (self-reduction) and luxation (emergency open lock) as condylar hypermobility disorders. High-yield: subluxation self-reducibility, luxation as medical emergency, syringe + manual reduction techniques.”
7. “Recognise prognostic factors — compliance, severity, chronicity, psychosocial factors, genetic predisposition, widespread chronic pain. High-yield: biopsychosocial influence on prognosis.”

L30 — Botulinum Toxin for Orofacial Pain

1. “Discuss evidence quality + limitations of botulinum toxin efficacy in OFP — strong evidence for chronic migraine + TN vs moderate-equivocal for bruxism + myofascial TMD. High-yield: sufficient evidence for TN + masseter hypertrophy; equivocal for bruxism, TMJ articular, myofascial.”
2. “Discuss indications for BTX in OFP management (TN, TMDs, neuropathic pain, chronic migraine prophylaxis) + evidence-based efficacy. High-yield: TN (83-91% improvement), muscular TMD (60-100 U bilateral), chronic migraine PREEMPT (155-195 U).”
3. “Explain mechanism of action of BTX at NMJ through SNARE cleavage + ACh blockade + pain neurotransmitter inhibition. High-yield: SNARE cleavage (A/C/E vs B/D/F/G), ACh release blockade, analgesic via Substance P/CGRP/glutamate.”
4. “Describe practical injection protocols (masseter, temporalis, lateral/medial pterygoid, sphenopalatine ganglion), dosing, localisation (palpation, EMG, US), needle gauges. High-yield: masseter/temporalis sites for TMD + dystonia, lateral pterygoid for TMJ dislocation/refractory TMD, trigger-zone for TN.”
5. “Describe contraindications, AEs, complications of BTX (hypersensitivity, infection, neuromuscular disorders, pregnancy/breastfeeding, transient dysphagia, long-term mandibular bone-loss). High-yield: absolute CI (myasthenia gravis, infection, pregnancy), transient (dysphagia, nasal speech), immunogenicity/antibody.”
6. “Explain available BTX preparations (Botox/Dysport/Xeomin/Myobloc) — formulations, potency units, conversion ratios, clinical differences in spread/onset/storage. High-yield: Botox/Dysport (NAPs present), Xeomin (pure neurotoxin), non-bioequivalent conversions (ONA:INCO 1:1, ONA:ABO 1:2.5).”

L31 — Occlusal Splint Therapy

1. “Evaluate critically the evidence — 2025 meta-analysis: splints NOT superior to other conservative treatments for pain + opening but better than counselling/placebo; stabilisation effective for arthralgia + TMD-attributed HA. High-yield: splints do NOT unload TMJ (biomechanical myth), do NOT stop sleep bruxism, do NOT permanently recapture discs, do NOT establish ideal occlusion.”
2. ▶ OFP Q2: “Compare stabilisation splint designs (flat plane, Michigan, Tanner) vs anterior repositioning appliances. High-yield: hard stabilisation first-line with strongest evidence; ARA reserved for Wilkes II with refractory symptoms due to permanent occlusal/skeletal change risk.”
3. “Outline rationale for splint therapy in TMD + bruxism — proposed mechanisms (foreign-body reflex, altered condylar loading, cognitive awareness) — recognising regression to mean + placebo. High-yield: mechanisms theories only; placebo enhanced by clinician reputation + environment.”
4. “Explain why hard splints preferred over soft — soft = ↑ EMG activity (‘chewing-gum effect’) + short-term ↑ sleep bruxism. High-yield: hard over soft for TMD + bruxism.”
5. “Distinguish NTI-tss + mini-anterior vs full-coverage stabilisation — NTI-tss inferior + significant risk of anterior open bite + lower-anterior tooth mobility. High-yield: NTI-tss limitations + AEs; stabilisation as preferred design.”
6. “Recommend clinical appliance selection stratified by diagnosis — muscle disorders → flat plane → ABP if refractory; disc displacements → flat plane → ARA for Wilkes II + locking. High-yield: diagnostic-based selection algorithm (Greene & Menchel 2018).”
7. “Describe evidence against neuromuscular + fringe appliance designs (myocentric, pivot/fulcrum, hydrostatic Aqualizer, MORA). High-yield: neuromuscular dentistry + athletic-performance claims unsubstantiated.”

L32 — Non-Odontogenic Toothache

1. “Differentiate odontogenic from non-odontogenic toothache — history, pulp testing, percussion, site vs source of pain. High-yield: referred vs primary pain, treating source not site, prevention of unnecessary endodontic treatment.”
2. “Describe prevalence, aetiology, pathophysiology, clinical features, diagnosis, management of conditions presenting as non-odontogenic toothache. High-yield: myofascial pain with trigger-point referral, neurovascular (migraine, TACs), sinus-origin, cardiac referral, trigeminal neuralgia, neuropathic pain.”
3. ▶ OFP Q1 (DDx): “Explain mechanism of referred pain in myofascial pain — trigger-point activation, convergence theory at trigeminal sensory complex, anatomical referral patterns. High-yield: anterior + posterior temporalis, masseter, SCM referral patterns; antidromic transmission.”
4. “Explain clinical presentation + diagnostic approach to neurovascular pain (migraine + TACs) presenting as OFP — autonomic features (tearing, congestion, dental hypersensitivity). High-yield: demographics, pain characteristics, associated autonomic symptoms, allodynia.”
5. “Discuss diagnosis + management of sinus-origin toothache — constant dull pain in maxillary posteriors, percussion sensitivity, imaging in virgin teeth. High-yield: viral vs bacterial aetiology, decongestants + nasal treatments, antibiotic indications.”
6. “Discuss management strategies for non-odontogenic toothache — behavioural, pharmacotherapy, physical therapy, trigger-point injections, splints, psychosocial referral. High-yield: patient education + reassurance, spray-and-stretch, habit reversal, LA injection technique.”
7. “Explain cardiac-origin OFP as rare but life-threatening referral from myocardial ischaemia — substernal symptoms, dyspnoea, nausea, emergency aspirin. High-yield: convergence of vagus + trigeminal, recognition of cardiac symptoms, emergency response.”

L33 — Extracapsular Disorders of TMD

1. ▶ OFP Q2 (myalgia component): “Discuss aetiology, pathophysiology, clinical features, diagnosis, conservative management of myalgia (local myalgia, myofascial pain, myofascial pain with referral). High-yield: palpation-based DC/TMD classification, trigger-point theory + central sensitisation, self-care + physio first-line.”
2. “Explain clinical features, diagnosis, management of headache attributed to TMD + high comorbidity with myofascial pain. High-yield: headache-myalgia coexistence (7.8-fold ↑ risk), DC/TMD diagnostic criteria.”
3. “Discuss masticatory muscle pain in systemic + central sensitisation disorders + chronic-pain pathophysiology + fibromyalgia comorbidity. High-yield: peripheral + central sensitisation, inhibitory/facilitatory pathway imbalance, education + behavioural therapies.”
4. “Discuss clinical features, aetiology, acute management of myospasm + muscle cramps (jaw-closing vs jaw-opening types, EMG). High-yield: acute involuntary contraction with severely limited ROM, ice + LA injection, muscle stretching.”
5. “Explain presentations + management of movement disorders (orofacial dyskinesia, oromandibular dystonia, Parkinsonian, drug-induced tardive dyskinesias). High-yield: involuntary sustained contractions + abnormal postures, ocular blinking + grimacing in dystonia, neuroleptic-associated tardive dyskinesias.”
6. “Describe myositis + myositis ossificans (progressive + traumatic forms) affecting masticatory muscles. High-yield: acute pain + swelling, CT imaging confirmation, surgical excision for traumatic form.”
7. “Describe aetiology + clinical features of giant cell arteritis — jaw claudication, systemic signs, ESR + temporal artery biopsy, CS management. High-yield: systemic granulomatous vasculitis, new-onset headache + scalp tenderness, vision-threatening ischaemic complications.”

L34 — Neuropathic Orofacial Pain including Burning Mouth Syndrome

1. ▶ OFP Q1 (primary): “Distinguish between PTTNP, persistent idiopathic facial pain, and trigeminal neuralgia. High-yield: ICOP diagnostic criteria, differential clinical features, role of imaging + neurological exam.”
2. “Explain classification, pathophysiology, triggers, pharmacological management of trigeminal neuralgia + first-line agents + neurosurgical options. High-yield: carbamazepine first-line, HLA-B1502 screening for Asian descent, neurovascular compression mechanism.*”
3. “Outline differential diagnosis of oral burning + systematic clinical assessment to exclude secondary causes before BMS diagnosis. High-yield: medication-related (ACE-I most common), nutritional deficiencies, autoimmune (Sjögren’s), systematic history + bloods.”
4. “Explain ICOP diagnostic criteria for BMS — epidemiology, pathophysiology, evidence-based management. High-yield: diagnosis of exclusion (>2 hr daily for >3 mo with normal exam), female predominance, topical/systemic clonazepam, antidepressants, capsaicin via TRPV1 depletion.”
5. ▶ OFP Q1: “Outline aetiology, pathogenesis, clinical features, diagnosis, management of neuropathic OFP conditions as a class. High-yield: pain mechanisms (nociceptive vs neuropathic vs nociplastic), peripheral + central sensitisation, neuroplasticity.”
6. “Describe trigeminal post-herpetic neuralgia — epidemiology, risk factors, prevention, topical/systemic therapies. High-yield: prevalence >50 y post-zoster, early antiviral + vaccination prevention, capsaicin + gabapentinoids.”
7. ▶ OFP Q1: “Discuss biopsychosocial model in chronic OFP neuropathic pain + pain-vulnerability predictors + CBT + multidisciplinary management. High-yield: psychological factors (catastrophising, depression, anxiety), Axis II dominance in chronic pain, early specialist referral (<12 mo) improves outcome.”

L35 — Oral Appliance Therapy for Snoring and OSA

1. ▶ OFP Q3 (primary): “Identify patient characteristics predicting MAA response vs non-response — anatomical, clinical, polysomnographic features. High-yield: responder (younger, lower BMI, female, retracted maxilla/mandible); non-responder (older, ↑ BMI, larger neck, nasal obstruction).”
2. ▶ OFP Q3: “Describe side effects + craniofacial changes with long-term MAA therapy + rationale for tolerating manageable AEs. High-yield: dry mouth (86%), occlusal changes (posterior open bite + ↓ overjet), TMJ (transient symptoms).”
3. ▶ OFP Q3: “Explain MOA, indications, clinical efficacy of MAA for primary snoring + mild-to-moderate OSA. High-yield: anterior mandibular movement ↑ velopharyngeal airspace, AHI reduction outcomes, patient preference over CPAP, clinical indications.”
4. “Describe pathophysiology of OSA + diagnostic testing (PSG levels, AHI calculation, polysomnogram interpretation). High-yield: Level 1 PSG reference standard, AHI thresholds (mild 5-15, moderate 15-30, severe >30), respiratory events, oxygen desaturation.”
5. “Outline clinical workflow for MAA therapy — assessment, appliance selection, titration, treatment success criteria. High-yield: history with Epworth, exam of dentition + TMJ, bite registration at 60-70% protrusion, titration 0.5 mm increments, follow-up PSG with appliance in situ, multidisciplinary sleep physician coordination.”
6. ▶ OFP Q3: “Identify risk factors + validated screening tools for SDB in dental setting. High-yield: STOP-BANG, Epworth Sleepiness Scale, clinical signs (retrognathia, neck circumference, airway crowding), AHI severity classification.”
7. “Explain role of dentistry in sleep medicine + scope of practice. High-yield: dental sleep medicine disciplines, scope limitations, collaboration with sleep physicians.”

L36 — Bruxism

1. ▶ OFP Q3 (overlap): “Describe diagnostic + management considerations for SDB comorbidity — SDB risk factors, sleep assessment referral, complex variable relationship between OSA + bruxism, bruxism sometimes protective for airway patency. High-yield: case-anchored OSA screening, weak bruxism-OSA correlation despite common co-presentation.”
2. ▶ OFP Q3 (primary mech): “Describe evolution, epidemiology, risk factors, aetiology, pathophysiology of sleep + awake bruxism — primary vs secondary, protective vs pathological roles. High-yield: sleep vs awake distinction, non-occlusal aetiologies (stress, medications, substance use, OSA), 2018 consensus redefining bruxism as non-pathological in healthy individuals.”
3. “Describe clinical features of bruxism through history + clinical signs (tooth wear/bruxofacets, masseter hypertrophy, tongue scalloping, linea alba, tooth fractures) + ‘possible/probable/definite’ diagnostic grading. High-yield: case-anchored presentations (dentist with wear, SDB patient with OSA-bruxism overlap, female with isolated masseter hypertrophy); specificity limitations of individual markers.”
4. “Discuss diagnostic investigations + risk-factor assessment (psychological: stress + anxiety; substance use: alcohol, cigarettes, cocaine, ADHD/antipsychotic medications; SDB screening: OSA-50, STOP-BANG, Epworth, Berlin). High-yield: medication-induced protocols, awake-bruxism stress link, weak OSA-bruxism correlation.”
5. “Explain differential diagnosis + exclusion of movement disorders mimicking bruxism — tardive dyskinesia, oromandibular dystonia, secondary causes (seizure, TBI, neurodegenerative). High-yield: dementia case with video-confirmed tardive dyskinesia misdiagnosed as bruxism, drug-induced extrapyramidal syndromes.”
6. “Explain management principles + decision-making — harmless vs risk vs protective behaviour classification, severity, treatment indication. High-yield: severity dictates management; protective bruxism in OSA should NOT be treated; flat-plane hard-material splints (NOT soft) for risk behaviour.”
7. “Discuss multimodal management strategies — patient education/reassurance, psychosocial therapy + habit reversal, physiotherapy + biofeedback, occlusal splint design + maintenance, adjuncts (BruxApp). High-yield: splints protect dentition but do NOT stop muscle activity; soft splints contraindicated; BTX high-cost, only 4-wk efficacy, not indicated for simple bruxism.”

OFP — Mock-only conditions: None — all OFP Mock Q1/Q2/Q3 content fully covered by L27-L36 LOs.

§1 — Prioritized Condition List

Tier 1 — Mock OSCE (8 confirmed cases: 5 Oral Med + 3 OFP)

Oral Med Mock Q1 (5 cases):

1. Squamous Cell Carcinoma of lateral tongue — ▶ OM 1 (exophytic ulcerated lesion, 6-week non-healing, 30 pack-year smoker, alcohol; histopath description + TNM staging + neck dissection + multidisciplinary mgmt). [[L10 OPMDs and Oral Cancer]] · [[L12 OPMDs Part IIIk]].
2. Oral Lichen Planus + secondary candidiasis in diabetic patient — ▶ OM 2 (recurrent ulceration + oral burning; bilateral white striations; superimposed candidiasis + HbA1c/diabetes link; DIF + immunology + biopsy + topical CS). Composite immune + infection + systemic case. [[L7 Allergies and Immune Mediated Disease I - OLP]] · [[L5 Viral, Bacterial and Fungal Infections of the Oral Cavity]] · [[L3 Investigations]].
3. Metastatic Disease to Mandible (prostate primary) — ▶ OM 3 (mandibular pain + systemic cancer history; differential vs SCC/MRONJ/ORN/infection; radiographic features; biopsy + imaging + bloods workup). [[L19 Bone Disease 3]].
4. Amalgam Tattoo with pigmented-lesion DDx — ▶ OM 4 (asymptomatic blue-grey lesion; DDx melanoma, melanotic macule, melanocytic naevus, smoker’s melanosis, Addison’s, drug-induced; radiopacity on imaging; reassurance vs excision). [[L6 Physical and Chemical Injuries]].
5. Actinic Cheilitis in outdoor worker — ▶ OM 5 (asymptomatic lip vermilion lesion in bricklayer; UV occupational exposure; dysplasia spectrum; topical 5-FU / cryotherapy / vermilionectomy). [[L11 OPMDs and Oral Cancer II]].

OFP Mock Formative (3 cases): 6. Post-traumatic Trigeminal Neuropathic Pain post-extraction of 37 — ▶ OFP Q1 (IAN/lingual nerve injury; ICOP criteria; QST + sensory mapping; gabapentin/TCA/SNRI + CBT + pain neuroscience education). [[L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome]]. 7. Disc Displacement With Reduction + intermittent locking — ▶ OFP Q2 (clicking + transient self-resolving locking, 42 mm opening maintained; DDwR not DDw/oR; conservative mgmt + stabilisation splint). [[L29 Intracapsular disorders of TMD]]. 8. Obstructive Sleep Apnoea with bruxism overlap — ▶ OFP Q3 (moderate OSA + retrognathia + Mallampati + STOP-BANG; AHI thresholds; MAA mechanism + responder profile + side effects vs TRD; OSA-bruxism comorbidity). [[L35 Oral Appliance Therapy for Snoring and OSA]] · [[L36 Bruxism]].

Tier 2 — Past-Year (still relevant)

• Trigeminal Neuralgia (2024) — also tested as DDx in OFP Q1. [[L34 ...]]
• Myofascial Pain with Referral (2024) — also tested as DDx in OFP Q2. [[L33 Temporomandibular disorders; Extracapsular disorders]]
• TMJ Internal Derangements (2025 Case 2 — DDw/oR with limited opening, distinct from ▶ OFP Q2 DDwR). [[L29 Intracapsular disorders of TMD]]
• Sleep Bruxism / Awake Bruxism (2024) — now overlaps ▶ OFP Q3. [[L36 Bruxism]]

Tier 3 — High-Yield from LO Annotations

Autoimmune blistering: Pemphigus Vulgaris, Mucous Membrane Pemphigoid, Linear IgA Disease, Erythema Multiforme · Lichenoid: Oral Lichen Planus, Lichenoid Drug Reaction, Contact Lichenoid Reaction · OPMDs: Epithelial Dysplasia, Leukoplakia, Erythroplakia, Oral Submucous Fibrosis · Infections: Primary Herpetic Gingivostomatitis, Oral Syphilis, Oral Tuberculosis · Salivary: Sjögren Syndrome, Pleomorphic Adenoma, Adenoid Cystic Carcinoma, Mucoepidermoid Carcinoma, Necrotising Sialometaplasia, Mucocele · Soft tissue: Pyogenic Granuloma, Schwannoma, Neurofibroma, Hemangioma, Kaposi’s Sarcoma · Bone: Osteomyelitis, MRONJ, Central Giant Cell Granuloma, Dentigerous Cyst, Odontogenic Keratocyst, Fibrous Dysplasia, Ameloblastoma, Osteosarcoma · Pain/Sleep: Burning Mouth Syndrome, Giant Cell Arteritis (emergency), TMJ Degenerative Joint Disease, Local Myalgia · Diagnostics: Direct Immunofluorescence, FBC, Iron Studies, HbA1c, B12 & Folate Studies, CBCT, MRI for TMJ, Sialometry, Challacombe Scale

§2 — Master Conditions Table

Condition	Lecture	Histo (Conv·Lect)	Labs (Conv·Lect)	Tier	Source	Flag
Squamous Cell Carcinoma (lateral tongue)	L10/L12	Y·Y	N·N	1 ▶ OM 1	L10 OPMDs and Oral Cancer / L12 OPMDs Part IIIk	TNM + neck dissection
Oral Lichen Planus + 2° candidiasis (diabetic)	L7/L5	Y·Y	Y·Y	1 ▶ OM 2	L7 Allergies and Immune Mediated Disease I - OLP / L5 Viral, Bacterial and Fungal Infections of the Oral Cavity	Composite immune + infection + systemic
Metastatic Disease to Mandible (prostate)	L19	N·Y	N·Y	1 ▶ OM 3	L19 Bone Disease 3	⚠ Mock stem light on histopath/labs
Amalgam Tattoo (+ pigmented DDx)	L6	Y·Y	N·N	1 ▶ OM 4	L6 Physical and Chemical Injuries	DDx: melanoma, melanotic macule, melanocytic naevus, Addison’s
Actinic Cheilitis (outdoor worker)	L11/L10	Y·Y	N·N	1 ▶ OM 5	L11 OPMDs and Oral Cancer II	UV occupational + vermilionectomy
Post-traumatic Trigeminal Neuropathic Pain (IAN/lingual, post-37 extraction)	L34	N·N	N·N	1 ▶ OFP Q1	L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome	ICOP + QST + sensory mapping
Disc Displacement With Reduction + intermittent locking	L29	N·N	N·N	1 ▶ OFP Q2	L29 Intracapsular disorders of TMD	Distinct from PY25 DDw/oR
Obstructive Sleep Apnoea + bruxism overlap	L35/L36	N·N	Y·Y	1 ▶ OFP Q3	L35 Oral Appliance Therapy for Snoring and OSA / L36 Bruxism	MAA + TRD + STOP-BANG + responder profile
Chronic Hyperplastic Candidiasis (still HY)	L5	Y·Y	Y·Y	2 (related to OM 2)	L5 Viral, Bacterial and Fungal Infections of the Oral Cavity	Co-presents with OLP in OM 2
Trigeminal Neuralgia	L34/L32	N·N	N·Y	2 PY24 + DDx OFP Q1	L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome	⚠ HLA-B*1502
Myofascial Pain with Referral	L33/L32	N·N	N·N	2 PY24 + DDx OFP Q2	L33 Temporomandibular disorders; Extracapsular disorders	—
TMJ Internal Derangements (DDw/oR limited opening)	L29	N·N	N·N	2 PY25	L29 Intracapsular disorders of TMD	Distinct from OFP Q2 (DDwR)
Sleep Bruxism / Awake Bruxism	L36	N·N	N·Y	2 PY24 + comorbidity OFP Q3	L36 Bruxism	⚠ Sleep studies
Mandibular Advancement Appliance	L35	N·N	Y·Y	1 ▶ OFP Q3	L35 Oral Appliance Therapy for Snoring and OSA	Mechanism + responder profile + side effects
Tongue-Retaining Device	L35	N·N	Y·Y	1 ▶ OFP Q3	L35 Oral Appliance Therapy for Snoring and OSA	Edentulous / MAA-intolerant
Pemphigus Vulgaris	L7/L8	Y·Y	Y·Y	3	L8 Allergies and Immune disease II	—
Mucous Membrane Pemphigoid	L7/L8	Y·Y	Y·Y	3	L8 Allergies and Immune disease II	—
Oral Lichen Planus	L7/L11	Y·Y	Y·Y	3	L7 Allergies and Immune Mediated Disease I - OLP	—
Contact Lichenoid Reaction	L7	Y·Y	N·Y	3	L7 Allergies and Immune Mediated Disease I - OLP	⚠ Patch test
Linear IgA Disease	L8	Y·Y	Y·Y	3	L8 Allergies and Immune disease II	—
Erythema Multiforme	L8	Y·Y	N·N	3	L8 Allergies and Immune disease II	—
Recurrent Aphthous Stomatitis	L8	Y·Y	N·N	3	L8 Allergies and Immune disease II	—
Primary Herpetic Gingivostomatitis	L5	Y·Y	Y·Y	3	L5 Viral, Bacterial and Fungal Infections of the Oral Cavity	—
Oral Syphilis	L5	Y·Y	Y·Y	3	L5 Viral, Bacterial and Fungal Infections of the Oral Cavity	—
Oral Tuberculosis	L5	Y·Y	Y·Y	3	L5 Viral, Bacterial and Fungal Infections of the Oral Cavity	—
Smoker’s Melanosis	L6	Y·Y	N·N	3	L6 Physical and Chemical Injuries	—
Traumatic Ulceration	L6	Y·Y	N·N	3	L6 Physical and Chemical Injuries	—
Frictional Keratosis	L6	Y·Y	N·N	3	L6 Physical and Chemical Injuries	—
Epithelial Dysplasia	L10/L12	Y·Y	N·N	3	L10 OPMDs and Oral Cancer	—
Leukoplakia	L10/L11	Y·Y	N·N	3	L10 OPMDs and Oral Cancer	—
Erythroplakia	L10	Y·Y	N·N	3	L10 OPMDs and Oral Cancer	—
Oral Submucous Fibrosis	L11	Y·Y	N·N	3	L11 OPMDs and Oral Cancer II	—
Oral Lichenoid Lesions	L11	Y·Y	N·Y	3	L11 OPMDs and Oral Cancer II	⚠ Drug history
Oral Lupus Erythematosus	L11/L8	Y·Y	Y·Y	3	L11 OPMDs and Oral Cancer II	—
Radiation Mucositis	L13	Y·Y	N·N	3	L13 Dental Management of Oral Cancer Patients	—
Osteoradionecrosis	L13	Y·Y	N·N	3	L13 Dental Management of Oral Cancer Patients	—
Pyogenic Granuloma	L14	Y·Y	N·N	3	L14 Soft Tissue Tumors	—
Schwannoma	L14	Y·Y	N·N	3	L14 Soft Tissue Tumors	—
Neurofibroma	L14	Y·Y	N·N	3	L14 Soft Tissue Tumors	—
Hemangioma	L14	Y·Y	N·N	3	L14 Soft Tissue Tumors	—
Kaposi’s Sarcoma	L14	Y·Y	Y·Y	3	L14 Soft Tissue Tumors	⚠ HHV8
Sjögren Syndrome	L15/L16	Y·Y	Y·Y	3	L15 Non neoplastic and neoplastic salivary gland diseases	—
Pleomorphic Adenoma	L15	Y·Y	N·N	3	L15 Non neoplastic and neoplastic salivary gland diseases	—
Adenoid Cystic Carcinoma	L15	Y·Y	N·N	3	L15 Non neoplastic and neoplastic salivary gland diseases	—
Mucoepidermoid Carcinoma	L15	Y·Y	N·N	3	L15 Non neoplastic and neoplastic salivary gland diseases	—
Necrotising Sialometaplasia	L15	Y·Y	N·N	3 (mimic)	L15 Non neoplastic and neoplastic salivary gland diseases	—
Mucocele	L15	Y·Y	N·N	3	L15 Non neoplastic and neoplastic salivary gland diseases	—
Xerostomia (drug-induced)	L16	N·N	Y·Y	3	L16 Dry Mouth	⚠ Clinical Challacombe
Osteomyelitis	L17	Y·Y	Y·Y	3	L17 Bone Disease 1	—
MRONJ	L17	Y·Y	Y·Y	3	L17 Bone Disease 1	—
Central Giant Cell Granuloma	L17	Y·Y	Y·Y	3	L17 Bone Disease 1	—
Dentigerous Cyst	L18	Y·Y	N·N	3	L18 Bone Disease 2	—
Odontogenic Keratocyst	L18	Y·Y	N·N	3	L18 Bone Disease 2	—
Fibrous Dysplasia	L18	Y·Y	Y·(implied)	3	L18 Bone Disease 2	⚠ Labs
Ameloblastoma	L19	Y·Y	N·N	3	L19 Bone Disease 3	—
Osteosarcoma	L19	Y·Y	Y·Y	3	L19 Bone Disease 3	—
Burning Mouth Syndrome	L34	N·N	Y·Y	3	L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome	—
Giant Cell Arteritis	L33	Y·Y	Y·Y	3 EMERG	L33 Temporomandibular disorders; Extracapsular disorders	—
TMJ Degenerative Joint Disease	L29	N·N	N·N	3	L29 Intracapsular disorders of TMD	—
Local Myalgia	L33	N·N	N·N	3	L33 Temporomandibular disorders; Extracapsular disorders	—
Trigeminal Post-herpetic Neuralgia	L34	N·N	N·N	3	L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome	—

Legend: Conv = clinical convention · Lect = lecturer presented. ⚠ flag → §4.

§3 — Per-Lecture Cram Sheets

L1 L1 Oral Soft Tissue and Lesion Evaluations

Source: L1 Oral Soft Tissue and Lesion Evaluations

1. Structured Lesion Evaluation - Morphology & Differential Diagnosis · Tier 1 · MOCK EXAM

• Key features / when to use: Entry-point assessment of any suspicious lesion; describe location, size, colour, outline, texture systematically; high-risk groups (tobacco/alcohol, >40 y, HPV); use at every appointment to detect change in existing lesions.
• Alternatives / considerations: Clinical exam alone cannot exclude malignancy; risk of premature closure if morphology “benign”; photographic documentation essential for follow-up; do not rely on symptom status.
• Companion investigations / adjuncts: Clinical photography (standardised angle/lighting/scale); incisional/excisional biopsy if red flags (>2 weeks, induration, non-healing); FBC/HbA1c if candidiasis; lymph node palpation + imaging if cancer-suspected; WHO OPMD classification reference.
• Histopath presented? Y (Convention: Y · Lecture: N) ⚠ DISAGREEMENT: OSCE pairs photo with histopath; L1 teaches clinical only.
• Labs presented? N
• Histopath: Dysplasia grading in leukoplakia/erythroplakia · invasive SCC w/ mitotic activity + perineural invasion · candidal hyphae · pigment-laden macrophages (amalgam) · actinic elastosis (cheilitis).
• Management: Systematic clinical assessment; develop differential; biopsy if red flag.

2. Induration, Ulceration & Tissue Palpation Assessment · Tier 1 · MOCK EXAM

• Key features / when to use: Mandatory for all lesions; induration = submucosal fibrosis/invasion (malignancy hallmark); non-healing >2 weeks → urgent biopsy; bimanual technique for floor of mouth/ventral tongue; fixation = advanced disease.
• Alternatives / considerations: Benign lesions (traumatic, candidiasis) lack induration; gentle palpation avoids trauma; rolled margins classic for SCC but not pathognomonic; neuropathic pain on palpation = perineural invasion.
• Companion investigations / adjuncts: Incisional biopsy from ulcer edge incl. submucosa; CBCT/MRI for bone invasion; sensory testing if neuropathy; cervical node palpation; 2-week recheck if benign-appearing but unhealed.
• Histopath presented? Y · Labs presented? N
• Histopath: Induration → fibrosis/inflammation beneath mucosa · ulceration with fibrin base · fixation = invasion · rolled margin = SCC morphology · lack of induration = benign.
• Management: Bimanual palpation; urgent biopsy if induration + non-healing + high-risk site.

3. High-Risk Anatomical Sites & SCC Risk Stratification · Tier 1 · MOCK EXAM

• Key features / when to use: Lateral tongue + FOM = highest risk (thin epithelium, high vascularity); ventral tongue, soft palate complex secondary; any lesion at these sites = urgent biopsy regardless of symptoms; age >40 + tobacco/alcohol + HPV elevate risk; vermilion border = UV cumulative.
• Alternatives / considerations: Low-risk sites permit longer observation; lymphatic drainage dictates nodal involvement (submandibular → jugulodigastric for lateral tongue); prior cancer history makes new lesion high-risk; assess biopsy/treatment site accessibility.
• Companion investigations / adjuncts: Lymph node mapping + palpation; OPG/CT/MRI for bone + nodal mets; HPV testing if oropharyngeal; photography with landmarks; baseline FBC/HbA1c if candidiasis at high-risk site.
• Histopath presented? Y · Labs presented? N
• Histopath: Thin epithelium → faster submucosal invasion · high vascularity → submandibular + jugulodigastric spread · actinic elastosis + atypia in vermilion.
• Management: Extra vigilance at high-risk sites; lower biopsy threshold.

4. Bimanual Palpation Technique · Tier 2

• Key features / when to use: Standard for any tongue/FOM complaint; assesses submucosal induration, nodules, fixation; essential in cancer screening + safe biopsy planning.
• Alternatives / considerations: Unilateral palpation misses bilateral lesions; excessive gauze drying irritates; semi-supine + chin-elevated improves access; document size, consistency, mobility.
• Companion investigations / adjuncts: Intraoral photo of palpated areas; incisional biopsy at induration; MRI for extensive induration; sensory testing; US-guided FNA of palpable nodes.
• Histopath presented? N · Labs presented? N
• Management: Grasp anterior 2/3 tongue with gauze; palpate lateral + dorsum; bimanual FOM (one intraoral, one submental).

5. Lymph Node Drainage Mapping · Tier 2

• Key features / when to use: All patients with suspected malignancy/high-risk lesions; lateral tongue → submandibular + jugulodigastric; FOM → bilateral submandibular; nodal fixation = advanced; serial exams detect enlargement.
• Alternatives / considerations: Palpable nodes may be reactive (infection); posterior cervical/supraclavicular nodes suggest distant mets; small hard fixed nodes > large mobile; HIV+ patients have reactive lymphadenopathy.
• Companion investigations / adjuncts: US-guided FNA of suspicious nodes; CT/CBCT nodal levels I–VI; FNA cytology if morphology concerning (round, heterogeneous); baseline FBC if HIV/EBV; serial palpation + measurement.
• Histopath presented? N · Labs presented? N
• Management: Systematic palpation of jugulodigastric, submandibular, submental, posterior cervical, supraclavicular.

Top LOs (verbatim):

• “Describe the pathophysiological basis for clinical signs like induration, ulceration, and fixation during lesion evaluation.”
• “Identify and record risk factors—such as tobacco and alcohol use—relevant to the presentation of oral lesions.”
• “Discuss the application of structured clinical workflows as adjuncts to obtaining an accurate history and differential diagnosis.”

Mock-exam / past-year flags: Foundational for all 5 Tier-1 mock cases.

L2 L2 Surgery in Oral Medicine

Source: L2 Surgery in Oral Medicine

1. Punch Biopsy · Tier 2

• Key features / when to use: Circular blade (3/4/6 mm) for keratinised soft tissue (gingiva, hard palate); minimal crushing with Adson’s forceps; single suture or none for small specimens.
• Alternatives / considerations: Difficult on mobile tissue (cheek, tongue, FOM); avoid if poorly keratinised; not for suspected malignancy needing margin assessment.
• Companion investigations / adjuncts: Pre-op photos with markings; 10% buffered formalin; clinical history; documentation of lesion location.
• Histopath presented? Y · Labs presented? N
• Histopath: Circular core; parakeratinised stratified squamous epithelium with normal fibrous base; keratinised soft tissue only.
• Management: First-line for keratinised soft tissues; quick, minimal wound.

2. Incisional Biopsy · Tier 2 · MOCK EXAM (SCC, candidiasis, actinic cheilitis)

• Key features / when to use: Wedge from lesion margin + adjacent normal; captures worst area for dysplasia/malignancy; multiple samples from large lesions; orientation suture (anterior/posterior) for re-excision.
• Alternatives / considerations: Crush artefacts risk; malignant cell seeding possible; shallow biopsy misses basal dysplasia; not for ulcerated lesions unless margin sampled.
• Companion investigations / adjuncts: Pre-op marking + serial photos; ruler scale; divided specimen (IHC + H&E); pathology request with anticoag status.
• Histopath presented? Y · Labs presented? Y
• Histopath: Wedge from lesion margin + deep margin; representative area + adjacent normal interface; margin status documented.
• Labs: 10% buffered formalin; specimen may be divided for IHC vs routine; pathology request includes location, duration, differential.
• Management: Large lesions, suspected malignancy, multiple morphologies; orientation suture essential.

3. Excisional Biopsy · Tier 2 · MOCK EXAM (amalgam tattoo, small fibroma)

• Key features / when to use: Complete removal with 2–5 mm margin; elliptical incision ≥3 mm from border with V-shaped depth; clinically benign-looking small localised lesions; combined diagnostic + therapeutic.
• Alternatives / considerations: Not for large/malignant requiring staging; hard palate difficult closure; vascular lesion bleeding risk; cosmetically sensitive areas need careful geometry.
• Companion investigations / adjuncts: Pre-op marking + ruler photos; vascular cauterisation if encountered; divided specimen if malignancy; clinical notes (colour, texture, symptoms).
• Histopath presented? Y · Labs presented? Y
• Histopath: Complete removal with 2–5 mm margin; full tissue depth; orientation marker suture.
• Labs: 10% buffered formalin for H&E; may divide for IHC + routine.
• Management: Complete removal + diagnostic intent; small localised; margins assessed.

4. Fine Needle Aspiration Cytology · Tier 1

• Key features / when to use: Aspiration of fluid/cells via fine needle; rules out vascular lesions (blood backflush = vascular); fluctuant cysts + lymph nodes; US-guided for deep lesions.
• Alternatives / considerations: Non-diagnostic if predominantly blood; limited to aspirable; cytology may be difficult with limited material; not for suspected malignancy requiring architecture.
• Companion investigations / adjuncts: US guidance for deep/impalpable; cyst symptom history; CT/MRI review; fluid analysis (protein, cell count, Gram/culture); clinical notes (painless swelling, mobility).
• Histopath presented? N · Labs presented? Y
• Labs: Aspiration of fluid/cells; rules out vascular; fluctuant cysts + lymph nodes; US-guided for deep lesions.
• Management: Non-surgical aspirate for cystic/vascular lesions + lymph nodes.

5. Direct Immunofluorescence Biopsy Site Selection · Tier 2

• Key features / when to use: From clinically affected margin + perilesional normal control; transport in sterile saline-soaked gauze or Michel’s medium (NOT formalin); detects linear/granular IgG/IgA/IgM at BMZ in autoimmune disease; fresh specimen essential.
• Alternatives / considerations: Formalin contraindicated (destroys Ig); transport delays reduce sensitivity; perilesional control omission limits dx; IIF (serum) may complement but less sensitive.
• Companion investigations / adjuncts: Clinical photos showing affected vs normal sites; pathology request specifying DIF + suspected disease; contact lab re: Michel’s medium pre-biopsy; concurrent serology (IIF, ELISA, anti-desmoglein/BP180); oral exam documenting extent.
• Histopath presented? Y · Labs presented? Y
• Histopath: Biopsy from clinically affected margin + perilesional normal; sterile saline-soaked gauze or Michel’s medium (NOT formalin); subepithelial linear/granular IgG/IgA/IgM at BMZ.
• Labs: Sterile pot with saline gauze or Michel’s medium; fresh specimen — delays reduce accuracy.
• Management: Specialised biopsy for suspected autoimmune/bullous (pemphigus, pemphigoid, linear IgA).

Top LOs (verbatim):

• “Explain the different surgical investigations used within oral medicine, specifically punch, incisional, and excisional biopsies.”
• “Describe best procedures to maximize information yield and minimize tissue artifacts during specimen collection and handling.”
• “Identify risk factors and contraindications, such as anticoagulation or vascularity, relevant to surgical intervention.”

Mock-exam / past-year flags: Biopsy techniques central to all 5 mock cases.

L3 L3 Investigations

Source: L3 Investigations

1. Full Blood Count · Tier 1

• Key features / when to use: Anaemia screen (low Hb → glossitis, candidosis, ulceration, oral burning); infection/inflammation (WCC); platelet count before surgery; MCV classifies anaemia (microcytic Fe / macrocytic B12-folate / normocytic).
• Alternatives / considerations: Repeat if bone marrow suppression suspected (medication); RDW elevated in Fe + B12/folate deficiency overlap; differential shifts: lymphs↑ viral, neuts↑ bacterial.
• Companion investigations / adjuncts: Iron Studies if microcytic; B12 & Folate Studies if macrocytic; coagulation if platelets abnormal; reticulocytes; peripheral film if atypical.
• Histopath presented? N · Labs presented? Y
• Labs: Hb 115–155 g/L; MCV 82–98 fL; WCC 4.0–11.0 × 10⁹/L; platelets 150–400 × 10⁹/L; RDW <16%.
• Interpretation: Anaemia + bone marrow disorders affecting oral mucosa.

2. Iron Studies · Tier 1

• Key features / when to use: IDA causing intraoral erythema + candidosis risk; ferritin most reliable for iron stores; transferrin saturation + serum iron for binding; clinical correlation with FBC + mucosal findings.
• Alternatives / considerations: Serum iron alone fluctuates; transferrin rises in deficiency; iron overload (hemochromatosis) → ↑ serum iron + ferritin; mucosal lesions can mimic B12/folate.
• Companion investigations / adjuncts: B12 & Folate Studies (overlap); Full Blood Count (MCV, RDW); reticulocytes + film if haemolysis; endoscopy if malabsorption/GI bleeding; fasting serum iron.
• Histopath presented? N · Labs presented? Y
• Labs: Ferritin (most reliable); serum iron; transferrin saturation; transferrin.
• Interpretation: IDA dx + exclude haemochromatosis; links to glossitis, impaired healing.

3. B12 & Folate Studies · Tier 1 · MOCK (candidiasis context)

• Key features / when to use: Macrocytic anaemia, elevated RDW, glossitis, oral burning, ulceration, candidosis; B12 can mimic OLP clinically; methotrexate/anticonvulsants deplete folate.
• Alternatives / considerations: MMA + homocysteine more specific for B12; IF antibodies if pernicious anaemia; folate often coexists with iron deficiency; oral lesions resolve post-supplementation.
• Companion investigations / adjuncts: Full Blood Count (MCV, RDW); Iron Studies (overlap); MMA + homocysteine if borderline B12; IF antibodies; GI referral if malabsorption; autoimmune gastritis screen.
• Histopath presented? N · Labs presented? Y
• Labs: B12 + folate; methylmalonic acid + homocysteine functional tests; intrinsic factor antibodies.
• Interpretation: Differentiates oral lesions (glossitis, ulceration) — local vs systemic deficiency.

4. HbA1c & Glucose Tolerance Test · Tier 1 · MOCK (candidiasis Case 2)

• Key features / when to use: Recurrent candidosis signals poor glycaemic control; HbA1c = 3-month avg (target <7%); GTT for impaired tolerance + undiagnosed diabetes; fasting BGL + 1-h + 2-h post-load.
• Alternatives / considerations: HbA1c unreliable in haemolytic anaemia/recent transfusion; fasting glucose alone misses postprandial; glycated albumin (2–3 wk) if recent changes; counsel on GTT requirements.
• Companion investigations / adjuncts: FBC; fasting lipids; U&E; LFTs (pre-metformin); urine microalbumin; annual eye screening (diabetic retinopathy).
• Histopath presented? N · Labs presented? Y
• Labs: HbA1c (gold-standard); fasting BGL + GTT; case: candidosis with HbA1c >7% resolved on control.
• Management: Improve glycaemic control → candidosis resolves; coordinate with GP/endocrinology.

5. Histopathology & Biopsy Specimen · Tier 1 · MOCK (all 5 cases)

• Key features / when to use: Mandatory for SCC, OPMDs, atypical lesions; diagnosis of exclusion for white lesions; DIF required for OLP/pemphigoid; site selection critical (most severe + lesion-normal margin + adequate depth).
• Alternatives / considerations: Brush biopsy/cytology insufficient for dysplasia grading; transport media essential (formalin H&E, Michel’s/saline DIF); crush/haemorrhage artefact reduces yield; discrepant report → contact pathologist.
• Companion investigations / adjuncts: DIF (fresh tissue/Michel’s); micro culture + PCR (sterile, no fixative); flow cytometry if lymphoma; special stains (PAS Candida, ZN TB, Gram bacteria); repeat biopsy if non-diagnostic.
• Histopath presented? Y · Labs presented? Y
• Histopath: Most severe change; epithelium + CT; DIF refrigerated; formalin for routine.
• Labs: Pathology request: clinical impression, history, fasting/preg/diabetic status; mock cases: SCC induration, candidiasis PAS hyphae, amalgam pigment, actinic acanthosis + dyskeratosis + solar elastosis.
• Management: Adequate specimen depth; detailed clinical history; pathologist re-review if discordance.

Top LOs (verbatim):

• “Explain the meaning of hematology, biochemistry, and microbiology investigation results used to identify systemic links to oral disease.”
• “Describe and relate the relevance of blood investigation results (e.g., FBC, Iron, B12, HbA1c) to health and disease manifestations like glossitis or candidosis.”
• “Describe best procedures for collecting swabs and blood samples to maximize information yield and avoid false results.”

Mock-exam / past-year flags: Lab interpretation directly supports Cases 1, 2, 4, 5.

L4 L4 Imaging of Hard and Soft Tissues

Source: L4 Imaging of Hard and Soft Tissues

1. OPG · Tier 2 · MOCK (Case 3 initial mandible screen)

• Key features / when to use: Large FOV broad overview; low dose; identifies bony abnormalities, perio bone loss, cysts, tumours; first-line screening.
• Alternatives / considerations: Intraoral PA for localised pathology; escalate to CBCT if ambiguous (sinus superimposition); contraindicated if patient cannot stand/position.
• Companion investigations / adjuncts: Intraoral PAs for periapical; CBCT for 3D extent; CT if soft-tissue/density needed; biopsy for symptomatic lesions; clinical palpation + history.
• Histopath presented? N · Labs presented? N
• Radiographic features: Broad alveolar outline; corticated vs non-corticated lucencies; root resorption; expansion; mandibular canal displacement.
• Indication: Screening for generalised bone loss, impacted teeth, cysts/tumours, TMJ, trauma overview.

2. CBCT · Tier 1 · MOCK

• Key features / when to use: 3D volumetric with 1:1 accuracy; multiplanar (axial/sagittal/coronal); dentoalveolar disease + bony detail; variable dose with ultra-low protocols available.
• Alternatives / considerations: OPG if broad overview sufficient; MSCT for complex bony lesions needing HU + soft tissue; contraindicated if patient cannot position; pregnancy unless urgent.
• Companion investigations / adjuncts: Intraoral first; MSCT for malignancy staging + soft-tissue invasion; MRI for soft tissue/salivary/TMJ; PET/CT for cancer staging; biopsy for indeterminate lesions.
• Histopath presented? N · Labs presented? N
• Radiographic features: Corticated/non-corticated borders; internal density (lucent/mixed/dense); root resorption; cortical expansion; canal displacement.
• Indication: Gold-standard for dentoalveolar when OPG inconclusive; implant planning; impacted teeth; TMJ; trauma 3D.

3. MSCT · Tier 1 · MOCK Case 3

• Key features / when to use: True 3D + HU density; superior soft tissue vs CBCT; fast; trauma + lesion characterisation + infection + soft-tissue invasion.
• Alternatives / considerations: CBCT for dental alveolar if soft tissue not needed; MRI for pure soft tissue (salivary, TMJ, nerve); PET/CT for staging + active infection.
• Companion investigations / adjuncts: OPG/intraoral for triage; MRI for soft-tissue extent + perineural invasion + marrow oedema; PET/CT for cancer grading; IV contrast for vascular/abscess/margins; biopsy mandatory for indeterminate.
• Histopath presented? N · Labs presented? N
• Radiographic features: HU density; cortical vs medullary; soft-tissue boundaries; adjacent structure invasion; calcification.
• Indication: Complex bony lesion characterisation; trauma + soft tissue; infection/abscess; malignancy staging (T); salivary; ORN assessment.

4. MRI · Tier 1

• Key features / when to use: Gold-standard soft tissue; no ionising radiation; TMJ disc, salivary, neural, vascular, soft-tissue tumour extent; T1/T2/STIR + gadolinium.
• Alternatives / considerations: Long acquisition + motion risk; contraindicated with ferromagnetic implants; may overestimate tumour due to oedema; misses fine bone + calcifications.
• Companion investigations / adjuncts: US/CT first for rapid soft tissue; CT for bony destruction; PET/CT for high-grade tumour; US-guided FNA for indeterminate lesions; serial imaging for benign stable lesions.
• Histopath presented? N · Labs presented? N
• Radiographic features: T1 anatomy + fat bright; T2 fluid bright; STIR oedema bright; gadolinium enhancement (heterogeneous = malignancy); DWI restriction for abscess/necrosis.
• Indication: TMJ internal derangement; soft-tissue tumour extent; salivary pathology; nerve assessment; infection/osteomyelitis marrow oedema; vascular mapping.

5. PET · Tier 2 · MOCK (Case 3 mets grading)

• Key features / when to use: Functional metabolic imaging; “hot” = high activity (malignancy/infection/growth); SPECT bone tracers ⁹⁹ᵐTc; PET ¹⁸F-FDG; co-registration with CT (PET/CT, SPECT/CT).
• Alternatives / considerations: SPECT/CT for anatomical localisation of hot lesion; CT/MRI for morphological detail if non-diagnostic; contraindicated in pregnancy; relative CI in renal impairment.
• Companion investigations / adjuncts: CT/CBCT for morphology of hot lesion; biopsy mandatory (high uptake = malignancy/infection); haematology + tumour markers for staging; serial PET/CT for treatment response; clinical correlation with symptoms.
• Histopath presented? N · Labs presented? N
• Radiographic features: Hot lesion = ↑ uptake (malignancy/infection/growth); cold = no uptake; bilateral symmetry; metastatic foci.
• Indication: Cancer grading; osseous metastasis screen; condylar hyperplasia activity; post-extraction infection; advanced cancer staging; treatment response.

Top LOs (verbatim):

• “Explain the meaning of imaging investigation results ranging from 2D radiographs to advanced 3D and functional modalities.”
• “Describe and relate the relevance of imaging results (e.g., CBCT for bone, MRI for soft tissue) to maxillofacial health and disease.”
• “Discuss the application of specific imaging modalities as adjuncts to clinical examination based on suspected pathology.”

Mock-exam / past-year flags: Case 3 (metastatic prostate→mandible) progression OPG → CBCT/CT → PET/SPECT.

L5 L5 Viral, Bacterial and Fungal Infections of the Oral Cavity

Source: L5 Viral, Bacterial and Fungal Infections of the Oral Cavity

1. Chronic Hyperplastic Candidiasis · Tier 1 · MOCK Case 2

• Clinical features: Bilateral anterior buccal commissures (symmetrical); rough non-homogeneous white patches with erythematous base; prolonged denture wear, CS use, antibiotic, HIV/immunosuppression; biopsy mandatory to rule out dysplasia.
• Differential diagnosis: Leukoplakia (CHC has PAS+ hyphae on biopsy; leukoplakia does not); OLP (Wickham striae + bilateral pattern); erythematous candidiasis (red atrophic vs white plaque).
• Relevant investigations: PAS staining of biopsy; Sabouraud culture + germ tube (C. albicans/C. dubliniensis); biopsy required for dysplasia exclusion; CFU 4,000–20,000/ml threshold.
• Histopath presented? Y · Labs presented? Y
• Histopath: Parakeratosis with nuclei in stratum corneum · hyperplastic epithelium · candidal hyphae in upper layers · inflammatory infiltrate in lamina propria · PAS+ hyphae.
• Labs: PAS + Sabouraud + germ tube; biopsy mandatory; CFU 4,000–20,000/ml.
• Management: Miconazole gel 3–4×/day × 3–4 weeks; address denture hygiene + immunosuppression.

2. Primary Herpetic Gingivostomatitis · Tier 1

• Clinical features: Children 6 mo–5 y; widespread oral ulcerations + swollen erythematous gingiva; prodrome malaise + fever; vesicles → coalescing irregular ulcers; bilateral cervical lymphadenopathy; 7–10 days; dehydration common; severe in immunocompromised.
• Differential diagnosis: Varicella zoster (clinical correlation + viral culture/PCR); RAS (no vesicles, no systemic symptoms); ANUG (necrotic interdental papillae, halitosis, no vesicles).
• Relevant investigations: PCR HSV-1 DNA (gold-standard); viral culture from vesicular fluid; serology 4-fold ↑ HSV-1 IgG; immunofluorescence; FBC if adult onset to exclude immunosuppression.
• Histopath presented? Y · Labs presented? Y
• Histopath: Ballooning degeneration · multinucleated giant cells · intranuclear eosinophilic inclusion bodies · acantholysis · superficial ulceration.
• Labs: PCR HSV-1; viral culture; serology IgG; immunofluorescence; FBC if adult.
• Management: Aciclovir 200 mg 5×/day × 7 d (severe/immunocompromised); hydration + analgesia; avoid contact transmission.

3. Oral Syphilis · Tier 2

• Clinical features: Primary: painless chancre (tongue/gingiva/palate/lip), indurated margin, painless lymphadenopathy (80%); Secondary: mucous patches highly infectious + maculopapular palms/soles rash; Tertiary: gumma on palate/tongue/tonsils + systemic features.
• Differential diagnosis: Candida (Candida wipes off; chancre is indurated non-wiped); traumatic ulcer (defined indurated margin in syphilis vs soft fibrinous in trauma); SCC (biopsy distinguishes).
• Relevant investigations: Nontreponemal VDRL/RPR (screen, 1–4 wk post-chancre); treponemal FTA-ABS/TP-PA/TP-EIA (confirm, lifelong positive); PCR T. pallidum; HIV co-test; partner notification.
• Histopath presented? Y · Labs presented? Y
• Histopath: Plasma cell infiltration perivascular · band-like lamina propria infiltrate · tertiary: granulomatous + caseous necrosis + giant cells · silver stains for spirochetes.
• Labs: VDRL/RPR + FTA-ABS/TP-PA + PCR; HIV co-test.
• Management: Benzathine penicillin 2.5 MU IM (primary/secondary) or 7.2 MU × 3 (late latent); defer elective dental during active lesions.

4. Pseudomembranous Candidiasis · Tier 2

• Clinical features: Immunocompromised (HIV, CS, broad-spectrum antibiotics); semi-adherent whitish creamy plaques; wipes off → red bleeding base; palate, dorsum tongue, buccal mucosa; often recurrent.
• Differential diagnosis: Leukoplakia (CHC does not wipe off); erythematous candidiasis (no white plaque, atrophic red); morsicatio (chronic habit, wipes partially).
• Relevant investigations: PAS smear/scraping (hyphae + yeasts); 10% KOH on fresh sample; Sabouraud culture + germ tube; CD4 if HIV suspected.
• Histopath presented? Y · Labs presented? Y
• Histopath: Superficial fungal infection (no epithelial invasion acute) · white pseudomembrane of epithelial debris + Candida · PAS hyphae + yeasts.
• Labs: PAS smear; KOH; Sabouraud + germ tube.
• Management: Nystatin 100,000 U 4–5×/day × 15 d OR clotrimazole 5 ml 3–4×/day × 2 wk; address predisposing factors.

5. Oral Tuberculosis · Tier 2

• Clinical features: Uncommon (0.1–0.5% TB cases); tongue most common; indurated ill-defined ulcer with hard necrotic base; mimics malignancy; systemic features (night sweats, fever, weight loss, cough, haemoptysis).
• Differential diagnosis: SCC (oral TB shows caseating granuloma + AFB; SCC shows infiltrating epithelium); traumatic ulcer (TB persists >4 wk + systemic; trauma heals 2 wk); syphilis gumma (treponemal serology).
• Relevant investigations: Ziehl–Neelsen on biopsy (AFB); sputum AFB microscopy × 3 monthly + culture (4–8 wk); GeneXpert MTB/RIF; WHO line probe for resistance; CXR.
• Histopath presented? Y · Labs presented? Y
• Histopath: Caseating granuloma · epithelioid macrophages + Langhans giant cells · lymphocytes + plasma cells · ZN+ AFB.
• Labs: Sputum AFB; culture; ZN; WHO line probe.
• Management: RIPE 2 months → RI 4 months; occupational infection control (ventilation, masks, BCG for high-risk HCWs).

Top LOs (verbatim):

• “Discuss the clinical features, histopathology, investigation, and management of primary candidal infections (Pseudomembranous, Erythematous, and Hyperplastic).”
• “Discuss the clinical features, histopathology, and stages (Primary, Secondary, Tertiary, Congenital) of Syphilis manifesting in the oral cavity.”
• “Discuss the clinical features, Ziehl–Neelsen histopathology, and management of primary and secondary oral Tuberculosis.”

Mock-exam / past-year flags: ▶ OM 2 — candidiasis is the SECONDARY infection in this case; primary diagnosis is OLP (see L7). Mock case tests both: PAS+ hyphae + miconazole mgmt + diabetic HbA1c link. Still DIRECT MOCK HIT.

L6 L6 Physical and Chemical Injuries

Source: L6 Physical and Chemical Injuries

1. Amalgam Tattoo · Tier 1 · MOCK Case 4

• Clinical features: Blue-grey/black/grey macule; well-defined to diffuse; gingiva/alveolar/buccal mucosa near restorations or extractions; asymptomatic, persistent; non-blanching, non-palpable.
• Differential diagnosis: Melanoma (amalgam radiopaque on OPG; biopsy if no radiopacity); melanosis/drug-induced (history of smoking/meds; no metallic particles); haemosiderin staining (trauma history).
• Relevant investigations: History of amalgam restoration/RCT/extraction near lesion; clinical exam (non-blanching); OPG/PA radiograph (densely radiopaque metallic fragments); biopsy if no radiopacity or melanoma suspected.
• Histopath presented? Y · Labs presented? N
• Histopath: Dark pigmented metal fragments along collagen fibres · fine black/brown granules + larger solid fragments · may stain reticulin · no inflammation · benign.
• Management: Reassurance; surgical excision optional for cosmesis or diagnostic uncertainty.

2. Smoker’s Melanosis · Tier 1

• Clinical features: Brown-grey diffuse pigmentation; lower labial gingiva (cigarette smokers); buccal mucosa (pipe); hard palate (reverse smokers); asymptomatic; female predominance.
• Differential diagnosis: Racial pigmentation (since childhood, family history, persistent despite cessation); Peutz-Jeghers (lip + GI polyps + family history); drug-induced (minocycline, chlorhexidine).
• Relevant investigations: Detailed smoking history; clinical exam noting distribution; OPG (no radiopacity); biopsy if atypical (↑ basal melanin + melanophages); exclude Addison’s/Peutz-Jeghers if indicated.
• Histopath presented? Y · Labs presented? N
• Histopath: ↑ basal melanin · incontinent melanin in superficial CT · melanophages in lamina propria · no dysplasia · reactive.
• Management: Smoking cessation → gradual resolution ~3 years; monitor reverse smokers for cancer risk.

3. Traumatic Ulceration · Tier 1

• Clinical features: Yellow fibrinopurulent membrane + erythematous surround; rapid onset (hours-days post-trauma); painful; any mucosal surface; rolled white hyperkeratotic border may develop; sharp tooth, denture, self-biting, natal teeth (Riga-Fede).
• Differential diagnosis: SCC (non-healing >3 wk, indurated, no clear trauma; biopsy if persistent >2 wk post-removal); aphthous (smaller, recurrent, no trauma); viral (vesicles preceding, prodromal symptoms).
• Relevant investigations: History identifying trauma source; clinical exam (assess induration, measure size); OPG to exclude bone pathology/foreign body; biopsy if persistent >14 days or SCC suspected; 2-week review.
• Histopath presented? Y · Labs presented? N
• Histopath: Full-thickness epithelium loss with abrupt “traumatic” edge · fibrinopurulent exudate · granulation tissue with mixed inflammation (neutrophils, eosinophils, lymphocytes) · hypertrophic adjacent epithelium · no dysplasia.
• Management: Remove trauma source; chlorhexidine + lignocaine gel; spontaneous resolution 10–14 days; biopsy if unhealed at 2 weeks.

4. Frictional Keratosis · Tier 1

• Clinical features: Ill-defined grey/white papules and plaques; rough diffuse texture; blends with adjacent mucosa; attached gingiva, retromolar pad, lateral tongue; asymptomatic; reactive; waxes/wanes with habit.
• Differential diagnosis: Leukoplakia (persistent despite trauma removal, dysplasia on biopsy); OLP (reticular Wickham striae, autoimmune, no trauma); candidosis (wipes off, antifungal-responsive).
• Relevant investigations: History of mechanical irritation (fractured tooth, rough restoration, denture, aggressive brushing); clinical exam; remove trauma + review 2 weeks; biopsy only if persistent or atypical; OPG if dental status review needed.
• Histopath presented? Y · Labs presented? N
• Histopath: Orthokeratosis or hyperparakeratosis with shaggy keratin · granular layer prominent · intracellular oedema in spinous layer · acanthosis · no inflammation in superficial CT · no dysplasia.
• Management: Eliminate irritation; 2-week review; biopsy if persistent.

5. Morsicatio Buccarum · Tier 2

• Clinical features: Irregular shaggy macerated appearance on non-keratinised mucosa (buccal, lower labial, ventral tongue); bilateral; usually asymptomatic; patients often unaware of habit; associated with anxiety/stress/parafunction.
• Differential diagnosis: Pseudomembranous candidosis (white plaques wipeable, antifungal-responsive); frictional keratosis (keratinised sites + defined margins); OLP (Wickham striae + symmetrical reticular).
• Relevant investigations: History of lip/cheek biting, anxiety, stress, awareness; clinical exam (bilateral, non-keratinised, shaggy, no induration); biopsy only if risk factors (smoking/alcohol) or unclear.
• Histopath presented? Y · Labs presented? N
• Histopath: Marked hyperparakeratosis with shaggy fissured surface · acanthotic epithelium + ballooned cells · bacterial colonies on keratin · benign non-dysplastic.
• Management: Reassurance + habit counselling; consider stress mgmt/CBT; biopsy if suspicious.

Top LOs (verbatim):

• “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of amalgam tattoos and other localized exogenous pigmentations.”
• “Discuss the aetiology, pathogenesis, the clinical and histopathologic features and the diagnosis and treatment of smoker’s melanosis.”
• “Describe the repertoire of responses of oral soft tissues to trauma.”

Mock-exam / past-year flags: Amalgam tattoo = Tier 1 MOCK Case 4.

L7 L7 Allergies and Immune Mediated Disease I - OLP

Source: L7 Allergies and Immune Mediated Disease I - OLP

1. Oral Lichen Planus · Tier 1

• Clinical features: Bilateral reticular Wickham’s striae; middle-aged to older, female predominance; variants (reticular/plaque/erythematous/erosive/papular/bullous); buccal mucosa + tongue + gingiva; asymptomatic → painful by variant.
• Differential diagnosis: Lichenoid drug reaction (drug history + resolution post-withdrawal); pemphigus (DIF “chicken-wire” IgG); leukoplakia (unilateral, homogeneous, not bilateral lacy).
• Relevant investigations: Biopsy with H&E + DIF (perilesional + Michel’s medium); IIF if pemphigus suspected; bloods (FBC, B12, folate, iron, hep C, ANA); medication review for lichenoid mimics; patch test if contact reaction suspected.
• Histopath presented? Y · Labs presented? Y
• Histopath: Band-like lymphocytic infiltrate confined to superficial CT · liquefaction degeneration of basal cells · no dysplasia · Wickham’s striae clinically · Civatte bodies.
• Labs: FBC, B12, folate, iron; ANA if Lupus overlap; anti-desmoglein if pemphigus; diabetes, thyroid, hepatitis C screen.
• Management: Topical CS (betamethasone 0.05% 2×/day); systemic for severe; lifelong surveillance for malignant transformation.

2. Lichenoid Drug Reaction · Tier 2

• Clinical features: Clinically/histologically identical to OLP; reticular/erosive/ulcerative; onset weeks-months after drug start (ACE-I, NSAIDs, antimalarials, β-blockers); may be unilateral/asymmetric; resolves on withdrawal.
• Differential diagnosis: OLP (no drug history, bilateral); lupus (DIF Lupus band test + serology); pemphigoid (DIF linear IgG/C3 at BMZ).
• Relevant investigations: Medication history with timeline; biopsy with H&E + DIF (perilesional — negative); withdrawal trial → resolution confirms; FBC if systemic monitoring.
• Histopath presented? Y · Labs presented? N
• Histopath: Band-like lymphocytic infiltrate identical to OLP · liquefaction degeneration basal · no dysplasia · DIF negative (like OLP).
• Management: Withdraw offending drug; topical CS for symptoms; lesions resolve weeks-months post-withdrawal.

3. Contact Lichenoid Reaction · Tier 2

• Clinical features: Localised to dental material contact (amalgam, gold, composite); unilateral, asymmetric; reticular/erythematous/erosive opposite restoration; burning/discomfort.
• Differential diagnosis: OLP (bilateral + no contact); contact stomatitis (acute presentation); dysplasia (induration, fixation, rapid growth).
• Relevant investigations: Biopsy with H&E + DIF (negative); patch testing for mercury and dental materials; replace restoration trial; clinical photographs.
• Histopath presented? Y · Labs presented? Y (Convention N · Lecture Y) ⚠ DISAGREEMENT: patch testing in lecture, not routine convention.
• Histopath: Band-like lymphocytic infiltrate (identical to OLP) · close proximity to dental material.
• Labs: Skin patch testing for mercury + dental materials.
• Management: Remove offending material (mercury commonest); biocompatible replacement; resolution follows removal.

4. Pemphigus Vulgaris · Tier 2

• Clinical features: Flaccid intraepithelial bullae → painful bleeding erosions; positive Nikolsky; oral often precedes skin; middle-aged; Ashkenazi/Mediterranean/Asian descent; female predominance.
• Differential diagnosis: Mucous membrane pemphigoid (tense subepithelial bullae); paraneoplastic pemphigus (lymphoproliferative context); erythema multiforme (target lesions, HSV trigger).
• Relevant investigations: Biopsy with H&E (suprabasal acantholysis) + DIF (intercellular IgG + C3 chicken-wire); IIF for circulating anti-desmoglein 3 (± 1); FBC, U&E, LFTs pre-immunosuppression.
• Histopath presented? Y · Labs presented? Y
• Histopath: Acantholysis · intraepithelial blistering · “tombstone” basal layer intact · no band-like infiltrate.
• Labs: DIF intercellular IgG + C3 chicken-wire; IIF anti-desmoglein 3 (± 1) pathognomonic.
• Management: Systemic CS + steroid-sparing (azathioprine, mycophenolate, rituximab); urgent dermatology/oral medicine referral.

5. Mucous Membrane Pemphigoid · Tier 2

• Clinical features: Tense subepithelial bullae rupturing to painful erosions; desquamative gingivitis common; ocular involvement (25% risk blindness); older female; chronic relapsing.
• Differential diagnosis: Pemphigus vulgaris (intra- vs sub-epithelial split; intercellular vs linear DIF); linear IgA (linear IgA vs IgG); erosive OLP (DIF negative, bilateral reticular).
• Relevant investigations: Biopsy with H&E (subepithelial split, basal layer intact) + DIF (linear IgG + C3 along BMZ); IIF anti-BP180/BP230; ophthalmology referral; FBC, U&E, LFTs.
• Histopath presented? Y · Labs presented? Y
• Histopath: Subepithelial blister · intact basal epithelium · band-like lymphocytic CT infiltrate · can mimic OLP on H&E alone.
• Labs: DIF linear IgG + C3 along BMZ; IIF + anti-BP180/BP230.
• Management: Topical CS mild; systemic CS + steroid-sparing (dapsone, mycophenolate) for moderate-severe; ophthalmology mandatory.

Top LOs (verbatim):

• “Explain the aetiology, pathogenesis, clinical and histopathologic features, and the diagnosis and treatment of Lichen planus.”
• “Describe the mechanisms involved in immunologically-mediated oral mucosal diseases, specifically the Type 1 (Th1) cell-mediated immune response.”
• “Discuss the differential diagnosis of allergic contact stomatitis (contact lichenoid reactions) and allergic mucosal reactions to systemic drug administration (lichenoid drug reactions).”

Mock-exam / past-year flags: OLP = Tier 1 ▶ OM 2 (primary diagnosis: recurrent ulceration + oral burning + bilateral white striations + secondary candidiasis in diabetic patient). DIRECT MOCK HIT.

L8 L8 Allergies and Immune disease II

Source: L8 Allergies and Immune disease II

1. Pemphigus Vulgaris · Tier 1

• Clinical features: Flaccid bullae → painful erosions; positive Nikolsky; oral preceding skin; middle-aged; Ashkenazi/Mediterranean/Asian; female predominance.
• Differential diagnosis: MMP (sub- vs intra-epithelial; tense vs flaccid); EM (target lesions + HSV trigger); paraneoplastic pemphigus (lymphoproliferative).
• Relevant investigations: Biopsy + DIF (intercellular IgG + C3 chicken-wire); IIF anti-desmoglein 3 (± 1); FBC + U&E + LFTs pre-immunosuppression.
• Histopath presented? Y · Labs presented? Y
• Histopath: Suprabasal acantholysis · acantholytic cells · basal “tombstone” intact · mixed inflammatory intraepithelial infiltrate · DIF intercellular IgG + C3.
• Labs: DIF + IIF + anti-desmoglein 3 (± 1).
• Management: High-dose systemic CS + steroid-sparing (azathioprine, dapsone, mycophenolate) or rituximab.

2. Mucous Membrane Pemphigoid · Tier 1

• Clinical features: Tense subepithelial bullae → erosions; desquamative gingivitis; ocular in 20% (blindness risk); 5th-6th decade female; can be drug-induced (furosemide, NSAIDs).
• Differential diagnosis: Pemphigus (intercellular IgG); linear IgA (IgA pattern, drug-trigger context); EM (target lesions).
• Relevant investigations: Biopsy + DIF (linear IgG + C3 at BMZ); IIF anti-BP180/BP230; ophthalmology referral; baseline FBC, U&E.
• Histopath presented? Y · Labs presented? Y
• Histopath: Subepithelial split with intact basal · BMZ separation · inflammatory infiltrate (lymphocytes, plasma cells) · linear IgG + C3 DIF.
• Labs: DIF linear IgG + C3; IIF + anti-BP180/BP230.
• Management: Topical/systemic CS + steroid-sparing (cyclophosphamide, rituximab) for severe; ophthalmology mandatory.

3. Recurrent Aphthous Stomatitis · Tier 1

• Clinical features: Minor (1-6 ulcers, 2-5 mm, heal 2 wk, non-keratinised); major (>5 mm, deeper, 1-month healing); herpetiform (clustered, 2 wk); painful halo of erythema; prodromal burning; idiopathic + genetic + stress/trauma/nutritional triggers.
• Differential diagnosis: HSV (vesicles + systemic prodrome + culture +); Behcet’s (oral + genital + ocular + skin); nutritional (associated glossitis + angular cheilitis).
• Relevant investigations: Biopsy if atypical/persistent (ulceration + lymphohistiocytic); FBC + folate + B12 + iron + zinc; coeliac serology; HSV culture; HLA-B51 if Behcet’s.
• Histopath presented? Y · Labs presented? N
• Histopath: Ulceration · loss of epithelium · lymphocytic infiltrate (CD8+ T-cells, NK, macrophages, mast cells) · non-specific dx clinical.
• Management: Remove predisposing factors (deficiency, trauma); topical CS, tetracycline; systemic immunomodulators (azathioprine, dapsone, colchicine) for severe.

4. Linear IgA Disease · Tier 2

• Clinical features: Skin urticarial/annular/targetoid; “jewel-like” clusters; oral erosive (after bullae rupture); painful linear pattern; drug-induced (vancomycin, NSAIDs, diclofenac) or chronic autoimmune.
• Differential diagnosis: MMP (IgG vs IgA pattern); dermatitis herpetiformis (coeliac + granular IgA); pemphigus (intercellular IgG).
• Relevant investigations: Biopsy + DIF (linear IgA at BMZ, “n-serrated”); IIF anti-BP180; FBC, U&E pre-systemic therapy.
• Histopath presented? Y · Labs presented? Y
• Histopath: Subepithelial separation at BMZ · clefts with eosinophils + polymorphs · DIF linear IgA pathognomonic.
• Labs: DIF linear IgA; IIF + anti-BP180.
• Management: Topical/systemic CS; dapsone or cyclosporine for refractory.

5. Erythema Multiforme · Tier 1

• Clinical features: Acute target skin lesions (3 zones); oral painful ulceration on lips + serosanguinous “haemorrhagic crust” on lips; 20-40 y, male > female; prodromal fever; HSV trigger (60-90%), drugs (NSAIDs, anticonvulsants), vaccines.
• Differential diagnosis: SJS/TEN (>10% BSA, severe mucous membrane involvement); pemphigus (flaccid bullae, intercellular IgG); HSV stomatitis (vesicles + viral culture, lacks target lesions).
• Relevant investigations: Biopsy + DIF (typically negative or fibrin at BMZ); HSV serology/PCR (recurrent cases); skin biopsy from target lesion; medication/trigger history.
• Histopath presented? Y · Labs presented? N
• Histopath: Epithelial hyperplasia + spongiosis · vesicles at epithelium-CT interface · apoptosis basal/suprabasal cells · lymphocytic/macrophage CT infiltrate · DIF negative (distinguishes from pemphigoid/pemphigus).
• Management: Eliminate trigger; topical CS; systemic CS severe; hospitalisation for SJS/TEN; prophylactic aciclovir for HSV-recurrent.

Top LOs (verbatim):

• “Evaluate the diagnosis and treatment of Pemphigus vulgaris.”
• “Evaluate the diagnosis and treatment of Mucous membrane pemphigoid.”
• “Evaluate the diagnosis and treatment of Erythema multiforme.”

Mock-exam / past-year flags: No direct mock — Tier 1 autoimmune blistering highly likely OSCE.

L9 L9 Benign Epithelial Pathosis

Source: L9 Benign Epithelial Pathosis · [previously omitted from master — added 2026-05-15 after tutorial review]

1. Leukoplakia (definition) · Tier 2

• Clinical features: White patch that cannot be rubbed off or characterised as any other disease (diagnosis of exclusion); homogeneous (uniform, flat, low-risk) vs non-homogeneous (verrucous, nodular, speckled, higher-risk); tobacco/alcohol users >40 y; usually asymptomatic; symptoms suggest dysplasia/SCC; lateral tongue + FOM + soft palate complex high-risk sites.
• Differential diagnosis: Frictional keratosis (resolves with trauma removal; no dysplasia); leukoedema (fades on stretching, symmetric); chronic hyperplastic candidiasis (PAS+ hyphae on biopsy); OLP (Wickham striae, reticular, bilateral).
• Relevant investigations: Trauma source removal + 2-week recheck (rules out frictional keratosis); incisional/excisional biopsy of persistent lesion (margin sampling, NOT necrotic centre); multi-site biopsy if large/multifocal; risk stratification (tobacco, alcohol, lesion morphology).
• Histopath presented? Y · Labs presented? N
• Histopath: Hyperkeratosis + acanthosis · variable dysplasia (mild/moderate/severe) · band-like lymphocytic infiltrate in non-homogeneous · dysplasia presence EXCLUDES frictional keratosis diagnosis.
• Management: Diagnosis of exclusion; biopsy all persistent; severe dysplasia → excision; surveillance 3-mo → 6-mo → 1-yearly after 5 y stable; smoking/alcohol cessation.

2. Nicotinic Stomatitis (Smoker’s Palate) · Tier 2

• Clinical features: Hard palate whitening + erythematous papules with central red dots (inflamed minor salivary duct orifices); chronic heat + chemical irritation from cigarette/cigar/pipe; reverse smoking causes more severe variant; usually asymptomatic; bilateral symmetric.
• Differential diagnosis: Candidiasis (wipes off, PAS+); OLP (Wickham striae, bilateral but typically not palate-only); leukoplakia (no central red dots); papillary hyperplasia (cobblestone, denture-related).
• Relevant investigations: Smoking history (type, duration, frequency); clinical exam for red dot pattern; biopsy only if persistent after 6-mo cessation or atypical features; smear/swab for candidiasis exclusion if suspected.
• Histopath presented? Y · Labs presented? N
• Histopath: Metaplastic squamous changes · inflamed minor salivary duct orifices (cardinal feature, NOT ulcers) · hyperkeratosis · chronic inflammation in connective tissue · absence of dysplasia (in classical form).
• Management: Smoking cessation → reversal expected within ~6 months; monitor with photo documentation; biopsy if persistent post-cessation; reverse smokers high-risk → biopsy threshold lower (oral cancer risk).

3. Chronic Hyperplastic Candidiasis (vs Leukoplakia distinction) · Tier 1 · ▶ OM 2 (2°)

• Clinical features: Bilateral anterior buccal commissures; rough non-homogeneous white patches that CANNOT be wiped off (distinguishes from pseudomembranous); denture wear + corticosteroid + antibiotic + HIV/immunosuppression + diabetes risk factors; biopsy mandatory to rule out underlying dysplasia.
• Differential diagnosis: Leukoplakia (CHC has PAS+ hyphae; leukoplakia does not); OLP (Wickham striae); pseudomembranous candidiasis (wipes off easily).
• Relevant investigations: Smear (active hyphae = active infection — superior to swab; swab only confirms 50% population carrier status); PAS biopsy; Sabouraud culture + germ tube; FBC + iron + B12 + folate + fasting glucose (systemic screen — “candidiasis is a disease of the diseased”).
• Histopath presented? Y · Labs presented? Y
• Histopath: Parakeratosis with nuclei in stratum corneum · hyperplastic epithelium · Candida hyphae invade upper layers · PAS+ hyphae · inflammatory infiltrate in lamina propria.
• Management: Amphotericin lozenges preferred (sugar-free, longer mucosal contact, saliva-stimulating, no warfarin interaction); duration ≥3 weeks (7-14 days insufficient); miconazole alternative but warfarin/statin interactions; address systemic predisposing factors (iron deficiency in fit male = urgent GI malignancy workup).

4. Drug-Induced Melanosis (Doxorubicin/Caelyx) · Tier 3

• Clinical features: Diffuse brown-grey mucosal pigmentation; chemotherapy patient (esp. doxorubicin/Caelyx for ovarian/breast cancer); benign in isolation but indicates cytotoxic exposure → ↑ oral SCC risk; bilateral.
• Differential diagnosis: Smoker’s melanosis (smoking history); racial pigmentation (since childhood); Addison’s (systemic + sun-exposed sites); Peutz-Jeghers (lip + GI polyps).
• Relevant investigations: Medication reconciliation (doxorubicin, antimalarials, minocycline, oral contraceptives, AZT); platelet count pre-biopsy (cytotoxics → thrombocytopenia); biopsy only if atypical.
• Histopath presented? Y · Labs presented? Y
• Histopath: ↑ basal melanin · incontinent melanin in superficial CT · melanophages in lamina propria.
• Labs: Platelet count + LFTs pre-biopsy if cytotoxic exposure.
• Management: Reassurance + photo documentation; cytotoxic patients = ↑ SCC risk → regular oral cancer screening; report any new red/white/ulcerated lesions urgently.

Top LOs (verbatim):

• “Discuss the aetiology, pathogenesis, clinical and histopathologic features and management of leukoplakia.”
• “Distinguish frictional keratosis from leukoplakia histologically by absence of dysplasia.”
• “Discuss the aetiology, pathogenesis, clinical features and management of nicotinic stomatitis.”
• “Distinguish chronic hyperplastic candidosis from leukoplakia via PAS staining + biopsy.”

Mock-exam / past-year flags: CHC ▶ OM 2 (secondary infection); leukoplakia/nicotinic stomatitis = foundational DDx for OPMD cases. Linked to mock cases 1, 2, 5.

L10 L10 OPMDs and Oral Cancer

Source: L10 OPMDs and Oral Cancer

1. Squamous Cell Carcinoma · Tier 1 · MOCK Case 1

• Clinical features: Non-healing ulcer ± swelling + surrounding keratosis/erythema; friable; high-risk sites (lateral tongue, FOM, ventral tongue, soft palate); male >55 y; tobacco/alcohol; asymptomatic until late; red flags = induration, fixation, non-healing >2 wk.
• Differential diagnosis: Traumatic ulcer (SCC has induration + fixation); candidiasis (wipes off, PAS+); leukoplakia/erythroplakia (SCC shows invasion on biopsy vs dysplasia only).
• Relevant investigations: Clinical exam + photography; incisional/excisional biopsy (gold standard); OPG/CBCT/CT/MRI for staging; PET for distant metastases; cervical node assessment; HPV/p16 status if oropharyngeal.
• Histopath presented? Y · Labs presented? N
• Histopath: Invasive tumour islands/isolated cells in CT · keratin pearl formation · nuclear hyperchromatism + pleomorphism · ↑ N/C ratio · abnormal mitoses · muscle + bone destruction (T4).
• Management: TNM-driven surgery ± neck dissection ± RT; follow-up 2-mo Y1-2, 6-mo Y3-5, annually thereafter.

2. Epithelial Dysplasia · Tier 1

• Clinical features: White/red/mixed patch; persistent; often incidental; tobacco/alcohol users; ↑ age; red flags (induration, non-blanching erythema, ulceration, rapid change).
• Differential diagnosis: Frictional keratosis (fades post-irritant removal); candidiasis (PAS+, antifungal-responsive); traumatic lesion (no mechanical cause, persists).
• Relevant investigations: Incisional biopsy (mandatory) + serial if chronic; full oral exam + photography baseline; CBCT/CT if invasion suspected; document tobacco/alcohol risk factors.
• Histopath presented? Y · Labs presented? N
• Histopath: Disordered architecture · nuclear pleomorphism + hyperchromatism · ↑ N/C ratio · abnormal mitoses · grades mild/moderate/severe (CIS).
• Management: Mild = monitor; moderate = close follow-up; severe = urgent excision; tobacco/alcohol cessation for all.

3. Leukoplakia · Tier 1

• Clinical features: White patch/plaque cannot rub off; homogeneous (uniform, flat) or non-homogeneous (nodular/verrucous/speckled); high-risk sites; tobacco/alcohol users >40 y; usually asymptomatic; symptoms suggest dysplasia/SCC; lacks response to stretch test.
• Differential diagnosis: Frictional keratosis (disappears post-trauma); leukoedema (fades on stretching); candidiasis (rubs off, antifungal-responsive).
• Relevant investigations: Incisional/excisional biopsy (diagnosis of exclusion); clinical exam + photo + stretch test; OPG if bone involvement; risk stratification (tobacco/alcohol, lesion morphology).
• Histopath presented? Y · Labs presented? N
• Histopath: Homogeneous: hyperkeratosis + acanthosis + ± lymphocytes · non-homogeneous: verrucous hyperplasia + bulbous rete + dysplasia (mild-severe) · erythroleukoplakia: atrophy + bulbous rete + dysplasia.
• Management: Diagnosis of exclusion; biopsy all persistent; PVL has ~45% transformation.

4. Erythroplakia · Tier 1

• Clinical features: Fiery red velvety patch; flat initially; may be indurated; ventral tongue/FOM/soft palate; tobacco/alcohol; higher malignancy risk than leukoplakia; often asymptomatic.
• Differential diagnosis: Erythematous candidiasis (PAS+, non-indurated, antifungal-responsive); erosive OLP (bilateral + Wickham’s striae); traumatic ulcer (mechanical cause).
• Relevant investigations: Incisional/excisional biopsy mandatory (highest dysplasia risk); clinical exam + photography (assess ulceration + induration); OPG/CBCT if invasion suspected; cervical node palpation/imaging if SCC.
• Histopath presented? Y · Labs presented? N
• Histopath: Minimal keratosis · atrophy or bulbous rete · moderate-severe dysplasia or CIS · band-like lymphocytes · 90% show severe dysplasia/CIS.
• Management: Highest OPMD risk; mandatory biopsy; FOM/ventral tongue high-risk; TNM if cancer.

5. Actinic Cheilitis · Tier 2 · MOCK Case 5

• Clinical features: Lower lip vermilion (>upper); blurred/effaced vermilion border; dry scaly + white/grey patches ± erythema; sun-exposed outdoor workers, elderly males; concerning signs = crusting, ulceration, induration.
• Differential diagnosis: Exfoliative cheilitis (inflammatory, reversible); herpes labialis (vesicular history, periodic); SCC/CIS (induration + rapid change → biopsy).
• Relevant investigations: Clinical exam + photography baseline; biopsy if ulcerated/indurated/severe dysplasia suspected; sun exposure history + SPF counsel; TNM only if SCC confirmed.
• Histopath presented? Y · Labs presented? N
• Histopath: Solar elastosis (hallmark) · variable dysplasia (mild-severe) · chronic lymphocytic inflammation · epithelial atrophy or hyperkeratosis · may show CIS.
• Management: Sun protection (SPF lip balm); topical 5-FU/imiquimod; cryotherapy/laser/PDT/vermilionectomy extensive; monitor for SCC.

Top LOs (verbatim):

• “Describe the histopathologic progression from normal mucosal variations to epithelial dysplasia and invasive squamous cell carcinoma.”
• “Identify clinical features of OPMDs and squamous cell carcinoma, such as non-healing ulcers, induration, and color changes (leukoplakia/erythroplakia).”
• “Discuss the aetiology and pathogenesis of oral cancer, including traditional risks like tobacco and heat, and emerging trends in non-traditional cohorts.”

Mock-exam / past-year flags: SCC = Tier 1 MOCK Case 1; actinic cheilitis = Tier 1 MOCK Case 5.

L11 L11 OPMDs and Oral Cancer II

Source: L11 OPMDs and Oral Cancer II

1. Actinic Cheilitis · Tier 1 · MOCK Case 5

• Clinical features: Lower lip vermilion; blurred/effaced border; dry scaly + white/grey patches ± erythema; crusting + ulceration advanced; induration concerning; chronic UV exposure (elderly males predominant).
• Differential diagnosis: Oral leukoplakia (lower lip vermilion + UV history distinguish); SCC (more indurated, fixed, bleeding); candidiasis (rubs off, antifungal-responsive).
• Relevant investigations: Incisional/excisional biopsy (gold-standard for dysplasia grading); dermoscopy/Wood’s lamp; sun damage assessment; consider full-thickness lip assessment if extensive.
• Histopath presented? Y · Labs presented? N
• Histopath: Solar elastosis (hallmark) · variable dysplasia · hyperkeratosis · chronic dermal inflammation · epithelial atrophy.
• Management: Sun protection (SPF 30+); topical 5-FU/imiquimod; cryotherapy/laser/PDT; vermilionectomy extensive/refractory.

2. Oral Leukoplakia · Tier 1

• Clinical features: White patch cannot rub off; homogeneous (uniform, thin, smooth) lower-risk vs non-homogeneous (speckled, verrucous, nodular) higher-risk; FOM, ventral tongue, soft palate predilection; does not fade on stretching.
• Differential diagnosis: Candidiasis (rubs off, pseudomembrane, antifungal-responsive); leukoedema (fades on stretching, symmetric, benign); OLP (Wickham striae, reticular, bilateral).
• Relevant investigations: Incisional/excisional biopsy (mandatory); toluidine blue (adjunctive); brush biopsy alternative; optical adjuncts (VELscope); document tobacco/alcohol.
• Histopath presented? Y · Labs presented? N
• Histopath: Homogeneous: hyperkeratosis + acanthosis + minimal dysplasia · non-homogeneous: verrucous hyperplasia + bulbous rete + dysplasia mild-severe + band-like lymphocytes · erythroleukoplakia: atrophy + bulbous rete + dysplasia.
• Management: Smoking/alcohol cessation; eliminate irritants; biopsy all suspicious; high-risk sites → early specialist.

3. Oral Submucous Fibrosis · Tier 2

• Clinical features: Pale marble-like keratotic areas on buccal/soft palate/tongue; fibrotic bands palpable; blanching; severe trismus + bilateral; burning sensation; areca nut/betel quid/gutka history; rapid with gutka.
• Differential diagnosis: Systemic sclerosis (generalised + Raynaud’s + digital ulcers); scar tissue (localised + no burning + no areca history); OLP (reticular + symmetric + Wickham’s).
• Relevant investigations: Incisional biopsy (mandatory); mouth opening measurement (trismus baseline); areca nut/gutka cessation counselling; long-term surveillance for transformation.
• Histopath presented? Y · Labs presented? N
• Histopath: ↑ collagen deposition + fibrosis lamina propria · hyalinised collagen (arecoline-induced) · ↓ vascularity · loss of elastic fibres · epithelial atrophy · juxta-epithelial hyalinisation.
• Management: Areca cessation (essential); pentoxifylline; intralesional steroids; physio/mouth-opening exercises; monitor for dysplasia.

4. Oral Lichen Planus · Tier 2

• Clinical features: Bilateral symmetrical; reticular Wickham’s striae most common + asymptomatic; erosive/atrophic painful + desquamative gingivitis; plaque mimics leukoplakia; buccal mucosa + gingiva + dorsum/lateral tongue.
• Differential diagnosis: Oral lichenoid lesion (localised to dental material, unilateral, no Wickham’s); leukoplakia (cannot rub off, asymmetric); pemphigoid (DIF linear IgG/C3 at BMZ).
• Relevant investigations: Incisional biopsy (mandatory AAOMP); DIF optional (fibrinogen at BMZ, not IgG/C3); exclude drug exposure; patch test if lichenoid suspected.
• Histopath presented? Y · Labs presented? Y (DIF + Lupus band)
• Histopath: Hyperkeratosis · basal cell degeneration “liquefactive” · band-like lymphocytic infiltrate · ulceration in atrophic/erosive · sawtooth rete · no neoplasia.
• Labs: DIF Lupus band test (fibrinogen/IgG at BMZ); biopsy recommended all suspected (AAOMP position).
• Management: Topical anti-inflammatory first-line (CS, tacrolimus); systemic for severe/refractory; manage comorbidities; address drug triggers; surveillance (erosive 1% transformation/10y).

5. Oral Lichenoid Lesions · Tier 2 · NEW WHO 2021

• Clinical features: Localised to dental material contact (amalgam/composite/gold/metal); unilateral asymmetric; white/erythematous/erosive; buccal + gingiva adjacent restoration; not bilateral/symmetric.
• Differential diagnosis: OLP (bilateral + Wickham’s + no contact); contact stomatitis (acute, resolves on removal); dysplasia (induration, fixation, rapid growth).
• Relevant investigations: Incisional biopsy (lichenoid infiltrate); patch testing for metal; material biocompatibility assessment; restoration removal/replacement; DIF (typically negative).
• Histopath presented? Y · Labs presented? Y (Convention N · Lecture Y) ⚠ DISAGREEMENT: patch testing in lecture, not routine.
• Histopath: Similar to OLP (band-like lymphocytes + basal degeneration) · localised to dental material contact · may show dysplasia · foreign-body giant cells/particles possible.
• Labs: Patch testing for metals; DIF typically negative (fibrinogen only).
• Management: Remove/replace causative material (gold-standard); topical CS; monitor for malignant transformation (lower risk than erosive OLP).

6. Oral Lupus Erythematosus · Tier 2

• Clinical features: Discoid red-purple macules/plaques; hyperkeratotic surface; sharply demarcated scalloped white borders + radiating striae; honeycomb appearance on hard palate; painful ulceration; female predominance; DLE alone or SLE (15-30% have DLE).
• Differential diagnosis: OLP (Wickham’s not scalloped radiating; symmetrical bilateral); SCC (indurated, fixed, rapid); pemphigoid (DIF linear IgG/C3 at BMZ).
• Relevant investigations: Incisional biopsy (basal vacuolar + band-like); DIF Lupus band test (fibrinogen ± IgG at BMZ; IgM at DEJ); ANA + anti-dsDNA + anti-SSA/Ro + anti-SSB/La + ESR + complement (SLE workup); rheumatology referral.
• Histopath presented? Y · Labs presented? Y
• Histopath: Acanthosis + atrophy · basal vacuolar degeneration · band-like + deep perivascular lymphocytes · sawtooth rete (less prominent than OLP) · painful ulceration · honeycomb palate.
• Labs: DIF Lupus band test +; SLE serology if systemic.
• Management: Immunosuppression (systemic CS, hydroxychloroquine, azathioprine, mycophenolate); topical CS; sun protection; rheumatology co-management.

Top LOs (verbatim):

• “Define and classify OPMDs according to the WHO 2020/2021 standards, distinguishing between established entities like leukoplakia and newly included conditions such as oral lichenoid lesions and graft versus host disease.”
• “Discuss the aetiology and pathogenesis of OPMDs by identifying major carcinogenic risk factors, including the synergistic effects of tobacco and alcohol, the role of areca nut in fibrosis, and the impact of high-risk HPV.”
• “Describe the clinical and histopathologic features of key OPMDs, such as the morphological variants of leukoplakia, the bilateral presentation of oral lichen planus, and the ‘honeycomb’ appearance of oral lupus erythematosus.”

Mock-exam / past-year flags: Actinic cheilitis = Tier 1 MOCK Case 5.

L12 L12 OPMDs Part IIIk

Source: L12 OPMDs Part IIIk

1. OSCC Histopathology & Microscopic Invasion · Tier 1 · MOCK Case 1

• Key features / when to use: Every confirmed cancer post-biopsy; T1-T4 margin + invasion depth; high-risk sites; differentiation grading affects prognosis; tumour islands + pleomorphism = aggressive.
• Alternatives / considerations: Well-differentiated SCC better prognosis but rarer; anaplastic = ↑ metastatic risk + worse 5-y survival; margin width ≥5 mm guides re-excision.
• Companion investigations / adjuncts: Clinical photo + measurements; CT/MRI for soft-tissue + bone invasion; PET-CT for distant mets staging; FNA ± US for cervical nodes (N staging); FBC + U&E + LFTs.
• Histopath presented? Y · Labs presented? N
• Histopath: Poorly differentiated SCC: irregular + disorganised · tumour islands invading CT + destroying muscle · nuclear pleomorphism · deep keratinisation + ↑ N/C ratio · abnormal mitoses.
• Management: Surgical resection (T + N) ± RT/chemo per TNM.

2. TNM Staging of Oral Cancer · Tier 1

• Key features / when to use: Every confirmed malignancy (mandatory for prognosis); after biopsy-proven SCC; determines surgical extent + adjuvant; establishes 5-y survival (Stage I >80% → Stage IV <15%).
• Alternatives / considerations: AJCC 8th edition (depth of invasion + HPV status) vs 7th; nomograms more nuanced; ctDNA emerging for monitoring.
• Companion investigations / adjuncts: CT/MRI for T + regional nodes; FNA + US for N+; PET-CT for M; cranial nerve exam (V3 = T4a); pre-treatment coagulation + oncology fitness.
• Histopath presented? N · Labs presented? N
• Management: T: Tis/T1 ≤2 cm / T2 >2-4 / T3 >4 / T4 invades adjacent; N: N0/N1 single ≤3 cm/N2a-c/N3 >6 cm; M0/M1; determines surgical margins, ND level (SOH vs radical), adjuvant.

3. Biopsy Protocol & Diagnostic Gold Standard · Tier 1

• Key features / when to use: Every persistent white/red patch (≥2 wk despite removal); suspicious lesion (induration, ulceration, ill-defined); high-risk sites; baseline for dysplasia grading + surveillance.
• Alternatives / considerations: Brush biopsy lower sensitivity; toluidine blue high false-positive; OCT emerging not standard.
• Companion investigations / adjuncts: Clinical photo + measurements; palpation + intraoral mapping; cervical US ± FNA if palpable nodes; CT/MRI if invasion; bloods if dysplasia/malignancy identified.
• Histopath presented? Y · Labs presented? N
• Histopath: Gold-standard for invasive islands + dysplasia · specimen documentation: visual + scale + margin marking · grades dysplasia mild/moderate/severe → progression risk.
• Management: Every persistent → incisional/excisional; if invasive → TNM staging.

4. Epithelial Dysplasia — Grading & Risk Stratification · Tier 2

• Key features / when to use: Every biopsy specimen; non-homogeneous/erythroplakic/high-risk site lesions; severity predicts transformation (mild 1%, moderate 5-10%, severe 40-50%); guides follow-up interval + treatment.
• Alternatives / considerations: WHO binary less informative than 3-grade; IHC (p53, Ki-67) emerging for borderline; e-cadherin loss predicts progression.
• Companion investigations / adjuncts: Photographic documentation; multiple samples for large lesions (field cancerisation); repeat biopsy if rapid growth; molecular testing (DNA ploidy, HPV) at specialist centres; serial clinical review.
• Histopath presented? Y · Labs presented? N
• Histopath: Disturbed differentiation + proliferation · disordered architecture + nuclear hyperchromatism · ↑ N/C ratio · severe = high-risk.
• Management: Severe = biopsy + close follow-up ± excision; moderate = clinical judgment + surveillance.

5. Surgical Margins & Neck Dissection Levels · Tier 2

• Key features / when to use: Every resectable T1-T4 (primary defect closure ± reconstruction); clear margin ≥5 mm for local control; <1 mm = close (re-excision consider); ND extent per N-status; guides adjuvant (positive/close margin = post-op RT ± chemo).
• Alternatives / considerations: Mohs not standard for intraoral SCC; neoadjuvant chemo to downstage T4 N2/3; selective ND (SOH) risk if high-risk features.
• Companion investigations / adjuncts: Pre-op CT/MRI for tumour + nodal mapping; FNA + US for N+; intra-op frozen section of margins; cranial nerve monitoring (V, VII, IX, X, XI); post-op imaging if high-grade.
• Histopath presented? N · Labs presented? N
• Management: T1-T2 N0: primary only; T3-T4 N0: + SOH ND ± RT; T1-T4 N1-N3: + SOH or radical modified ND ± post-op RT.

Top LOs (verbatim):

• “Identify the clinical and histopathologic features of oral squamous cell carcinoma (OSCC) and epithelial dysplasia, including high-risk anatomical sites and microscopic indicators of invasion.”
• “Describe the diagnosis of suspicious oral lesions through a systematic clinical assessment, differential diagnosis of white/red patches, and the ‘gold standard’ biopsy protocol.”
• “Explain the treatment and management of oral cancer based on TNM staging, including surgical and radiotherapy protocols and long-term post-treatment surveillance.”

Mock-exam / past-year flags: SCC = Tier 1 MOCK Case 1.

L13 L13 Dental Management of Oral Cancer Patients

Source: L13 Dental Management of Oral Cancer Patients

1. Radiation Mucositis · Tier 2

• Clinical features: Erythema → confluent ulceration during weeks 2-4 of RT; peaks ~3 weeks post-initiation; mucosa in irradiated field; opioid analgesia often required; PEG feeding if dysphagia severe; rapid progression; preventable with assessment.
• Differential diagnosis: Candidosis (pseudomembranous, antifungal-responsive, secondary to mucositis); HSV reactivation (vesicles preceding, immunosuppressed); traumatic ulceration/secondary infection.
• Relevant investigations: WHO mucositis grading (0-4); intraoral photo at each review; oral hygiene + plaque scoring; microbiological swab if secondary infection (Candida).
• Histopath presented? Y · Labs presented? N
• Histopath: Inflamed mucosa with ulceration · erythematous → confluent ulcers · acute mucosal damage (50-70 Gy) · may necessitate PEG if dysphagia.
• Management: Benzydamine; soft toothbrushes; moisturising paste (Oral 7); aggressive pain control; PEG if needed.

2. Osteoradionecrosis · Tier 1

• Clinical features: Exposed necrotic bone in irradiated jaw, persisting ≥8 wk; mandible predominant; often after extraction/infection/denture trauma; pain + drainage + ulceration; spontaneous or post-procedure; progressive bone resorption; severe cases pain + purulent + fracture risk.
• Differential diagnosis: MRONJ (bisphosphonate/denosumab history vs RT); osteomyelitis (infection + acute inflammation + culture +); dry socket (resolves weeks vs persistent >8 wk).
• Relevant investigations: OPG showing bone density changes + sequestration; CBCT for architecture + necrosis extent; intraoral exam documenting exposure; culture if purulent drainage.
• Histopath presented? Y · Labs presented? N
• Histopath: Ischaemic bone necrosis with no viable osteocytes · failure of healing · bacterial colonisation · fibrous marrow replacement + chronic inflammation.
• Management: Prevention via pre-RT clearance + alveolectomies; HBO 2-3 ATA 100% O₂; surgical + antibiotics if established.

3. Xerostomia & Salivary Gland Dysfunction · Tier 1

• Clinical features: Permanent at >30 Gy; thick ropey saliva then progressive ↓; dysgeusia (taste bud damage + no saliva); dental hypersensitivity + dysphagia + mastication difficulty; ↑ candidosis + accelerated caries; nutritional + GORD; ↓ QoL.
• Differential diagnosis: Sjögren (autoimmune serology + biopsy + no RT history); medication-induced (temporal drug correlation + normal gland imaging); secondary candidosis (antifungal-responsive).
• Relevant investigations: Sialometry (unstim + stim, <0.3 mL/min unstim = hyposalivation); Challacombe Scale; oral exam (erythema, candidosis, caries); MRI/US glands if structural pathology.
• Histopath presented? N · Labs presented? Y
• Labs: Sialometry results; oral pH (acidic → caries); ↓ protective proteins (IgA, lysozyme, amylase).
• Management: Saliva substitutes (Biotene, OralSeven, GC Dry Mouth Gel); xylitol gum/lozenges (avoid acidic sugar-free); pilocarpine; electrostimulation (GenNarino); 5000 ppm fluoride.

4. Radiation-Induced Caries · Tier 1

• Clinical features: Rapid-onset caries secondary to salivary loss; smooth-surface + cervical lesions; can affect all dentition within 1 yr if untreated; dysgeusia + altered diet (high-sugar supplements); advanced = cavitated coronal destruction.
• Differential diagnosis: Non-radiation caries (no RT history, normal salivary flow); erosion (acidic substances, wear pattern); secondary candidosis (concurrent antifungal needed).
• Relevant investigations: Bitewings + PAs (interproximal + smooth-surface + cervical); sialometry to confirm xerostomia; dietary assessment (high-sugar, acidic frequency); intraoral photo documenting extent/progression.
• Histopath presented? Y · Labs presented? N
• Histopath: Rapid caries secondary to salivary loss · cervical + smooth-surface lesions · preventable with education/compliance.
• Management: Prevention: 5000 ppm F daily; strict sugar avoidance; 3-6-mo dental visits; GIC over amalgam; aggressive preventive; avoid extractions to preserve bone integrity.

5. Trismus · Tier 2

• Clinical features: Myofibrotic contracture of masticatory muscles (masseter, pterygoid, TMJ) from RT fibrosis; progressive restricted opening; weeks-months post-RT or insidious over years; impairs mastication + hygiene + dental access; may coexist with other late complications; ↓ QoL.
• Differential diagnosis: TMJ internal derangement (clicking + MRI disc displacement); MPD (pain-limited + trigger points + physio-responsive); radiation fibrosis vs surgical scar (field mapping + surgical history).
• Relevant investigations: Bite/opening measurement in mm (serial); MRI TMJ + masticatory muscles if structural pathology suspected; palpation for fibrosis + tenderness; functional assessment (3 fingers interincisally).
• Histopath presented? N · Labs presented? N
• Management: Preventive jaw-opening exercises (20 reps × 3/day) starting immediately post-RT + continuing indefinitely; physio + massage; gradual progressive stretching + custom stents; surgical release/Z-plasty for severe refractory.

6. Pre-Radiation Dental Work-Up · Tier 1

• Clinical features: Initial assessment phase pre-RT; comprehensive dental exam + radiographs; identify teeth in high-dose field; extract non-restorable + periapical + periodontal + impacted + non-functional teeth; patient education re: complications + lifestyle + long-term dental commitment.
• Differential diagnosis: Preventive extraction vs conservative treatment (tumour prognosis + field dose + compliance + dental prognosis); teeth near field boundary (intermediate risk); pre- vs post-RT extractions (ORN risk emphasises pre-treatment).
• Relevant investigations: OPG comprehensive baseline; PAs for periapical + bone level; radiation field/dose from oncology (teeth >30 Gy stricter); dietary counselling + social/occupational history + dental awareness assessment; establish proposed fields with oncology.
• Histopath presented? N · Labs presented? N
• Management: Extractions 7-10 days before RT (allows primary healing); alveolectomy for smooth ridge; soft-tissue closure to bury sites; oral hygiene + diet + fluoride pre-RT; 5 mm EVA stents to prevent backscatter near metals; follow-up during RT for acute complications.

Top LOs (verbatim):

• “Identify the clinical features of acute and chronic radiation-induced adverse effects, such as radiation mucositis, salivary gland dysfunction, and osteoradionecrosis.”
• “Describe the dental diagnosis and management protocols required for a pre-radiation therapy work-up, including the specific criteria for pre-treatment extractions.”
• “Explain the long-term treatment and preventive strategies for managing post-radiation complications, focusing on radiation caries, trismus exercises, and salivary stimulants.”

Mock-exam / past-year flags: Indirectly via Case 1 (SCC follow-up) + Case 3 (mets management).

L14 L14 Soft Tissue Tumors

Source: L14 Soft Tissue Tumors

1. Pyogenic Granuloma · Tier 2

• Clinical features: Soft painless red-purple gingival lesion; bleeds easily; common gingiva (extraoral too); rapid growth; wide age range; pregnancy/trauma/chronic irritation; sessile or pedunculated.
• Differential diagnosis: Hemangioma (blanches on diascopy); peripheral giant cell granuloma (more bluish, gingival, central giant cells); Kaposi’s sarcoma (HHV8 + immunosuppression).
• Relevant investigations: Excisional biopsy (diagnostic gold-standard); histopath (lobular capillary hemangioma pattern); diascopy blanching test; clinical assessment for vascular response.
• Histopath presented? Y · Labs presented? N
• Histopath: Highly vascularised granulation tissue · surface ulceration + subacute infiltrate · lobular capillary hemangioma pattern · brisk mitoses (up to 10/HPF) without pleomorphism · often pedunculated.
• Management: Surgical excision + curettage + removal of causative agent (15.8% recurrence if irritants retained).

2. Inflammatory Papillary Hyperplasia · Tier 2 (combined)

• Clinical features: FEP: smooth round 1-2 cm nodule, labial/tongue/palate; fibrous epulis: pink gingival nodule (inflamed gingiva); denture hyperplasia: sessile/pedunculated under denture (vestibular sulcus); IPH: 2 mm nodules cobblestone hard palate (Candida-associated).
• Differential diagnosis: FEP vs fibroma (histopath); denture hyperplasia = epulis fissuratum (same entity); IPH vs candidiasis (histology + culture).
• Relevant investigations: Excisional biopsy (gold-standard); histopathological exam; Candida culture for IPH; remove causative irritant before dx confirmation.
• Histopath presented? Y · Labs presented? N
• Histopath: FEP: nonencapsulated fibrous CT + collagen + fibroblasts + vessels + chronic inflammation · epulis: mature fibrous tissue + dystrophic calcification · denture hyperplasia: epithelial hyperplasia + pseudo-epitheliomatous · IPH: papillary projections + stratified squamous + chronic inflammation + Candida.
• Management: Surgical excision + remove irritants (sharp tooth, ill-fitting denture); antifungal + denture hygiene for IPH; new well-fitting dentures.

3. Schwannoma · Tier 2 (NF-1/NF-2)

• Clinical features: Neurofibroma: submucosal nontender mass, tongue/buccal/vestibule, posterior mandible intraosseously, blends with normal tissue, NF-1 systemic (café-au-lait + axillary freckling + Lisch nodules + dermal NFs); Schwannoma: solitary encapsulated mass, painless, NF-2 (bilateral vestibular VIII + meningiomas + hearing loss).
• Differential diagnosis: Neurofibroma vs schwannoma (encapsulation differs, histology definitive); solitary vs NF-1-associated (systemic features); NF-2 presentation: bilateral schwannomas pathognomonic.
• Relevant investigations: Histopath (gold-standard); MRI for intraosseous/deep + bone expansion + skeletal features; NF-1 criteria (≥2 of: family history, ≥6 café-au-lait, freckling, ≥2 NFs, ≥2 Lisch nodules, optic glioma, osseous lesion); surveillance for MPNST (NF-1 1000-fold risk).
• Histopath presented? Y · Labs presented? N
• Histopath: Neurofibroma: unencapsulated · Schwann cell proliferation + wavy nuclei + collagen in myxoid + perineurial cells + mast cells · Schwannoma: encapsulated · Antoni A (palisaded around Verocay bodies) + Antoni B (myxoid).
• Management: Solitary NF: excision (5% recurrence if incomplete); NF-1 dermal NFs: surgical/laser/electrodesiccation; plexiform NFs: pain mgmt + excision + mTOR/imatinib/MEK inhibitors trials; Schwannoma: complete resection curative.

4. Hemangioma · Tier 2

• Clinical features: True neoplasm (endothelial proliferation); infantile (shortly after birth, 60% head/neck, well-demarcated red); smooth reddish/purple, sessile/polypoid/pedunculated; blanches on pressure; female predominance; proliferative phase 9-12 mo → involution over years.
• Differential diagnosis: Vascular malformation (does not involute); pyogenic granuloma (gingival, rapid, trauma history); port wine stain (no complete blanching, at birth).
• Relevant investigations: History of rapid growth → stabilisation/involution (diagnostic); diascopy (blanching); biopsy NOT indicated (bleeding risk); MRI/angiography if extent assessment needed; IHC for endothelial phenotype.
• Histopath presented? Y · Labs presented? N
• Histopath: Capillary: multilobular endothelial cell proliferation + pericytes · cavernous: large dilated vascular spaces lined by endothelium · rapid growth phase ↑ VEGF + FGF + IGF + MMP-9.
• Management: Observation (self-involute by age 9); laser therapy for specific locations; corticosteroids pharmacotherapy; AVOID biopsy.

5. Kaposi’s Sarcoma · Tier 3

• Clinical features: Angioproliferative malignant endothelial neoplasm; HHV8-driven, aggressive in immunosuppression/AIDS; oral in 70% of cutaneous AIDS-KS; hard palate most common, then gingiva + tongue; red-purple macules/patches → nodules; advanced: haemorrhage + pain + ulceration + bone infiltration.
• Differential diagnosis: Hemangioma (benign, no immunosuppression, blanches); pyogenic granuloma (reactive, single, gingival/trauma); other vascular lesions (HHV8 + immunosuppression status differentiate).
• Relevant investigations: HIV serology + CD4; HHV8 serology + tissue identification; histopath + IHC (HHV8); staging CT/MRI; excisional/incisional biopsy for definitive dx.
• Histopath presented? Y · Labs presented? Y (Convention emphasises HHV8 serology; lecture: tissue ID primary) ⚠ DISAGREEMENT
• Histopath: Early “patch”: small jagged endothelial-lined spaces + slit-like vessels dissecting collagen + extravasated RBCs/lymphocytes · advanced: spindle cells + hyaline globules + ↑ mitoses.
• Labs: HHV8 in peripheral blood + lesional tissue; HIV mandatory.
• Management: Local excision; RT; chemo; immunosuppression adjustment; HAART in AIDS; mortality 20-25% advanced; prognosis tied to immune status.

Top LOs (verbatim):

• “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of pyogenic granulomas, highly vascularized proliferations of granulation tissue that bleed easily and are often associated with pregnancy or trauma.”
• “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of neurilemomas (Schwannomas), focusing on their encapsulated Antoni A/B histologic patterns and their specific association with Neurofibromatosis Type 2 (NF-2).”
• “Describe the aetiology, pathogenesis, clinical and histopathologic features, diagnosis, and treatment of Kaposi’s sarcoma, an angioproliferative malignancy driven by Human Herpesvirus 8 (HHV8) that is highly aggressive in immunosuppressed or AIDS patients.”

Mock-exam / past-year flags: Tier 2-3 — reactive vs neoplastic differentiation.

L15 L15 Non neoplastic and neoplastic salivary gland diseases

Source: L15 Non neoplastic and neoplastic salivary gland diseases

1. Sjögren Syndrome · Tier 1

• Clinical features: Keratoconjunctivitis sicca + xerostomia + parotid swelling (1/3); middle-aged females 9:1; secondary form with RA/SLE; fatigue (80%) + arthralgia (60-70%) + cutaneous vasculitis (10%); 5% develop B-cell lymphoma.
• Differential diagnosis: Sialadenosis (non-inflammatory bilateral, painless, metabolic aetiology); sialadenitis (acute infection, purulent, painful gland); Sjögren mimics (GVHD, IgG4-related disease).
• Relevant investigations: Schirmer test ≤5 mm/5 min; unstimulated saliva ≤0.1 mL/min; anti-SSA/Ro (wt 3); anti-SSB/La + RF + ANA; minor salivary biopsy with focus score ≥1/4 mm²; ocular staining ≥5; ACR/EULAR 2016 classification.
• Histopath presented? Y · Labs presented? Y
• Histopath: Focal lymphocytic sialadenitis (hallmark) · focus score ≥1 foci/4 mm² (aggregate ≥50 lymphocytes) · acinar destruction + fibrosis · lymphoid infiltrate with germinal centres.
• Labs: Anti-SSA/Ro, anti-SSB/La, RF, ANA, ESR, hypocomplementaemia, monoclonal gammopathy.
• Management: Symptom mgmt + saliva stimulants; strict caries prevention; lymphoma surveillance (MALT 5-10%).

2. Pleomorphic Adenoma · Tier 1

• Clinical features: Slow-growing painless parotid mass (most common site); mobile or fixed; 3rd-6th decades; female 2:1; may remain undiagnosed for years; rapid enlargement = malignant transformation warning (7% progress to carcinoma ex PA).
• Differential diagnosis: Warthin’s (bilateral/multifocal 5-10%, smoking 4-8× risk, older males); mucoepidermoid carcinoma (younger, more aggressive); other benign (oncocytoma, lipoma).
• Relevant investigations: US/CT/MRI for size + location + extension; FNA or small incisional biopsies (may not be representative); clinical exam (mobility, skin fixation, nerve involvement).
• Histopath presented? Y · Labs presented? N
• Histopath: Mixed epithelial + myoepithelial · myxoid/chondroid/hyalinised stroma · metaplasia (adipose, osseous, squamous, sebaceous) · bosselated surface with pseudopods · intravascular permeation (does not ↑ recurrence).
• Management: Complete surgical excision with clear margins (incomplete encapsulation/extracapsular extension/rupture ↑ recurrence); excellent prognosis; monitor transformation.

3. Adenoid Cystic Carcinoma · Tier 2

• Clinical features: Hard mass with slow relentless growth; perineural invasion → numbness + paraesthesia + pain + facial/tongue weakness (classic neuro signs); >30% in minor glands; >50% distant mets (lungs, bone, liver, brain); median age 57; female 1.5:1.
• Differential diagnosis: PA (benign, slow without neuro symptoms, lacks perineural); MEC (cribriform vs mucin-cyst, lower mets, better prognosis); other minor salivary tumours (PLGA, acinic cell).
• Relevant investigations: CT/MRI for size + perineural + bone invasion; FNA cytology; histopathology essential for grading (tubular/cribriform/solid); neuroimaging if perineural invasion; chest imaging for mets.
• Histopath presented? Y · Labs presented? N
• Histopath: Biphasic (ductal + basaloid myoepithelial dark angulated) · “Swiss cheese” cribriform · tubular · solid (worst prognosis) · perineural invasion frequent · high-grade transformation (comedo necrosis, >10 mitoses/10 HPF).
• Management: Wide surgical excision + clear margins; RT for residual; 10-y survival 50-70%.

4. Mucoepidermoid Carcinoma · Tier 2

• Clinical features: Most common malignant salivary in children/young adults; peak 2nd decade; slow-growing mass varying by site/grade; cystic intraoral MEC mimics mucocele; mucinous MEC fluctuates (cyst rupture); can follow childhood RT/chemo (8-y latency).
• Differential diagnosis: Mucocele (benign, blue translucent, fluctuating, no systemic findings); PA (benign, older, painless); low-grade vs high-grade MEC (10-y survival 90%/70%/25%).
• Relevant investigations: US/CT/MRI; FNA or core needle biopsy; histology essential for grading (low/intermediate/high); clinical exam (fixation, skin/nerve involvement); chest imaging for staging.
• Histopath presented? Y · Labs presented? N
• Histopath: Mucin-filled cysts (varying shapes/sizes) + cribriform in dense desmoplastic stroma · mucocytes (pale cytoplasm, peripherally displaced nuclei) + intermediate + epidermoid cells · extensive sclerosis · peritumoral lymphoid infiltrate with germinal centres.
• Management: Surgical excision + clear margins; RT for local control select cases; grade-dependent prognosis.

5. Necrotising Sialometaplasia · Tier 2 · SCC MIMIC

• Clinical features: Benign self-limiting inflammatory disorder; “punched-out” ulcer posterior hard palate; mimics SCC clinically; triggered by smoking, local trauma (dentures, surgery), LA injection, unknown allergen.
• Differential diagnosis: SCC (NS preserves lobular architecture, lacks cytological atypia, resolves spontaneously); MEC (different histology, aggressive); traumatic ulcer (location, aetiology).
• Relevant investigations: Biopsy essential to rule out malignancy (preserved lobular + central squamous metaplasia + necrotic acini + mixed infiltrate); clinical exam (posterior palate, chronic punched-out); history of trauma/smoking.
• Histopath presented? Y · Labs presented? N
• Histopath: Preserved lobular arrangement · central ductal squamous metaplasia · islands of hyperplastic squamous · necrotic acini + diffuse mixed infiltrate (lymphocytes, plasma cells, neutrophils, macrophages, eosinophils).
• Management: Self-limiting 3-10 weeks; biopsy critical to exclude malignancy; symptomatic (analgesics, chlorhexidine); no surgery.

6. Mucocele · Tier 2

• Clinical features: Soft painless swelling; blue/translucent to pink; fluctuates in size; children/young adults due to trauma; lower lip vermilion + FOM (ranula); may rupture and recur.
• Differential diagnosis: Ranula (FOM location, mucous retention cyst vs extravasation); chronic mucocele vs fibroepithelial polyp (fibrotic organisation post-rupture); other benign (lipoma, hemangioma, fibroma).
• Relevant investigations: Clinical history (trauma) + palpation (soft, fluctuant); biopsy for dx (pseudocyst, muciphages, no epithelial lining); imaging not routinely needed; intraoral exam (location, size, mobility).
• Histopath presented? Y · Labs presented? N
• Histopath: Pseudocystic cavity (no true epithelial lining) with mucus · foamy histiocytes (muciphages) + neutrophils + granulation tissue · ruptured: granulation + muciphages · chronic: fibrosis · associated gland: acinar atrophy + ductal dilatation + periductal hyalinisation + fibrosis.
• Management: Surgical excision + underlying minor salivary gland (curative); cryotherapy alternative; warn re: adjacent gland damage + sensory nerve injury.

Top LOs (verbatim):

• “Describe the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of Sjogren syndrome.”
• “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of pleomorphic adenoma.”
• “Discuss the aetiology, pathogenesis, clinical features, histopathologic features, diagnosis and treatment of adenoid cystic carcinoma.”

Mock-exam / past-year flags: No direct mock — Tier 1-2; necrotising sialometaplasia critical SCC mimic pitfall.

L16 L16 Dry Mouth

Source: L16 Dry Mouth

1. Medication-Induced Xerostomia · Tier 2

• Clinical features: Polypharmacy >5 drugs, elderly; anticholinergics (highest xerogenic risk); sympathomimetics; sticky dry mucosa; dry fissured tongue; ↓ palatal moisture; no salivary pooling FOM.
• Differential diagnosis: Sjögren (negative autoimmune markers); radiation-induced (history of HN RT); primary vs secondary (isolated drug vs concurrent systemic).
• Relevant investigations: Sialometry (unstim + stim); medication review (xerogenic drugs + timing); FBC + electrolytes if polypharmacy systemic effects; off-medication baseline if feasible.
• Histopath presented? N · Labs presented? Y ⚠ DISAGREEMENT (Convention Y · Lecture emphasises clinical Challacombe over labs)
• Labs: Unstim <0.1 mL/min hyposalivation; 0.1-0.3 hypofunction; stim <0.5-0.7 hyposalivation; 0.7-1.0 hypofunction; anticholinergics + sympathomimetics block parasympathetic.
• Management: Withdraw medication if possible; saliva substitutes + gustatory/mechanical stimulation; high-F toothpaste; antimicrobial rinses; dietary counselling.

2. Sjögren’s Syndrome · Tier 2

• Clinical features: Keratoconjunctivitis sicca + xerostomia + arthralgia + parotid swelling; positive autoantibodies; secondary form with RA/SLE.
• Differential diagnosis: Primary vs secondary (concurrent autoimmune); drug-induced (no antibodies, improves on cessation); radiation-induced (HN RT history).
• Relevant investigations: Anti-SSA/Ro + anti-SSB/La (wt 3 each); unstim saliva ≤0.1 mL/min; ocular staining ≥5 + Schirmer ≤5 mm; minor salivary biopsy with focus ≥1; ACR-EULAR ≥4.
• Histopath presented? Y · Labs presented? Y
• Histopath: Focal lymphocytic sialadenitis (labial biopsy) · focus score ≥1/4 mm².
• Labs: Anti-SSA/SSB; sialometry; Schirmer; ocular staining; ACR-EULAR.
• Management: Early DMARDs (pilocarpine, cevimeline); immunosuppressants (CS, hydroxychloroquine, mycophenolate) for systemic; salivary stimulation + substitutes; aggressive hygiene + fluoride; ophthalmology + treat 2° candidosis/sialadenitis.

3. Radiation-Induced Salivary Gland Dysfunction · Tier 2

• Clinical features: Thick ropey saliva post-treatment; progressive flow ↓ (>50% drop common); severe hyposalivation >30 Gy (often null); parotid more radiosensitive; dry erythematous mucosa + tongue atrophy; mucositis → chronic xerostomia.
• Differential diagnosis: Medication-induced (RT history vs polypharmacy); Sjögren (no RT, positive serology, biopsy); GVHD (post-transplant systemic).
• Relevant investigations: Sialometry pre-RT baseline vs post-RT decline; Challacombe scale; radiation dose mapping (gland exposure); baseline FBC + iron + B12 if BMS overlap; salivary pH if accelerated caries risk.
• Histopath presented? Y · Labs presented? Y
• Histopath: Acinar atrophy + fibrosis · loss of parenchyma · minimal lymphocytic infiltrate (unlike Sjögren) · chronic sialadenitis.
• Labs: No specific markers; baseline serology to rule out concurrent Sjögren.
• Management: IMRT minimising gland dose; photobiomodulation (630-830 nm, 2-10 J/cm², 1-3×/wk) preserves function; aggressive salivary substitutes; pilocarpine/cevimeline if residual; 5000 ppm F + antimicrobial rinses; ORN/caries surveillance.

4. Oral Candidosis Secondary to Dry Mouth · Tier 2 · MOCK (Case 2 link)

• Clinical features: Angular cheilitis (fissuring/erythema at corners); glossitis (red, papillae loss); erythematous/atrophic dorsum (“bald tongue”); denture stomatitis (palatal erythema under denture); pseudomembranous thrush; chronic hyperplastic (non-wipeable at commissures).
• Differential diagnosis: Erythema migrans (migrating, superficial, dorsum only); OLP (bilateral keratotic striae, reticular/erosive); angular cheilitis from B12/Fe deficiency (assess haematinics, may coexist).
• Relevant investigations: Oral smear/cytology PAS (hyphae + pseudohyphae); sialometry (confirm hyposalivation); cultured swab (C. albicans most common); FBC + iron + B12 (nutritional); glucose if diabetic symptoms.
• Histopath presented? Y · Labs presented? Y
• Histopath: PAS+ hyphae + pseudohyphae · acute inflammatory infiltrate.
• Labs: Candida culture; haematinics; HbA1c if diabetes.
• Management: Treat xerostomia (stimulants/substitutes); topical antifungals (nystatin, miconazole, fluconazole gel) mild-moderate; systemic (fluconazole, itraconazole) severe/refractory/immunocompromised; denture hygiene (clean nightly, no overnight wear); dietary counselling; nutritional deficiencies; review steroid inhaler rinsing.

5. Salivary Flow Rate Interpretation · Tier 3

• Clinical features: Unstim >0.3 normal / 0.1-0.3 hypofunction / ≤0.1 hyposalivation; stim >1.0 normal / 0.7-1.0 hypofunction / ≤0.5-0.7 hyposalivation; Challacombe ≥1 = dryness; single point limited (anxiety/dehydration); baseline change > absolute value; individual variability high.
• Differential diagnosis: True hyposalivation vs xerostomia symptom (objective vs subjective); situational low (repeat standardised conditions); non-linear symptom-flow (typically >50% drop from baseline before symptoms).
• Relevant investigations: Unstim sialometry (5-min draining post 1-h fast); stim sialometry (paraffin/citric acid); Challacombe Scale (10 items, 1-3 mild/4-6 moderate/7-10 severe); unstim:stim ratio (preserved stim = drug/systemic); repeat for consistency.
• Histopath presented? N · Labs presented? Y
• Labs: None for flow interpretation; underlying cause workup as indicated.
• Management: Establish baseline + trend; Challacombe to track; combine subjective + objective + Challacombe; counsel re: fluctuations; monitor complications (caries, candidosis, sialadenitis) by severity.

Top LOs (verbatim):

• “Differentiate xerostomia, salivary gland hypofunction, and hyposalivation using subjective symptoms, objective flow-rate thresholds, and their clinical overlap.”
• “Apply a structured diagnostic approach to dry mouth using medical and dental history, clinical examination, subjective screening tools, sialometry, the Challacombe Scale, laboratory investigations, and Sjögren’s syndrome classification criteria.”
• “Summarize management of dry mouth by addressing underlying causes, providing symptomatic treatments and saliva substitutes, stimulating residual salivary function, managing oral complications, and applying preventive strategies for high-risk patients.”

Mock-exam / past-year flags: Candidosis 2° to dry mouth links to MOCK Case 2.

L17 L17 Bone Disease 1

Source: L17 Bone Disease 1

1. Tori and Exostosis · Tier 1

• Clinical features: Exophytic hard bony masses (uninodular or multinodular); torus palatinus midline palate; torus mandibularis lingual mandible (bilateral symmetrical); covered by mucosa; ulceration from trauma possible; asymptomatic until interference with prosthetics; sites for BRONJ/MRONJ.
• Differential diagnosis: Exostoses vs tori (exostoses often clear trauma history; tori developmental); osteoma (solitary dense bony growth); bilateral symmetry distinguishes tori from malignancy.
• Relevant investigations: Clinical exam sufficient (palpation confirms hardness); OPG/PA radiographs (radiopaque masses); CBCT if surgical removal planned; no biopsy needed.
• Histopath presented? Y · Labs presented? N
• Histopath: Localised non-neoplastic overgrowth of mature lamellar bone · covered by mucosa.
• Management: Reassurance + monitor; surgical removal if interfering with dentures, function, or recurrent trauma/ulceration; counsel BRONJ risk if on antiresorptives.

2. Osteomyelitis · Tier 1

• Clinical features: Deep throbbing pain + fever + irritability + fatigue + nausea; swelling + redness + warmth around bone; paresthesia (nerve compression); mobile teeth + draining sinus possible; bone sequestra; mandible more susceptible.
• Differential diagnosis: MRONJ (myelitis follows odontogenic source vs MRONJ bisphosphonate exposure); ORN (RT history vs infection); acute (<1 mo, responds to antibiotics) vs chronic suppurative (fistula, sequestration, abscess).
• Relevant investigations: OPG/CBCT/CT for bone lysis + sequestra + periosteal reaction; CRP + ESR elevated; blood cultures + intraoral swabs; post-extraction or periodontal source root-cause; biopsy if dx unclear.
• Histopath presented? Y · Labs presented? Y
• Histopath: Bone necrosis with empty lacunae · inflammatory infiltrate · possible fibrinolysis.
• Labs: ↑ CRP, ESR; ↑ ALP possible; positive culture (S. aureus, S. viridans, anaerobes); blood cultures if hematogenous.
• Management: Acute: antibiotics + drainage + fluid resuscitation; chronic: surgical curettage + sequestrectomy + long-term antibiotics + fistula drainage; remove non-vital teeth; improve hygiene; manage predisposing (diabetes, immunodeficiency).

3. MRONJ · Tier 1

• Clinical features: Exposed necrotic bone in jaw >8 wk without prior radiation/trauma; bisphosphonate (zoledronic, alendronate, ibandronate) or denosumab exposure; often spontaneous or post-dentoalveolar surgery; pain + swelling + drainage + ulceration + sequestration; gingival necrosis severe.
• Differential diagnosis: Osteomyelitis (bacterial source vs antiresorptive); ORN (RT vs antiresorptive); extraction socket necrosis (resolves vs persists/worsens).
• Relevant investigations: Bisphosphonate/denosumab exposure history (drug, dose, duration); CBCT/CT for bone density + sequestration + necrosis extent; OPG localised density changes; biopsy for definitive if uncertain; no specific labs.
• Histopath presented? Y · Labs presented? Y
• Histopath: Dense bone with irregular cellular regions · suppression of remodelling · empty lacunae (osteonecrosis) · fibrosis.
• Labs: Exposure history; vitamin D + calcium; CRP/ESR non-specific.
• Management: Conservative for osteoporotic; avoid invasive procedures; excellent OH; smoking cessation; surgical debridement/sequestrectomy for extensive or uncontrolled infection; consider calcitonin, HBO; liaise with prescribing physician.

4. Central Giant Cell Granuloma · Tier 2

• Clinical features: Painless expansile anterior mandible (70%); young patients (60% <30 y); female predilection; brown/reddish on-section (hemosiderin); asymptomatic swelling or tooth displacement; non-aggressive (slow) vs aggressive (rapid + root resorption + cortical perforation).
• Differential diagnosis: Hyperparathyroidism brown tumour (histologically identical; PTH + calcium + phosphate + ALP distinguish); ameloblastoma (multilocular, posterior, older); aneurysmal cyst/cherubism (cherubism bilateral, familial).
• Relevant investigations: OPG/CBCT (unilocular to multilocular radiolucency 0.5-10 cm anterior mandible); serum PTH + calcium + phosphate + ALP (exclude HPT); biopsy for definitive (multinucleated giant cells + spindled stroma + hemosiderin + extravasation + osteoid).
• Histopath presented? Y · Labs presented? Y
• Histopath: Multinucleated giant cells in vascular stroma · spindled (mesenchymal) cells + mononuclear · hemosiderin · RBC extravasation · osteoid possible.
• Labs: PTH (exclude hyperparathyroidism); ↑ ALP possible; serum Ca + vitamin D.
• Management: Surgical curettage non-aggressive; intralesional CS or calcitonin for recurrent; 15-20% recurrence.

5. Sclerotic Bone Island · Tier 2

• Clinical features: Asymptomatic incidental finding; solitary round/oval well-defined radiopaque lesion intramedullary; posterior mandible around apices of vital teeth; no systemic disease or medication history.
• Differential diagnosis: Condensing osteitis (tooth non-vital, low-grade infection); osteoma (larger, exophytic, solitary); fibrous dysplasia (larger, expansile, “ground glass”).
• Relevant investigations: OPG/PA sufficient; CBCT clarifies if surgical planning; vitality testing of associated teeth (normal — rules out condensing osteitis); no biopsy needed.
• Histopath presented? N · Labs presented? N
• Management: Conservative observation; reassure benign; periodic radiographic monitoring; document location; no intervention.

Top LOs (verbatim):

• “Explain the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of tori and exostosis.”
• “Explain the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of osteomyelitis.”
• “Explain the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of osteonecrosis, including bisphosphonate-induced osteonecrosis.”

Mock-exam / past-year flags: Differential for Case 3 metastatic disease.

L18 L18 Bone Disease 2

Source: L18 Bone Disease 2

1. Dentigerous Cyst · Tier 1

• Clinical features: Unilocular radiolucency around crown of unerupted tooth; 10-15% jaw cysts; children + young adults with permanent teeth; painless enlargement often incidental; upper canine or lower 3rd molar most common.
• Differential diagnosis: OKC (multilocular, scalloped, parakeratinised); periapical cyst (non-vital tooth); ameloblastoma (multilocular, older, larger).
• Relevant investigations: OPG ± CBCT confirming radiolucency relationship to crown; vitality tests on associated teeth (should be vital); biopsy for histopathology; panoramic to assess extent + neighbouring teeth.
• Histopath presented? Y · Labs presented? N
• Histopath: Thin flattened non-keratinised stratified squamous epithelium (2-4 layers) · continuous with reduced enamel epithelium · mucous/ciliated columnar metaplasia possible · fibrous wall non-inflamed unless infected.
• Management: Surgical enucleation or marsupialisation; conservative in young patients for eruption; monitor for rare recurrence.

2. Odontogenic Keratocyst · Tier 1

• Clinical features: 5-10% jaw cysts; males > females; 70-80% mandibular (50% angle/ramus); often asymptomatic with swelling/discharge; high recurrence up to 60%; 10% multiple (Gorlin-Goltz); tooth displacement or pathological fracture.
• Differential diagnosis: Dentigerous cyst (unilocular, parakeratin vs orthokeratin); ameloblastoma (bucco-lingual expansion); multilocular radiolucencies (scalloped + parakeratinised corrugated epithelium unique to OKC).
• Relevant investigations: OPG + CBCT for multilocular + scalloped margins; vitality tests (teeth vital); biopsy (parakeratinised corrugated + daughter cysts diagnostic); genetic testing if Gorlin-Goltz (PTCH1); screening for multiple cysts.
• Histopath presented? Y · Labs presented? N
• Histopath: Regular stratified squamous epithelium 5-8 cells thick + palisaded basal · corrugated parakeratinised or orthokeratinised surface · thin friable fibrous capsule + little inflammation · satellite/daughter cysts in wall · antero-posterior growth in medullary bone.
• Management: Surgical enucleation with careful capsule removal; marsupialisation for large; consider cryotherapy or Carnoy’s; genetic counselling if Gorlin-Goltz.

3. Nasopalatine Canal Cyst · Tier 2

• Clinical features: Midline anterior maxilla between central incisors; male:female 4:1; ages 30-60; palatal swelling with pain/discharge (mucoid, salty); anterior teeth remain vital; incidental finding common.
• Differential diagnosis: Periapical cyst (non-vital tooth, palatal less typical); dentigerous (unerupted tooth); anterior maxillary cysts (NPCC midline + vitality of teeth).
• Relevant investigations: OPG shows heart-shaped/oval radiolucency in midline; vitality testing confirms anterior teeth vital; biopsy (respiratory epithelium + neurovascular bundle diagnostic); CT/CBCT confirms nasopalatine duct origin.
• Histopath presented? Y · Labs presented? N
• Histopath: Respiratory epithelium (ciliated columnar to stratified squamous) · blood vessels + nerve fibres (nasopalatine duct origin) · fibrous wall · inflammatory features if infected.
• Management: Surgical enucleation (palatal or transalveolar); conservative observation if asymptomatic incidental; marsupialisation if large; avoid unnecessary endodontic treatment (teeth vital).

4. Traumatic Bone Cyst · Tier 2

• Clinical features: Affects 10-20 y predominantly (young males 60%); mandibular body (molar-premolar); asymptomatic incidental; painless radiolucency; associated teeth vital + no root resorption; scalloping between roots.
• Differential diagnosis: Dentigerous (crown of unerupted tooth); OKC (multilocular, older); simple = traumatic bone cyst (same entity); periapical cyst (non-vital tooth).
• Relevant investigations: OPG (radiolucency 1-10 cm well-defined to ill-defined); vitality tests (teeth vital — key); aspiration may yield serosanguinous fluid; biopsy shows no epithelial lining + fibrovascular + fibrin + haemorrhage; CT/CBCT for extent.
• Histopath presented? Y · Labs presented? N
• Histopath: No epithelial lining (pseudocyst) · cortical bone cap · fibrovascular tissue lining · fibrin + haemorrhage · bone resorption + remodelling · serosanguinous fluid possible.
• Management: Surgical exploration + haemorrhage stimulation; rapid spontaneous healing 6 months; excellent prognosis; rare recurrence.

5. Fibrous Dysplasia · Tier 2

• Clinical features: Painless facial asymmetry/swelling in adolescence; quiesces at puberty; ground-glass appearance; malocclusion + displaced teeth; headache + hearing loss if extensive craniofacial; monostotic 70% / polyostotic 25% / McCune-Albright 3% (café-au-lait + endocrine).
• Differential diagnosis: Paget’s (older + different radiographic); ossifying fibroma (neoplastic + encapsulated); cementoma variants; age of onset + GNAS mutation distinguish from neoplastic.
• Relevant investigations: OPG/CBCT (ground-glass + diffuse poorly-delineated margins; mixed radiolucent-opaque → dense/opaque with maturation); serum ALP elevated; AVOID RT (↑ osteosarcoma risk); genetic counselling/GNAS testing if syndromic.
• Histopath presented? Y · Labs presented? Y (Convention Y · Lecture implied) ⚠ DISAGREEMENT
• Histopath: Woven bone with irregular trabeculae (“Chinese characters”) · highly cellular fibroblastic stroma · NO osteoblastic rimming · blends into normal bone without capsule · maturation into lamellar over time · ↑ calcification mature.
• Labs: ↑ ALP active; Ca + PO4 normal; PTH normal (distinguishes from brown tumour); McCune-Albright screen if polyostotic.
• Management: Conservative + stabilises at skeletal maturity; surgical recontouring for cosmesis/function; AVOID RT (osteosarcoma risk); 25-50% regrowth especially young; careful monitoring McCune-Albright.

6. Cemento-Osseous Dysplasia · Tier 3

• Clinical features: Primarily Black women (periapical form 14:1 F:M); asymptomatic incidental; mandibular anterior periapical; mixed lucent-radiopaque; teeth vital; no cortical expansion; multiple lesions common; radiolucency → mature radiopaque mass with radiolucent rim.
• Differential diagnosis: Periapical cyst (non-vital tooth, vital in dysplasia); fibrous dysplasia (broader distribution, different demographics); HPT brown tumour (PTH + Ca + phosphate).
• Relevant investigations: OPG (circumscribed apical radiolucencies <1 cm with variable radiopacity); vitality tests (teeth vital — crucial); intact lamina dura; ALP + Ca + phosphate + PTH (exclude HPT); avoid unnecessary endodontic/extraction (osteomyelitis risk); radiographic follow-up.
• Histopath presented? Y · Labs presented? Y
• Histopath: Cementum-like droplets + globules within bone · irregular trabecular bone + fibrous tissue · hypercementosis · dense sclerotic periphery florid · varies by stage.
• Labs: Serum ALP, Ca, phosphate, PTH (exclude HPT + brown tumour).
• Management: No treatment (benign self-limiting); AVOID surgical (osteomyelitis risk due to poor vascularity); AVOID endodontic/extractions; maintain dentition + hygiene; periodic radiographic monitoring; patient counselling to prevent unnecessary intervention.

Top LOs (verbatim):

• “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of dentigerous cyst.”
• “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of odontogenic keratocyst / keratocystic odontogenic tumour.”
• “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of nasopalatine canal cyst.”

Mock-exam / past-year flags: Case 3 metastatic disease cyst-vs-malignancy differential context.

L19 L19 Bone Disease 3

Source: L19 Bone Disease 3

1. Metastatic Disease to the Jaws · Tier 1 · MOCK Case 3

• Clinical features: Posterior mandible most common (80%); paresthesia of IAN (numb chin syndrome) red flag; mobile teeth + painful swelling; older adults with known cancer history; primaries: breast, prostate, lung, kidney, thyroid; first presenting sign in 50%; simulates periapical/periodontal disease.
• Differential diagnosis: Odontogenic vs primary bone tumour (clinical context + paresthesia + history of malignancy); osteolytic “moth-eaten” vs osteoblastic prostate; primary tumour identification via IHC.
• Relevant investigations: OPG + CT/MRI for extent; biopsy with histopath + IHC (primary site); PSA prostate; systemic imaging (chest CT, bone scan, PET); ALP + serum calcium for bone turnover.
• Histopath presented? N (Convention: Y · Lecture: Y) ⚠ DISAGREEMENT: mock stem doesn’t explicitly request histopath
• Labs presented? N (Convention: Y · Lecture: Y) ⚠ DISAGREEMENT: PSA + ALP + bone scan highly relevant
• Histopath: Infiltrating nests/cords of pleomorphic epithelial cells in fibrous stroma · prostate metastasis: glandular structures with PSA+ immuno · perineural invasion · better-differentiated than primary bone tumours · osteoblastic lesions for prostate.
• Labs: PSA elevated; ALP elevated (bone turnover); hypercalcemia advanced; bone scan osteoblastic/mixed; biopsy + IHC confirms primary.
• Management: Radical surgery + chemo/hormone therapy; survival typically <1 yr.

2. Ameloblastoma · Tier 2

• Clinical features: Posterior mandible most common; expansile multilocular “soap-bubble” or “honeycomb” radiolucency; painless swelling; young adults (4th decade); loose/mobile teeth; bucco-lingual expansion; often incidental.
• Differential diagnosis: OKC vs odontogenic myxoma vs ameloblastoma (multilocular + reverse polarity epithelium diagnostic); lateral periodontal cyst (anterior mandible); unicystic mimics dentigerous.
• Relevant investigations: OPG + CBCT for extent + multilocular pattern; biopsy with histopath (islands with reversed polarity definitive); MRI if soft tissue unclear; clinical correlation with age + location.
• Histopath presented? Y · Labs presented? N
• Histopath: Islands/nests of odontogenic epithelium in fibrous stroma · peripheral palisading of columnar cells with reversed polarity · central stellate reticulum · cystic cavities in unicystic · no calcified tissue.
• Management: Surgical excision (conservative enucleation unicystic; wider resection multicystic); 10-80% recurrence by type; follow-up essential.

3. Osteosarcoma · Tier 2

• Clinical features: Rapid swelling + pain + loose teeth; “sunburst” + Codman’s triangle; young adults (3rd-4th decade); male predominance; paresthesia (IAN involvement); aggressive growth; jaw 6-8% of gnathic osteosarcomas.
• Differential diagnosis: Chondrosarcoma vs Ewing’s (radiographic + histologic; osteoid production diagnostic for osteosarcoma); metastatic (primary site history); ameloblastoma (benign + epithelial origin); fibrous dysplasia transformation (rare <1%).
• Relevant investigations: OPG + CT/MRI for extent + soft tissue; biopsy with histopath (osteoid production diagnostic); ALP elevated; imaging features (“sunburst”, spiking root resorption, widened PDL); bone/PET scan for metastatic screening.
• Histopath presented? Y · Labs presented? Y
• Histopath: Malignant mesenchymal cells (pleomorphic + spindled + polygonal) · osteoid production (diagnostic hallmark) · high mitotic + atypical mitoses + hyperchromatism · necrotic areas · variants (osteoblastic, chondroblastic, fibroblastic); gnathic better differentiated.
• Labs: ↑ ALP; imaging mixed radiolucent-radiopaque + “sunburst”; spiking root resorption + widened PDL; biopsy confirms.
• Management: Radical surgery + chemo ± RT; 30-50% survival; 70% local recurrence; lung/brain mets common.

4. Adenomatoid Odontogenic Tumour · Tier 2

• Clinical features: Unilocular well-defined radiolucency around unerupted canine/premolar; young adults (10-30 y); slight female predilection; asymptomatic (routine radiograph discovery); slow-growing; rare anterior maxilla/mandible.
• Differential diagnosis: Ameloblastoma vs OKC vs AOT (cuboidal/columnar epithelium in whorls/rosettes + duct-like structures characteristic); dentigerous cyst (unerupted tooth context but different epithelial pattern); odontogenic myxoma (no epithelial nests).
• Relevant investigations: OPG + CBCT (unilocular well-defined radiolucency); biopsy with histopath (epithelial whorls/rosettes + nodular cementum-like definitive); vitality testing of associated tooth.
• Histopath presented? Y · Labs presented? N
• Histopath: Cuboidal to columnar odontogenic epithelium in whorls/rosettes · fibrous CT stroma · no significant atypia · nodular cementum-like masses possible · duct-like structures common.
• Management: Conservative surgical enucleation; excellent prognosis; minimal recurrence.

5. Benign Cementoblastoma · Tier 3

• Clinical features: Attached to tooth root (mandibular 1st molar most common); well-defined radiopacity fused to root; young adults (<30 y); tender swelling on buccal/lingual; localised pain + cortical expansion; tooth resorption + mobile tooth.
• Differential diagnosis: Condensing osteitis (biopsy differentiates; cementoblastoma has reversal lines + pagetoid); osteoblastoma (similar histology, not root-attached); odontoma (internal entirely calcified); hypercementosis (gradual vs discrete).
• Relevant investigations: OPG + PA radiograph (radiopacity fused to root); CBCT for 3D extent; vitality (tooth typically vital); biopsy with histopath (sheets/trabeculae of cementum-like + reversal lines diagnostic).
• Histopath presented? Y · Labs presented? N
• Histopath: Sheets/trabeculae of cementum-like calcified tissue · prominent reversal lines + pagetoid appearance · cementoblasts/cementoclasts within or around · resembles osteoblastoma · attached directly to tooth root.
• Management: Surgical extraction of associated tooth + lesion; 35-60% recurrence; monitor.

Top LOs (verbatim):

• “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of ameloblastoma.”
• “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of osteosarcoma.”
• “Discuss the aetiology, pathogenesis, clinical features, radiographic features, histopathologic features, diagnosis and treatment of metastatic disease.”

Mock-exam / past-year flags: Metastatic disease (prostate→mandible) = Tier 1 MOCK Case 3.

L27 L27 Defining Orofacial Pain

Source: L27 Defining Orofacial Pain

1. 2020 IASP Pain Definition & Nociception vs Pain · Tier 1

• Key features / when to use: Foundational definition for all orofacial pain assessment; distinguishes pain (subjective experience) from nociception (sensory input); biopsychosocial influence; respects patient report; “my 10 ≠ your 10.”
• Alternatives / considerations: 1979 IASP definition (tissue-damage-centric, superseded); biomedical reductionism misses neuropathic/nociplastic; older theories underestimate psychological dimensions.
• Companion investigations / adjuncts: OPQRST pain history; NRS/VAS scales + qualitative narrative; red-flag screening for true tissue damage vs amplification.
• Histopath presented? N · Labs presented? N
• Key concepts: Pain always personal · pain ≠ nociception · verbal description one of several behaviours · patient report respected.
• Clinical application: Recognise multidimensional pain; avoid dismissing without visible damage.

2. Nociplastic · Tier 1

• Key features / when to use: Classify patients into one of three pathways → treatment selection; nociceptive (injury-based → inflammation/protection); neuropathic (nerve disease → neuropathic agents); nociplastic (sensitised CNS, no clear pathology → psychosocial focus); informs prognosis.
• Alternatives / considerations: Gate control historical, less actionable; mixed mechanisms common (PHN = neuropathic + nociplastic); older “inflammatory” vs “nerve” dichotomy expanded.
• Companion investigations / adjuncts: Imaging (CBCT) + pulp vitality for nociceptive; QST + HLA-B*1502 for neuropathic (carbamazepine); Axis II screening (PHQ-4, pain manikin) for nociplastic.
• Histopath presented? N · Labs presented? N
• Key concepts: Nociceptive: normally functioning nociceptors · neuropathic: lesion/disease somatosensory NS · nociplastic: altered nociception with no tissue/nerve damage · comparison: stimulus, neuron, site, function.
• Clinical application: Use pain characteristics (location, trigger, descriptors) → assign mechanism → targeted therapy.

3. Physiological vs Pathophysiological Pain · Tier 2

• Key features / when to use: Acute injury → physiological/protective; chronic (>3 mo post-healing) → pathophysiological/non-protective; guides counselling (“pain serves no protective purpose now”); prognostic marker.
• Alternatives / considerations: Acute vs chronic cutoff varies (3/6/12 mo); some physiological transitions to pathophysiological with sensitisation; historical “pain is good” narratives delay chronic management.
• Companion investigations / adjuncts: Timeline of injury + healing; Axis II screening for early chronic-pain risk (anxiety, catastrophising, depression); imaging only if exam suggests ongoing damage.
• Histopath presented? N · Labs presented? N
• Key concepts: Physiological: tissue injury, site = source, resolves · pathophysiological: persists post-healing, PNS/CNS dysfunction · 1/15 Australians in chronic pain · $22-45k/y cost.
• Clinical application: Triage acute (short reassurance/first-aid) vs chronic (longer functional/psychosocial rehab).

4. Sensory-Discriminative vs Motivational-Affective Pain Components · Tier 2

• Key features / when to use: Assess both in every consultation: sensory (location, intensity, quality) + affective (emotion, anxiety, catastrophising); empathy-centred; affective dominates chronic pain; CBT targets affective.
• Alternatives / considerations: Pure sensory focus ignores emotional suffering; pure psychological dismisses real nociceptive/neuropathic pathology.
• Companion investigations / adjuncts: Pain manikin (diffuse pattern → high affective load); PHQ-4 or GCPS for depression/anxiety + pain-related disability; behavioural observations (facial expression, catastrophising language).
• Histopath presented? N · Labs presented? N
• Key concepts: Sensory-discriminative: localisation + intensity + quality · motivational-affective: emotion + arousal + behaviour · shaped by childhood learning, conditioning, context, mood, expectation.
• Clinical application: Validate emotional component; never “I don’t believe the pain” — “I believe your suffering.”

5. Biopsychosocial Model + Enhanced Facial Nociception · Tier 1

• Key features / when to use: Acute (somatosensory high) → chronic (psychosocial dominant); facial pain heightened amygdala + lateral parabrachial nucleus → greater emotional weight; Axis I + Axis II required for TMD; “motion picture” (longitudinal) not “snapshot.”
• Alternatives / considerations: Biomedical model reductionist; pure psychosocial attribution dismissive; facial pain poor habituation (“repeated slaps feel equally intense”).
• Companion investigations / adjuncts: Psychosocial history (childhood, generational trauma, cultural, support, economic); Axis II tools (PHQ-4, GCPS, pain manikin); longitudinal case assessment.
• Histopath presented? N · Labs presented? N
• Key concepts: Axis I: somatosensory · Axis II: psychosocial · facial pain greater affective salience (amygdala, PBL) · chronic pain: psychosocial dominant · factors: genes, lifestyle, learning, age, beliefs, behaviour, support.
• Clinical application: Address pain holistically; never treat only the tooth/joint; integrate psychological factors early.

6. TMD Diagnostic Framework · Tier 1

• Key features / when to use: TMD = musculoskeletal/neuromuscular of TMJ + masticatory muscles; prevalence 4.6%; DC/TMD on all suspected TMD: Axis I (physical) + Axis II (psychological); bDC/TMD for general practice (<10 min); imaging only if alters care.
• Alternatives / considerations: Occlusion-based theories disproven; Helkimo Index outdated; disc displacement low clinical sensitivity (0.34-0.54) without imaging.
• Companion investigations / adjuncts: PHQ-4, GCPS, pain manikin (Axis II); MRI/CT/CBCT only if findings alter management; palpation thresholds (0.5 kg pole, 1.0 kg muscles); click vs crepitus.
• Histopath presented? N · Labs presented? N
• Key concepts: Orofacial pain prevalence 17-26% · TMD diverse · DC/TMD sensitivity (myalgia 0.90/0.99, arthralgia 0.89/0.98, DDwR 0.34/0.92) · ICOP primary international standard · no occlusion-pain link.
• Clinical application: DC/TMD framework + both axes + tailored imaging.

Top LOs (verbatim, High-yield preserved):

• “Define and classify orofacial pain according to the 2020 IASP definition, distinguishing nociceptive, neuropathic, and nociplastic mechanisms, and explain how pain differs from nociception. High-yield: 2020 IASP definition revision, distinction between nociception and pain perception, three pain types with clinical examples, the mind-body connection.”
• “Distinguish physiological (acute, protective) from pathophysiological (chronic, non-protective) pain presentations, and explain how the biopsychosocial model accounts for biological, psychological, and social factors in pain perception. High-yield: acute vs chronic pain paradigm shift, psychosocial dominance in chronic pain, biopsychosocial axes (I and II).”
• “Explain the enhanced neurobiological basis for facial pain, including heightened amygdala activation and craniofacial nociceptive processing. High-yield: facial pain greater emotional weight, lateral parabrachial nucleus activation, lack of habituation.”

Mock-exam / past-year flags: Foundational for all OFP cases.

L28 L28 TMD

Source: L28 TMD

1. TMD Axis I Physical Examination · Tier 1 · PAST YEAR 2025

• Key features / when to use: Every suspected TMD patient (pain >3 mo, functional limitation, acute locking); medicolegal documentation; 80-90% sensitivity with history; superior to Helkimo; triages to specialist vs bDC/TMD.
• Alternatives / considerations: Helkimo “archaic”; supplemental muscle sites (lateral pterygoid, temporalis tendon) for specialist only; click vs crepitus (clicks discrete, crepitus grating “gravel” = degenerative).
• Companion investigations / adjuncts: MRI only if disc position alters management (DDw/oR with limited opening); CT/CBCT for DJD grading; sleep study if OSA-bruxism; bloodwork (FBC, inflammatory markers) if systemic arthritis (RF, anti-CCP, ESR).
• Histopath presented? N · Labs presented? N
• Key features / procedure: Palpation force 0.5 kg pole, 1.0 kg muscles (thumbnail blanch); pain location confirm (temporalis/masseter/TMJ); jaw opening (pain-free, MAO ≥40 mm, max assisted); TMJ noises (click vs crepitus on open/close + lateral/protrusive); 2-sec palpation for pain ID, 5-sec for myalgia subtyping; joint locking (open vs wide-open).
• Clinical application: Axis I → first-line management; “familiar pain” reproduction essential; opening patterns + click/crepitus distinguish disc displacement vs DJD.

2. TMJ Anatomy Applied to Clinical Findings · Tier 1

• Key features / when to use: Retrodiscal tissue pain severe (highly innervated/vascularised); disc central pain rare (avascular); condyle-fossa incongruency + ligamentous laxity → subluxation/luxation; lateral pole = capsular/discal; anterior opening pain = disc-condyle dysfunction.
• Alternatives / considerations: Disc position by exam only 34% sensitivity; accessory ligaments rarely clinical in isolation; eminence morphology variation (flat vs convex) affects loading.
• Companion investigations / adjuncts: MRI for disc morphology (biconcave, biplanar, irregular); CBCT if bony variants (condylar hyperplasia, aplasia, hypoplasia); no routine imaging for asymptomatic variation.
• Histopath presented? N · Labs presented? N
• Key features / procedure: Upper (meniscus-fossa) + lower (meniscus-condyle) joint spaces · disc central avascular/innervated vs retrodiscal tissue innervated/vascularised · joint capsule fibrous loosely arranged · condyle ball-shaped + fossa shallow (incongruent, unstable) · lateral pole palpation (0.5 kg) targets fibrous capsule; posterior (1.0 kg) reaches retrodiscal + synovium.
• Clinical application: Retrodiscal involvement → severe constant pain; disc posterior displacement → clicking; capsular pain worse on wide opening; disc pain anterior joint space.

3. TMD Symptom Questionnaire · Tier 1

• Key features / when to use: Initial pain characterisation (OPQRST); DC/TMD SQ1-14 mandatory; 3Q triage screen (pain ≥1 wk, pain with opening/chewing, locking ≥1 wk); history = 80% of diagnosis.
• Alternatives / considerations: Pain quality guides differential (dull/aching musculoskeletal; burning/stinging neuropathic; pulsating migraine); onset triggers (trauma, gum chewing, prolonged opening, stress); parafunction perpetuates pain.
• Companion investigations / adjuncts: Sleep history if OSA-bruxism (snoring, somnolence, witnessed apneas); medication review (stimulants, antipsychotics exacerbate bruxism; opioids complicate); psychosocial screening if >3 mo for Axis II.
• Histopath presented? N · Labs presented? N
• Key features / procedure: Onset · provoking factors (chewing, opening, jaw movement, talking, yawning, parafunction) · quality (bright/dull, pricking, itching, stinging, burning, aching, pulsating, throbbing) · radiation · severity (NRS 0-10 or Wong-Baker) · timing · SQ1-14: pain location/onset, headache temporal, jaw noises, locking history, open-lock + reduction manoeuvre.
• Clinical application: Pain modified by jaw function (SQ4/SQ7) = musculoskeletal; clicking ± intermittent locking → DDwR; locking without click, opening <40 mm → DDw/oR with limited opening; wide-open locking requiring manoeuvre → subluxation/luxation.

4. Axis II Psychosocial Screening + Pain Manikin · Tier 1

• Key features / when to use: Mandatory if pain >3 mo; pain manikin (diffuse → widespread sensitisation, poor prognosis); PHQ-4 (≥6 = significant distress); GCPS quantifies intensity + disability.
• Alternatives / considerations: Pain drawings with many arrows = poorer outcomes (early referral); PHQ-4 brief not diagnostic; GCPS functional impact complements numerical pain.
• Companion investigations / adjuncts: If PHQ-4 ≥6 + pain >3 mo: psychology referral for CBT/ACT; sleep assessment if daytime somnolence; no bloodwork unless comorbid depression suggests metabolic screen (HbA1c, TSH).
• Histopath presented? N · Labs presented? Y (psychometric scores act as “lab-equivalent”)
• Key features / procedure: Pain Manikin: localised (0-2 sites) → regional (3-4) → widespread (≥5); PHQ-4 (0-3 none / 4-6 mild / 7-9 moderate / 10-12 severe; anxiety items 1-2, depression items 3-4); GCPS: pain intensity (current/worst/average) + disability (daily/recreational/work) 0-10 each; functional impact severity.
• Clinical application: Diffuse + high PHQ-4 → specialist + psychology; localised + low PHQ-4 → conservative + 3-mo review; high disability despite low intensity → psychological factors → coping/pacing; >12 mo + high psychosocial burden → early specialist improves outcome.

5. TMD) for General Practice · Tier 2

• Key features / when to use: Axis I + II in <10 min (vs full 30-45 min); common presentations (myalgia, arthralgia, headache-TMD, DJD, subluxation, acute closed lock); broad groupings (Painful vs Joint-related TMDs); removes unreliable items.
• Alternatives / considerations: Full DC/TMD if dx unclear, specialist exam needed, expanded taxonomy (ankylosis, fibromyalgia, systemic arthritides); bDC/TMD ultra-brief Axis II (pain drawing only); training via distance learning.
• Companion investigations / adjuncts: Imaging only if dx changes management (e.g., crepitus + limited opening → CBCT if surgery considered); sleep referral if bruxism + STOP-BANG ≥3; no adjunctive for most cases.
• Histopath presented? N · Labs presented? N
• Key features / procedure: E1a (pain ID): temporalis + masseter + TMJ only; E2 (opening): pain-free + MAO + max assisted; E3 (TMJ noises + locking): single 3-step movement screen; E4 (palpation): temporalis (ant/mid/post) + masseter (origin/body/insertion) + TMJ pole; Axis II: pain drawing only.
• Clinical application: Myalgia (familiar pain on muscle palpation) → soft diet + jaw stretches + stress mgmt; arthralgia → NSAIDs + optional splint 3-4 wk; headache attributed (familiar HA on temporalis palpation) → same as myalgia; DJD (crepitus) → imaging if progressive; disc displacement (clicking ± locking) → if no functional limitation, conservative.

Top LOs (verbatim, High-yield preserved):

• “Perform a systematic clinical examination using the DC/TMD protocol… High-yield: palpation force (0.5 kg pole, 1.0 kg muscles), pain/familiar pain/referred pain distinction, opening patterns (deviation vs deflection), click identification.”
• “Apply the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) framework… High-yield: Axis I physical diagnoses, pain provocation, familiar pain reproduction, click vs crepitus distinction.”
• “Administer and interpret Axis II psychosocial screening tools (pain drawing, GCPS, PHQ-4)… High-yield: PHQ-4 anxiety/depression screening, pain manikin for diffuse vs localised, disability impact.”

Mock-exam / past-year flags: PAST YEAR 2025 Case 2 directly tests DC/TMD exam protocol + internal derangement DDx + indications for MRI.

L29 L29 Intracapsular disorders of TMD

Source: L29 Intracapsular disorders of TMD

1. Disc Displacement With Reduction · Tier 1 · PAST YEAR 2025 Case 2

• Clinical features: Reproducible click on opening/closing (≥1 of 3 cycles); normal opening ≥40 mm; ipsilateral deviation with spontaneous correction; possible mild TMJ discomfort on loading; disc returns to position during function.
• Differential diagnosis: Subluxation (click vs condylar “jump” without disc); early DDw/oR (lack of normal opening or clicking progression); muscular dysfunction (deviation without joint noise).
• Relevant investigations: DC/TMD palpation + listening for click reproducibility; MRI (fat-sat T2 sagittal closed/open) confirming anterior disc displacement reducing on opening; clinical opening + deviation; photo of opening pattern.
• Histopath presented? N · Labs presented? N (MRI = imaging equivalent)
• Clinical signs: Click ≥1/3 cycles · normal opening ≥40 mm · ipsilateral deviation with correction · possible TMJ pain.
• Imaging findings: MRI: anterior disc displacement closed → reduces open; effusion + bilaminar zone changes; crumpled disc morphology.
• Management: Conservative first-line (soft diet, physio, NSAIDs); oral appliances if refractory; specialist for persistent.

2. Disc Displacement Without Reduction With Limited Opening · Tier 1 · PAST YEAR 2025 Case 2

• Clinical features: Limited opening <35-40 mm (initially 25-30); NO clicking (loss of prior sounds); ipsilateral deflection (no correction = “closed lock”); restricted contralateral excursion; hard end-feel (mechanical block); possible preauricular pain; jaw “stuck.”
• Differential diagnosis: DJD (crepitus distinguishes; closed-lock silent); muscular pain-limited (soft vs hard end-feel); myospasm (high muscle tone vs disc obstruction).
• Relevant investigations: DC/TMD palpation (hard end-feel + no click); opening measurement <35 mm; MRI sagittal T1/T2 closed showing anterior disc displacement without reduction; contralateral excursion restriction; clinical photos.
• Histopath presented? N · Labs presented? N
• Clinical signs: Limited opening · no click · ipsilateral deflection · hard end-feel.
• Imaging findings: MRI: disc permanently displaced anteriorly · fails to reduce · mechanical block.
• Management: Conservative (soft diet, stretching); arthrocentesis/arthroscopy for specialist; anterior repositioning splint if acute.

3. Disc Displacement Without Reduction Without Limited Opening · Tier 2 · PAST YEAR 2025 Case 2

• Clinical features: History of prior closed-lock; normal opening (≥40 mm) — adaptation over time; no clicking; minimal/absent deflection; possible mild TMJ tenderness; prior “stuck” episodes resolved spontaneously.
• Differential diagnosis: Resolved acute DDw/oR (adapted state); chronic low-grade synovitis (pain without mechanical sign); late DJD (imaging distinguishes).
• Relevant investigations: DC/TMD palpation (normal opening + minimal deflection); MRI sagittal T1/T2 showing anterior displacement persisting but not obstructive; opening measurement; patient history; assess pain on palpation vs mechanical resistance.
• Histopath presented? N · Labs presented? N
• Clinical signs: Normal opening · no click · minimal deflection · history of prior locking.
• Imaging findings: MRI: anterior displacement persists · no mechanical obstruction.
• Management: Conservative; reassurance about adaptation; NSAIDs/physio if pain.

4. Subluxation · Tier 2 · PAST YEAR 2025 Case 2

• Clinical features: Excessive anterior condylar translation beyond eminence at max opening; opening >40 mm; “jump” or “thud” at end-range; patient can “wiggle” back; no clicking; preauricular depression at full opening; usually painless; hypermobility/ligamentous laxity (Ehlers-Danlos, Marfan).
• Differential diagnosis: DDwR (clicking vs no click); luxation (patient self-reduces in subluxation; luxation requires external intervention); normal translation (excessive in subluxation).
• Relevant investigations: DC/TMD palpation (opening >40 mm + condylar jump + self-reduction); observation of preauricular depression; CT/CBCT or MRI (condyle anterior to eminence + normal disc); genetic screening if hereditary laxity suspected.
• Histopath presented? N · Labs presented? N
• Clinical signs: Excessive translation · opening >40 mm · jump/thud · self-reduces · no click · preauricular depression · usually painless · ligamentous laxity.
• Imaging findings: Condyle anterior to eminence · normal disc position.
• Management: Education + reassurance; habit control (avoid wide opening); specialist only if recurrent.

5. Luxation · Tier 2 · EMERGENCY

• Clinical features: Condyle trapped anterior to eminence (open-lock); cannot voluntarily close; after sudden wide opening (yawning, dental procedures, forced intubation); anxious + cannot self-reduce; bilateral or unilateral; hard end-feel.
• Differential diagnosis: Subluxation (self-reduces); severe muscle spasm (limited opening not open-lock; soft end-feel); anterior disc displacement (does not trap condyle anteriorly).
• Relevant investigations: Clinical observation (cannot close + condylar prominence bilaterally anterior); CT/CBCT sagittal (bilateral anterior condylar position); neuro exam to rule out stroke/facial palsy; anxiety assessment.
• Histopath presented? N · Labs presented? N
• Clinical signs: Open lock · cannot close · after wide opening · anxious · hard end-feel.
• Imaging: Condyle anterior to eminence; no disc involvement.
• Management: EMERGENCY — syringe method (5-10 mL between posterior molars; bite + roll) OR manual reduction (thumbs on lower molars, downward then posterior); LA/auriculotemporal block; post-reduction soft diet + NSAIDs; specialist follow-up.

6. Osteoarthritis) · Tier 1

• Clinical features: Coarse grating crepitus (“rubble”) during opening/closing; limited opening <35 mm; pain at rest + exacerbated by function; joint stiffness especially after rest; progressive symptoms; morning stiffness; pain on palpation of lateral pole; prior trauma/chronic overload.
• Differential diagnosis: DDw/oR (limited opening without crepitus); muscular pain-limited (soft vs hard end-feel, no joint noise); subluxation/luxation (hypermobility); rheumatoid arthritis (systemic markers, multiple joints).
• Relevant investigations: DC/TMD palpation (crepitus + limited opening); CT/CBCT or OPG (sclerosis, erosion, flattening, osteophytes); MRI for soft tissue if specialist intervention; opening measurement; ESR/CRP if inflammatory osteoarthritis.
• Histopath presented? N · Labs presented? N (CT/OPG = imaging)
• Clinical signs: Crepitus · limited opening <35 mm · pain at rest + function · joint stiffness.
• Imaging findings: CT/OPG: sclerosis · erosion · flattening · osteophytes “bird’s-beak” · pseudocysts · condylar resorption possible.
• Management: Conservative first-line (soft diet, NSAIDs, physio, oral appliances); address mechanical overload; specialist for severe.

7. Synovitis and Capsulitis · Tier 2

• Clinical features: Synovitis: constant deep aching ↑ with movement; localised preauricular; possible effusion; pain worse with function; acute malocclusion from effusion. Capsulitis: tenderness at lateral pole; pain at rest + movement; localised warmth if acute; pain with contralateral excursion (lateral capsule stretching); soft end-feel.
• Differential diagnosis: Arthralgia from disc displacement (mechanical signs vs inflammatory); myalgia (muscle-based, palpable trigger vs capsular tenderness); septic arthritis (fever, systemic, rapid onset vs subacute synovitis).
• Relevant investigations: DC/TMD palpation (0.5 kg force at lateral pole); MRI T2/STIR (effusion + synovial thickening + bilaminar hyperintensity); opening measurement; joint warmth/swelling; ESR/CRP if septic suspected; US for effusion if MRI unavailable.
• Histopath presented? N (Convention N · Lecture Y — inflammatory pathology shown) ⚠ DISAGREEMENT: rarely biopsied
• Labs presented? N
• Clinical signs: Constant deep pain ↑ with movement · localised tenderness · effusion possible · soft end-feel.
• Imaging findings: MRI T2/STIR: effusion · synovial inflammation · bilaminar zone signal changes.
• Management: NSAIDs, ice/heat; rest; physio; specialist for refractory; arthrocentesis/CS injection.

Top LOs (verbatim, High-yield preserved):

• “Differentiate the four DC/TMD disc displacement categories… High-yield: disc displacement with vs without reduction, clicking mechanics, closed-lock concept, MRI confirmation.”
• “Describe subluxation and luxation as condylar hypermobility disorders… High-yield: subluxation self-reducibility, luxation as medical emergency, syringe and manual reduction.”
• “Discuss degenerative joint disease… High-yield: crepitus as cardinal sign, CT/OPG findings, osteophyte morphology.”

Mock-exam / past-year flags: DDwR with intermittent locking = ▶ OFP Q2 (clicking + transient self-resolving locking, 42 mm maintained — distinct from PY25 Case 2 DDw/oR). PAST YEAR 2025 Case 2 (DDw/oR with limited opening) tests opposite end of spectrum. Both DIRECT HITS.

L30 L30 Botox

Source: L30 Botox

1. SNARE Protein Cleavage Mechanism · Tier 1

• Key features / when to use: Foundational mechanism across all BoNT serotypes; light chain cleaves SNARE (SNAP-25 for A/C/E; synaptobrevin for B/D/F/G; syntaxin for C); prevents ACh release; basis for motor paralysis + nociceptor inhibition (Substance P, CGRP, glutamate).
• Alternatives / considerations: Essential for predicting serotype-specific clinical profiles + cross-resistance with antibodies; mechanism extends beyond motor to sensory/pain modulation.
• Companion investigations / adjuncts: Immunological screening for pre-existing antibodies if prior exposure; EMG to confirm NM blockade; baseline sensory testing for neuropathic conditions.
• Histopath presented? N · Labs presented? N
• Key facts / dose / mechanism: Light-chain protease cleaves SNARE complex · inhibits ACh + pain mediators exocytosis · lasts ~3 mo · nerve terminals regenerate SNARE → restored function.
• Clinical application: Explain mechanism to patients; predicts onset (24-72 h), duration, immunogenicity with repeat dosing.

2. Trigeminal Neuralgia Treatment with Botox · Tier 2

• Key features / when to use: Refractory cases after carbamazepine failure/intolerance; V3 submucosal/subcutaneous trigger zone injections (~43 U); V2 sphenopalatine ganglion (CAD-CAM guidance); 83-91% pain improvement.
• Alternatives / considerations: Carbamazepine first-line (HLA-B*1502 if Asian); microvascular decompression for surgical candidates; pregabalin/gabapentin alternatives; cost-benefit vs one-time injections.
• Companion investigations / adjuncts: Pre-Rx HLA-B*1502 if carbamazepine + Asian descent; EMG-guided or US for accuracy; MRI to exclude secondary causes; baseline pain/QoL questionnaires.
• Histopath presented? N · Labs presented? N
• Key facts / dose / mechanism: 25-140 U across 8-25 sites (no standardised protocol) · site selection by subjective pain + tactile allodynia · analgesic via CGRP/Substance P inhibition.
• Clinical application: Document VAS/NRS pre-/post-injection; follow-up at 2 + 12 weeks; reinject when effects wane.

3. Muscular TMD Dosing + Efficacy · Tier 2

• Key features / when to use: Myofascial pain failing ≥3 mo conservative; bilateral 60-100 U (20-25 U per masseter, 20 U per temporalis); reduces pain + improves ROM + decreases occlusal force.
• Alternatives / considerations: Conservative first-line (splint, physio, habit reversal) preferred; cost-benefit unclear; needle phobia; long-term bone-loss risk at TMJ/mandible; equivocal efficacy vs anaesthetics.
• Companion investigations / adjuncts: Baseline EMG of masticatory muscles; US or EMG guidance; assess SDB (OSA) contributing to bruxism; pain drawing + GCPS (Axis II).
• Histopath presented? N · Labs presented? N
• Key facts / dose / mechanism: Bilateral 60-100 U · combines muscle relaxation + analgesic via neuropeptide inhibition · moderate-to-high study bias · sufficient evidence for masseter hypertrophy; equivocal for myofascial alone.
• Clinical application: Refractory myofascial TMD + bruxism-related hypertrophy; counsel transient weakness/dysphagia; monitor mandibular bone changes long-term.

4. Botulinum Toxin Preparations + Conversion · Tier 2

• Key features / when to use: Three TGA-registered (Botox/Dysport/Xeomin); Botox + Dysport contain NAPs (slower spread); Xeomin pure (faster onset, room-temp storage); Myobloc BoNT/B (ready-to-use, short duration); select by spread/onset/storage.
• Alternatives / considerations: Units proprietary + non-interchangeable; conversion controversial except ONA:INCO (1:1); higher dilution ↑ spread risk.
• Companion investigations / adjuncts: Pre-injection history for prior toxin + antibody status; vascular assessment (colour Doppler) for facial injections; storage temperature verification.
• Histopath presented? N · Labs presented? N
• Key facts / dose / mechanism: ONA:INCO = 1:1 · ONA:ABO = 1:2.5 · ONA:RIMA = 1:50 · freeze-dried powders need 0.5-5 mL saline · 30-gauge needle standard · onset ~3-7 d, 3-mo duration · excipients (albumin, sucrose).
• Clinical application: Conversion dosing clinical judgment; document product + dose per site; educate on brand differences if switching.

5. Contraindications + Immunogenicity · Tier 2

• Key features / when to use: Absolute CI: myasthenia gravis, Lambert-Eaton, infection at site, hypersensitivity (albumin), pregnancy/breastfeeding; immunogenicity rises with high doses + short intervals (<3 mo) + long-term (>10 y).
• Alternatives / considerations: Neutralizing antibodies → loss of effect; repeat dosing counsel essential; mandibular/TMJ bone loss long-term; adverse spread (dysphagia, nasal speech) transient.
• Companion investigations / adjuncts: Medical history for NM disorders; pregnancy status; baseline CBCT/OPG for TMD to detect bone changes; antibody titres if treatment resistance after 2+ courses.
• Histopath presented? N · Labs presented? Y (antibody formation)
• Key facts / dose / mechanism: Common AEs: localised pain/bruising, transient weakness, headache, flu-like (immune); rare: ptosis, diplopia, respiratory failure · mandibular bone loss preclinical/early human · albumin theoretical prion risk.
• Clinical application: Counsel immunogenicity; 3-mo minimum interval; refer for antibody testing if 3rd course no response; long-term TMJ monitoring.

6. Chronic Migraine PREEMPT Protocol · Tier 2

• Key features / when to use: FDA-approved 2010 for chronic migraine (≥15 days/mo); 155-195 U across 31 sites (frontalis, corrugator, procerus, occipitalis, temporalis, trapezius, cervical paraspinal); every 12 wk; min 3 sessions over 12 mo.
• Alternatives / considerations: Preventive meds (topiramate, propranolol, amitriptyline) first-line; CGRP mAbs (erenumab, fremanezumab) emerging; cost-benefit vs oral; patient preference.
• Companion investigations / adjuncts: Baseline headache diary (≥14 d/mo); PSG if SDB cofactor; colour Doppler US for facial/scalp vascular anatomy; pain severity + disability scales pre/post.
• Histopath presented? N · Labs presented? Y (headache frequency documentation)
• Key facts / dose / mechanism: PREEMPT 1+2 trials safety/efficacy; frontalis 20 U (4 sites), corrugator 10 U (2), procerus 5 U (1), occipitalis 30-40 U (6-8), temporalis 40-50 U (8-10), trapezius 30-50 U (6-10), cervical paraspinal 20 U (4) · reduces CGRP/Substance P.
• Clinical application: Standardised protocol; document sites + doses; educate 1-2 wk lag; monitor systemic spread; reinject 12-wk intervals.

Top LOs (verbatim, High-yield preserved):

• “Explain the mechanism of action of botulinum toxin… High-yield: SNARE cleavage (A/C/E vs B/D/F/G), ACh release blockade, analgesic mechanisms via Substance P/CGRP/glutamate.”
• “Discuss indications for botulinum toxin in OFP management… High-yield: TN (83-91% pain improvement), muscular TMD (60-100 U bilateral), chronic migraine PREEMPT (155-195 U).”
• “Describe contraindications, adverse effects, and complications… High-yield: absolute CI (myasthenia gravis, infection, pregnancy), transient AEs, immunogenicity/antibody formation.”

Mock-exam / past-year flags: PAST YEAR 2025 (3 pharmacological treatments for trigeminal neuropathy).

L31 L31 Occlusal Splint Therapy

Source: L31 Occlusal Splint Therapy

1. Flat Plane Stabilisation Splint · Tier 2

• Key features / when to use: First-line for muscle disorders + sleep bruxism; maxillary (Michigan) or mandibular (Tanner); joint stabilisation + tooth protection + force redistribution; relaxes elevator muscles + ↓ bruxism episodes.
• Alternatives / considerations: Hard splints preferred over soft (avoids “chewing-gum effect”); canine guidance lacks evidence of superiority; soft splints ↑ EMG + short-term bruxism; splints do NOT permanently ↓ bruxism itself.
• Companion investigations / adjuncts: DC/TMD diagnosis first; baseline bite registration + serial occlusal exams; photo (anterior/lateral); PHQ-4 for catastrophising; STOP-BANG if SDB-bruxism overlap.
• Histopath presented? N · Labs presented? N
• Key features / evidence: Joint stabilisation · protect teeth · redistribute occlusal forces · relax elevator muscles · ↓ bruxism episodes.
• Indication: Muscle disorders (myalgia, myofascial, tension HA from sleep bruxism); primary sleep bruxism; TMD-attributed headache.

2. Anterior Repositioning Appliance · Tier 3

• Key features / when to use: Mandible anteriorly via guiding ramp; reduces disc pressure; temporarily “recapture” disc in clicking/locking; precursor to comprehensive procedures; Wilkes II disc displacement with acute pain or occasional locking.
• Alternatives / considerations: Risk of permanent occlusal/skeletal changes long-term — careful patient selection + close monitoring; asymptomatic clicking does NOT require treatment; splints do NOT permanently recapture; physio + NSAIDs first-line.
• Companion investigations / adjuncts: DC/TMD + MRI-confirmed disc displacement; baseline occlusal + dental photos; serial bite assessments (4-6 wk initially) for occlusal drift; psychological assessment for catastrophising; sleep study if SDB-TMD overlap.
• Histopath presented? N · Labs presented? N
• Key features / evidence: Anterior mandible via guiding ramp · reduces disc pressure · “recapture” intent in clicking/catching/locking.
• Indication: Acute TMJ pain from disc displacement; sleep bruxers with nocturnal TMJ locking; Wilkes II with refractory.

3. NTI-tss · Tier 3

• Key features / when to use: Mini-anterior engaging 2-4 maxillary incisors; disengages posterior; proposed trigeminal inhibition; rarely recommended due to adverse effects.
• Alternatives / considerations: Not superior to flat-plane (inferior in some studies); significant risk of anterior open bite + lower-anterior mobility long-term; aspiration/swallowing risk; placebo effect significant.
• Companion investigations / adjuncts: DC/TMD; baseline intraoral photos documenting anterior tooth + overbite/overjet; serial photos 3-mo for early open bite or mobility; anterior tooth mobility at baseline + follow-up; sleep assessment if concurrent bruxism; psychological eval if catastrophising.
• Histopath presented? N · Labs presented? N
• Key features / evidence: Disengages posterior · ↓ jaw-closing muscle activity · may reduce acute pain + improve limited opening.
• Indication: TMD with acute pain + limited opening; sleep bruxism (controversial); tension HA with myofascial trigger.

4. Hard vs Soft Splint Material · Tier 2

• Key features / when to use: Hard (PMMA, 120-150 MPa) first-line; soft (silicone 5-15 MPa) cheaper short-term; material choice fundamentally influences success + safety.
• Alternatives / considerations: Soft ↑ EMG (“chewing-gum effect”) + short-term bruxism — opposite to relaxation goal; no significant difference in TMD symptom reduction but hard has better outcomes; semi-flexible (PEEK) + flexible (nylon) less common.
• Companion investigations / adjuncts: Baseline muscle palpation + EMG if available; clenching/grinding habit history; 2-4 wk follow-up palpation for ↑ muscle tension; patient tolerance + comfort; brief cognitive screen for health anxiety.
• Histopath presented? N · Labs presented? N
• Key features / evidence: Hard stronger + easier to adjust · soft ↑ EMG (“chewing-gum”) + short-term ↑ bruxism · no significant difference in TMD symptom reduction.
• Indication: Hard: all TMD + sleep bruxism; soft: very short-term low-cost trial only.

5. Diagnostic-Based Appliance Selection Algorithm Greene & Menchel 2018 · Tier 2

• Key features / when to use: Three-pathway: (1) Muscle disorders → flat plane → ABP if refractory; (2) Disc displacements → flat plane → ARA for Wilkes II + locking; (3) Joint inflammation → flat plane → ARA if severe; return to flat plane after resolution.
• Alternatives / considerations: Diagnosis-driven > empiric; physio + NSAIDs concurrently; selection does not guarantee efficacy (splints not superior in 2025 meta-analysis); placebo + regression to mean drive success; psychological factors influence prognosis.
• Companion investigations / adjuncts: Complete DC/TMD (Axis I + II); MRI if disc displacement; baseline pain VAS + jaw opening + functional limitation scores; serial assessments 4-6 wk; psychological referral if Axis II elevated; sleep medicine referral for SDB screen.
• Histopath presented? N · Labs presented? N
• Key features / evidence: Muscle disorders: flat plane → ABP if refractory · disc displacements: flat plane → ARA for Wilkes II locking · joint inflammation: flat plane → ARA if severe · return to flat plane after resolution.
• Indication: All TMD presentations; guides initial + progressive selection.

Top LOs (verbatim, High-yield preserved):

• “Outline the rationale for splint therapy… High-yield: mechanisms theories only; placebo enhanced by clinician reputation + environment.”
• “Compare major stabilisation splint designs vs anterior repositioning… High-yield: hard stabilisation splints first-line; ARA reserved for Wilkes II with refractory.”
• “Distinguish NTI-tss and mini-anterior vs full-coverage stabilisation… High-yield: NTI-tss limitations + AEs; stabilisation splints as preferred design.”

Mock-exam / past-year flags: PAST YEAR 2025 Case 2 — non-pharmacological treatments.

L32 L32 Non-Odontogenic Toothache

Source: L32 Non-Odontogenic Toothache

1. Myofascial Pain with Trigger Point Referral · Tier 1 · PAST YEAR 2024

• Clinical features: Adults (any age, stress-related peaks); hyperexcitable nodule in taut muscle band (masseter, temporalis, SCM); tender to palpation; refers pain 80% of time; aching/dull; triggered by clenching + nail-biting + parafunction; hours-days; 7% receive unnecessary endodontic treatment.
• Differential diagnosis: Pulpitis (pulp tests negative on source tooth); myocardial ischemia (substernal + dyspnea); TMJ disorders (clicking/crepitus + joint tenderness).
• Relevant investigations: Palpation of masseter, temporalis, SCM (force 1.0 kg, 5 sec for myofascial subtyping); pain vs familiar pain vs referred pain; trigger-point injection response (LA without adrenaline).
• Histopath presented? N · Labs presented? N
• Management: Patient education + reassurance; psychosocial distress; pain-free jaw function; habit reversal; spray-and-stretch (ethyl chloride); jaw stretching exercises; physio; trigger-point injection; splint if bruxism; psychological referral; botulinum toxin (equivocal evidence).

2. Trigeminal Neuralgia · Tier 1 · PAST YEAR 2024

• Clinical features: 50+ years; brief electric shock/stabbing/shooting (fraction-second to 2 min); triggered by light touch; unilateral; episodic frequent attacks; V2 or V3; wakes patient from sleep; severe QoL impact.
• Differential diagnosis: Cluster headache (autonomic features); migraine (longer + pulsating); post-traumatic neuropathy (trauma history); MS (especially if bilateral TN).
• Relevant investigations: MRI for neurovascular compression (superior cerebellar artery impinging trigeminal root); imaging to rule out tumours/schwannomas; neurological exam; HLA-B*1502 screening if Asian descent before carbamazepine.
• Histopath presented? N · Labs presented? N
• Management: First-line carbamazepine (blood/liver monitoring); second-line gabapentin, pregabalin, baclofen; surgical (MVD with Teflon, Gamma Knife, percutaneous); botulinum toxin (83-91% pain improvement).

3. Neurovascular Pain — Migraine + TACs · Tier 1

• Clinical features: Female 3.2:1; ~40 y onset; 70% unilateral; moderate-severe pulsating; 62% alveolar, 32% mucosal; <1 wk duration (1/3 chronic); wakes 35%; tearing + nasal congestion + rhinorrhoea + nausea + photophobia + phonophobia; dental hypersensitivity/allodynia.
• Differential diagnosis: Odontogenic pulpitis (positive pulp tests + percussion sensitivity); sinus-origin (constant dull, worsens on bending); myofascial (trigger point palpable, muscle nodule).
• Relevant investigations: Pain character history (laterality, location, pulsating); autonomic screening (tearing, congestion); allodynia (hypersensitivity despite normal vitality); imaging NOT indicated unless atypical.
• Histopath presented? N · Labs presented? N
• Management: Preventive for migraine (topiramate, amitriptyline, propranolol); acute (triptans, NSAIDs); TACs specific (cluster: oxygen, sumatriptan, verapamil; paroxysmal hemicrania: indomethacin); patient education on triggers; psychological support.

4. Sinus-Origin Toothache · Tier 2

• Clinical features: Referred via maxillary V2; constant dull aching in maxillary posterior teeth; percussion + temperature sensitive; ↑ on bending over; virgin teeth → sinusitis suspected; viral most common; bacterial = high fever + >7 d + worsening.
• Differential diagnosis: Odontogenic maxillary pain (positive pulp tests, radiographic caries/apical); migraine (unilateral + pulsating + autonomic); myofascial (trigger-point reproducible).
• Relevant investigations: Sinus CT or X-ray for sinusitis (fluid level, mucosal thickening); percussion on teeth (hypersensitivity without pulp disease); pulp testing negative; clinical assessment for nasal congestion + drainage.
• Histopath presented? N · Labs presented? N
• Management: Most viral — decongestants + analgesics + nasal sprays/washes + nasal steroids; antibiotics only bacterial (>7 d + fever + worsening); avoid unnecessary dental treatment on virgin teeth; ENT if persistent/recurrent.

5. Cardiac-Origin Orofacial Pain · Tier 1 · EMERGENCY

• Clinical features: Myocardial ischemia → referred orofacial/dental (6% solely orofacial); substernal pressure radiating to left neck/shoulder/arm; dyspnea + nausea + fatigue + “impending doom”; triggered by exertion or heavy meals; vagus + trigeminal convergence at medulla/C1-C3.
• Differential diagnosis: Angina/acute MI (substernal + dyspnea + left-arm radiation — EMERGENCY); myofascial (localised trigger point, no systemic); odontogenic (positive pulp tests + radiographic + no chest/systemic).
• Relevant investigations: 12-lead ECG (ST changes); troponin assay (elevated MI); cardiac biomarkers; vital signs; cardiology consult if any suspicion.
• Histopath presented? N · Labs presented? Y
• Labs: ECG (ST elevation/depression, T-wave inversion); troponin elevation; cardiac enzymes; lactate if severe.
• Management: CALL EMERGENCY SERVICES; aspirin 300-325 mg chewed if not contraindicated; O₂ if SpO₂ <94%; nitrates if available; urgent cardiology; avoid dental treatment until cleared.

Top LOs (verbatim, High-yield preserved):

• “Describe the prevalence, aetiology, pathophysiology, clinical features, diagnosis, and management… High-yield: myofascial pain with trigger-point referral, neurovascular pain (migraine, TACs), sinus-origin, cardiac referral, trigeminal neuralgia, neuropathic pain.”
• “Explain the mechanism of referred pain in myofascial pain… High-yield: anterior + posterior temporalis, masseter, SCM referral patterns; antidromic transmission.”
• “Explain the clinical presentation and diagnostic approach to neurovascular pain… High-yield: demographics, pain characteristics, associated autonomic symptoms, allodynia.”

Mock-exam / past-year flags: PAST YEAR 2024 myofascial + 2025 trigeminal neuropathy differential.

L33 L33 Temporomandibular disorders; Extracapsular disorders

Source: L33 Temporomandibular disorders; Extracapsular disorders

1. Myofascial Pain with Referral · Tier 1 · PAST YEAR 2024 + 2025

• Clinical features: Females predominantly; central sensitisation + stress; parafunction exacerbates; pain radiates beyond muscle boundary; insidious onset with psychological stressors; site of pain ≠ source.
• Differential diagnosis: Local myalgia (palpation site only vs spreading); fibromyalgia (widespread polyarticular vs musculoskeletal); neuropathic (dermatomal vs myofascial).
• Relevant investigations: DC/TMD palpation (1 kg force, 5 sec → spreading/referred pain replication); pain drawings + GCPS (Axis II); CRP/ESR if systemic; EMG if myospasm suspected.
• Histopath presented? N · Labs presented? N
• Labs / diagnostic tests: DC/TMD palpation sens 0.86, spec 0.98.
• Management: Education + reassurance; stress management + habit reversal; physio (stretching, massage); flat-plane hard splint; analgesics + muscle relaxants; trigger-point injection if refractory; psychological/psychiatric referral if comorbid anxiety/depression.

2. Local Myalgia · Tier 1

• Clinical features: Acute-to-chronic; pain strictly at palpation site (no spreading); post-local-trauma, joint inflammation, or DOMS; resolves 3-7 d if traumatic trigger; protective co-contraction.
• Differential diagnosis: Myofascial with referral (spreading vs localised); myositis (focal swelling + redness + warmth vs localised tenderness); trigger-point sensitivity (passive vs provocation-based reproduction).
• Relevant investigations: DC/TMD palpation (1 kg force, 5 sec) for single-site pain; protective muscle guarding; FBC + CRP if infectious; US if trauma/abscess suspected.
• Histopath presented? N · Labs presented? N
• Labs / diagnostic tests: DC/TMD palpation sens 0.90, spec 0.99; imaging only if trauma.
• Management: Reduce contributing factors (posture, stress); analgesics + anti-inflammatories; ice/heat; physio + gentle stretching; splint if 2° to TMJ disease; activity modification.

3. Myositis · Tier 2

• Clinical features: Constant acute pain + swelling + erythema + warmth; masseter most common; acute post-trauma/infection; functional limitation + trismus; resolves or progresses to myositis ossificans.
• Differential diagnosis: Cellulitis (spreading non-demarcated erythema); local myalgia (acute severe + systemic vs simple tenderness); abscess (purulent vs inflammatory); progressive myositis ossificans (rapid bone formation).
• Relevant investigations: FBC (↑ WBC if infectious); CRP + ESR; CT gold-standard for myositis ossificans + calcification; MRI for soft-tissue extent; US for abscess; cultures if infectious; biopsy if ossification/uncertain.
• Histopath presented? Y (Convention: Y · Lecture: N) ⚠ DISAGREEMENT: lecture omits detail
• Labs presented? N (Convention: Y · Lecture: N) ⚠ DISAGREEMENT
• Histopath: Inflammatory infiltration + oedema · myositis ossificans: osteoblastic proliferation + new bone formation.
• Labs: FBC leukocytosis; ↑ ESR/CRP; cultures if infection.
• Management: Conservative for traumatic myositis ossificans (NSAIDs, activity modification); surgical excision after quiescence; spontaneous resolution possible; antibiotics if infectious; ice + immobilisation acute; physio delayed.

4. Myospasm · Tier 2

• Clinical features: Acute sudden involuntary sustained tonic contraction (muscle cramp); localised severe pain + severely limited mandibular ROM; acute malocclusion common; jaw-closing (masseter/temporalis → limited opening); jaw-opening (lateral pterygoid → difficulty closing); related to deep pain + metabolic fatigue.
• Differential diagnosis: Tetanus (generalised vs localised); protective co-contraction (involuntary sustained vs reflex guarding); tardive dyskinesia/dystonia (chronic involuntary vs acute transient); seizure-related (brief vs prolonged).
• Relevant investigations: Needle EMG only definitive test (Convention: clinical mgmt without routine EMG) ⚠ DISAGREEMENT; clinical exam (acute trismus or deviation); screening for triggers (OSA, medication, substance use); assess underlying myositis/joint pathology if recurrent.
• Histopath presented? N · Labs presented? Y (Convention: N · Lecture: Y — EMG gold-standard per lecture) ⚠ DISAGREEMENT
• Management: Acute pain reduction via ice or LA injection; muscle stretching to full length once pain controlled; heat post-acute; benzodiazepines for severe; address underlying causes (bruxism, medications); physio + biofeedback; botulinum toxin only if refractory.

5. Giant Cell Arteritis · Tier 1 · EMERGENCY

• Clinical features: Systemic granulomatous vasculitis of medium/large arteries; >50 y predominantly; female predominance (higher in white populations); new-onset headache + scalp tenderness; jaw claudication (chewing/speaking pain); vision-threatening ischaemic; fever + polymyalgia rheumatica.
• Differential diagnosis: TMD myofascial pain (systemic inflammatory + scalp tenderness + ↑ ESR vs localised); tension headache (vision-threatening + claudication absent); other vasculitides (large-artery vs small-vessel); infectious (negative cultures vs positive serology).
• Relevant investigations: FBC + ESR (markedly elevated >50 mm/hr) + CRP; temporal artery biopsy (gold-standard granulomatous + giant cell inflammation); temporal artery US adjunct; ophthalmology immediately if vision symptoms; MRI/CT if atypical; ESR/CRP monitor during CS.
• Histopath presented? Y · Labs presented? Y
• Histopath: Granulomatous inflammation of medium + large arteries · giant cells · intimal proliferation.
• Labs: Markedly ↑ ESR + ↑ CRP + possible anaemia; temporal artery biopsy confirmatory.
• Management: Urgent CS (IV then oral) to prevent vision loss; high-dose initial with gradual taper; ESR/CRP guide dosing; ophthalmology + rheumatology co-management; antiplatelet (aspirin) consider; NSAIDs insufficient; long-term CS with bone protection (Ca, vit D).

6. Oromandibular Dystonia · Tier 2

• Clinical features: Involuntary sustained contraction of masticatory + suprahyoid + intrinsic tongue muscles; females predominantly; idiopathic 63%; mean onset 31-58 y; jaw deviation + teeth grinding + grimacing + tongue protrusion; ocular blinking; functional impairment with speech + eating.
• Differential diagnosis: Bruxism (involuntary grinding + posturing vs simple clenching without abnormal posture); tardive dyskinesia (drug-induced choreoathetoid vs sustained dystonic); myospasm (chronic involuntary sustained vs acute transient); seizure-related (epileptiform vs dystonic).
• Relevant investigations: Needle EMG (involuntary motor unit activity sustained pattern); clinical exam + video documentation of abnormal movements; neuro exam for secondary causes; brain MRI if secondary suspected (basal ganglia, post-stroke); medication-induced screening (neuroleptics, metoclopramide); serology if systemic features (Wilson’s, SLE).
• Histopath presented? N · Labs presented? N
• Management: Motor-suppressive (anticholinergics, benzodiazepines); botulinum toxin first-line injections (masseter, temporalis, lateral pterygoid, tongue); deep brain stimulation for refractory generalised; baclofen for systemic; speech + swallowing therapy; splints may reduce; psychological support.

Top LOs (verbatim, High-yield preserved):

• “Discuss the aetiology, pathophysiology, clinical features, diagnosis, and conservative management of myalgia… High-yield: palpation-based DC/TMD classification, trigger-point theory + central sensitisation, nociceptor activation, self-care + physio first-line.”
• “Describe the aetiology and clinical features of giant cell arteritis… High-yield: systemic granulomatous vasculitis, headache + scalp tenderness, ESR + temporal artery biopsy, vision-threatening complications.”
• “Explain the presentations and management of movement disorders… High-yield: involuntary sustained contractions + abnormal postures, ocular blinking in oromandibular dystonia, neuroleptic-associated tardive dyskinesias.”

Mock-exam / past-year flags: PAST YEAR 2024 + 2025 Case 2.

L34 L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome

Source: L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome

1. Trigeminal Neuralgia · Tier 1 · PAST YEAR 2024

• Clinical features: >50 y; female 2:1; V2/V3 distribution; electric shock/stabbing (fraction-second to 2 min); trigger zones (light touch, talking, chewing); normal between episodes; severe QoL impact.
• Differential diagnosis: PTTNP (trauma history + persistent vs paroxysmal); cluster headache (autonomic features absent in TN); TMD-attributed (poor localisation, palpation tenderness vs trigger zones).
• Relevant investigations: MRI to rule out neurovascular compression (classical) or secondary (MS, tumour); HLA-B*1502 before carbamazepine if Asian descent (SJS risk); clinical diagnosis primarily.
• Histopath presented? N · Labs presented? Y (Convention: N · Lecture: Y — HLA-B*1502) ⚠ DISAGREEMENT
• Management: First-line carbamazepine, then gabapentinoids/pregabalin/baclofen; refractory: MVD, rhizotomy, balloon compression, gamma knife.

2. Post-traumatic Trigeminal Neuropathic Pain · Tier 1 · PAST YEAR 2025 Case 1

• Clinical features: Post-dental trauma (extraction, implant, restoration, RCT, LA injection); onset <6 mo; persists >3 mo; hyperalgesia + allodynia; unilateral (rarely crosses midline); burning + foreign-body “fishbone” sensation; 40-50 y; female predominance; associated psychosocial stressors.
• Differential diagnosis: TN (trauma history + persistent continuous vs paroxysmal); PIFP (PTTNP has identifiable trauma + trigeminal distribution vs PIFP poor localisation); PHN (no prior zoster rash).
• Relevant investigations: CBCT or OPG post-trauma for nerve injury/implant position; sensory testing (touch, pinprick, temperature); avoid imaging if no obvious abnormality (~15% show none); early referral (<12 mo) improves prognosis.
• Histopath presented? N · Labs presented? N
• Management: Avoid irreversible dental treatment if no obvious cause; minimise perioperative inflammation; topical (LA, capsaicin); systemic (TCA amitriptyline 10-200 mg, gabapentin 300-3600 mg, pregabalin 300-600 mg, clonazepam 1-10 mg); CBT/mindfulness; 50% pain reduction = clinical success.

3. Persistent Idiopathic Facial Pain · Tier 2

• Clinical features: Middle age + female predominance; daily/near-daily continuous; poorly localised (non-dermatomal); dull/aching/nagging; may spread; no identified dental cause; aggravated by stress; co-exists with fibromyalgia + IBS + chronic migraine; normal neurological exam.
• Differential diagnosis: PTTNP (PIFP no trauma + poor localisation vs dermatomal + trauma); TN (continuous vs electric shock attacks); odontogenic (PIFP ruled out by investigations).
• Relevant investigations: Comprehensive neurological exam (normal = criterion); pulp testing negative; imaging (dental/mandibular) excludes structural; exclusion of systemic (blood tests for nutritional/metabolic/autoimmune); MRI if red flags.
• Histopath presented? N · Labs presented? Y (exclusion-based)
• Labs / investigations: FBC + iron + B12 + folate (nutritional); ESR if GCA; psychological screening Axis II.
• Management: Specialist multidisciplinary (pain physician + psychology); TCA (amitriptyline), gabapentinoids, SNRIs (venlafaxine), anticonvulsants (pregabalin); CBT + psychological support; difficult chronic course.

4. Trigeminal Post-herpetic Neuralgia · Tier 2

• Clinical features: >50 y (>60 ↑ risk); prior herpes zoster rash same trigeminal division (V1 most common); burning/itching; moderate intensity; continuous or intermittent electric shock; allodynia + hyperalgesia; unilateral; persists >3 mo post-rash; severe initial zoster = higher risk; immunocompromised ↑ risk.
• Differential diagnosis: TN (zoster rash history + burning vs electric shock + no trigger zones); PTTNP (rash vs trauma history + spontaneous burning vs trauma-associated); post-treatment complication (rash precedes neuralgia by weeks-months vs immediate post-procedure).
• Relevant investigations: Clinical diagnosis based on zoster rash history; no specific investigations; MRI optional if atypical; sensory testing (allodynia/hyperalgesia); consider HbA1c (diabetes risk) + immunocompromised status if recurrent.
• Histopath presented? N · Labs presented? N
• Management: Prevention: early antiviral (acyclovir/valacyclovir <72 h of rash) + vaccination >50 y (Shingrix/Zostavax); topical capsaicin + lidocaine patch; gabapentinoids (gabapentin 300-3600 mg, pregabalin), TCA (amitriptyline), SNRI (venlafaxine); pain management referral.

5. Burning Mouth Syndrome · Tier 2

• Clinical features: Postmenopausal female (0.1-3.9%); >2 hr daily for >3 mo; burning quality; superficial oral mucosa; normal intraoral appearance; no identifiable local/systemic cause; dysaesthesia + xerostomia + dysgeusia in 2/3; anxiety + depression + personality disorders common; diagnosis of exclusion.
• Differential diagnosis: BMS primary vs secondary (exclude medications [ACE-I most common], B6 high-dose neuropathy, zinc toxicity >80 mg/d); candidiasis (plaques, culture/KOH); nutritional deficiency (normal B12/folate/iron/glucose); Sjögren (negative serology).
• Relevant investigations: FBC + iron studies (ferritin, serum iron, TIBC) + serum folate + B12 + HbA1c + TSH; Sjögren serology (anti-SSA/SSB) + SLE screen; medication review (ACE-I, B6/zinc supplements); cranial nerve exam (normal); exclude oral mucosal lesions; saliva testing NOT recommended (unreliable).
• Histopath presented? N · Labs presented? Y
• Labs / investigations: FBC + iron + ferritin + folate + B12 + HbA1c + TSH; Sjögren + ANA; medication + supplement history.
• Management: Multidisciplinary specialist (oral medicine + psychology); topical clonazepam; systemic clonazepam; antidepressants (amitriptyline, venlafaxine); capsaicin topical (TRPV1 depletion); experimental (alpha-lipoic acid, PEA, low-level laser); expectation management + CBT; chronic course.

Top LOs (verbatim, High-yield preserved):

• “Distinguish between PTTNP, PIFP, and TN… High-yield: ICOP criteria, differential clinical features, role of imaging + neurological exam.”
• “Explain the classification, pathophysiology, triggers, and pharmacological management of trigeminal neuralgia… High-yield: carbamazepine first-line, HLA-B1502 screening for Asian patients, neurovascular compression mechanism.*”
• “Outline the differential diagnosis of oral burning and apply a systematic clinical assessment to exclude secondary causes before diagnosing burning mouth syndrome. High-yield: medication-related (ACE-I most common), nutritional deficiencies, autoimmune (Sjögren’s), systematic history + blood investigations.”

Mock-exam / past-year flags: PTTNP = ▶ OFP Q1 (IAN/lingual nerve injury post-extraction of 37; ICOP criteria; QST + sensory mapping; pharm + CBT + pain neuroscience). PAST YEAR 2025 Case 1 (PTTNP post-restoration 16) + 2024 (TN). DIRECT MOCK HIT.

L35 L35 Oral Appliance Therapy for Snoring and OSA

Source: L35 Oral Appliance Therapy for Snoring and OSA

1. Mandibular Advancement Appliance · Tier 1 · LECTURER HINT

• Key features / when to use: MAA advances mandible anteriorly → ↑ velopharyngeal airspace; first-line for primary snoring + mild-moderate OSA (AHI 5-30); second-line for severe after CPAP failure; patient-preferred over CPAP despite lower absolute AHI reduction; “Mean Disease Alleviation = Efficacy + Compliance.”
• Alternatives / considerations: CPAP superior for severe (achieves AHI <5); positional therapy for position-dependent mild; weight loss + lifestyle (may ↓ AHI by 14-20).
• Companion investigations / adjuncts: Baseline PSG (Level 1) to establish severity + phenotype; follow-up PSG with appliance in situ post-titration; O₂ desaturation nadir + arousal index (REM + supine AHI may persist).
• Histopath presented? N · Labs presented? Y
• Key facts: AHI reduction baseline 24-30 → 9-14 · responders 40-60% AHI reduction · REM + supine AHI may remain elevated.
• Labs / sleep-study findings: Baseline AHI: mild 5-15, moderate 15-30, severe >30 · responders 40-60% reduction · O₂ desaturation improvement · REM + supine may remain elevated · Level 1 PSG reference.
• Indication: First-line for primary snoring; preferred alternative to CPAP in mild-moderate OSA; severe OSA after CPAP failure.

2. MAA Responder vs Non-Responder Profile · Tier 1

• Key features / when to use: Responder: younger, lower BMI (<30), female, retracted maxilla/mandible, lower facial height, shorter airway; non-responder: older, ↑ BMI (>30), larger neck circumference (≥43 cm M, ≥41 F), male, nasal obstruction, minimal tongue forward movement; baseline AHI <20 more likely respond, ≥30 less likely.
• Alternatives / considerations: Non-responders may benefit from multistep (MAA + positional + weight loss + EPAP ± O₂); CPAP if non-responder predicted; cephalometric/CBCT may identify barriers.
• Companion investigations / adjuncts: Cephalometric or CBCT for maxillary/mandibular position + airway; PSG phenotyping (loop gain, arousal threshold, O₂ desaturation slope); fasting glucose, lipids, HbA1c if metabolic syndrome.
• Histopath presented? N · Labs presented? Y
• Key facts: Responders: younger + lower BMI + female + retracted maxilla/mandible + lower facial height + shorter airway · non-responders: older + ↑ BMI + larger neck + male + nasal obstruction + minimal tongue movement · PSG: low loop gain + low baseline AHI + higher arousal threshold.
• Labs / sleep-study findings: Responders baseline AHI <20; non-responders ≥30 · low loop gain + arousal threshold correlate with success · anatomical imaging favours response · female independently better efficacy.
• Indication: Prognostication; younger lower-BMI female with retracted maxilla = most likely responder.

3. MAA Side Effects + Craniofacial Changes · Tier 1 · LECTURER HINT

• Key features / when to use: Counsel upfront: dry mouth (86%), excessive salivation (60%), tooth discomfort (59%), masseter pain (45%), TMJ pain (37%), jaw discomfort (41%); ~2% cannot tolerate; transient TMD typically resolves; long-term changes (posterior open bite, ↓ overjet/overbite, mandibular crowding, interproximal gaps) manageable.
• Alternatives / considerations: TRD if MAA-intolerant; bite changes manageable via periodic occlusal adjustments; TMD screening at baseline + during therapy.
• Companion investigations / adjuncts: Baseline dental photos + cephalometric radiographs; periodic intraoral photography (6-12 mo) to track bite changes; clinical TMJ exam pre-treatment + follow-up.
• Histopath presented? N · Labs presented? N
• Key facts: Short-term AEs (dry mouth, salivation, tooth/masseter/TMJ/jaw discomfort) · ~2% cannot tolerate · long-term: mandibular backward rotation + ↑ anterior facial height + posterior open bite · dental: ↓ overjet/overbite + mandibular crowding + interproximal gaps · TMJ: no significant alterations in most; transient symptoms.
• Indication: Counsel on dry mouth + bite-change risks; monitor compliance; reassure transient TMJ symptoms.

4. Tongue-Retaining Device · Tier 2 · LECTURER HINT

• Key features / when to use: Silicone bulb engages tongue forward via suction (no mandibular advancement, no dental forces); for edentulous or severe periodontal where MAA unsuitable; MAA-intolerant (jaw pain, TMD); often uncomfortable + lower adherence than MAA.
• Alternatives / considerations: First-line remains MAA for dentate; CPAP for MAA-intolerant + moderate-severe OSA; weight loss + positional therapy adjuncts.
• Companion investigations / adjuncts: Same diagnostic PSG pre-treatment as MAA; follow-up PSG with TRD in situ; patient tolerance assessment at 2-4 wk follow-up.
• Histopath presented? N · Labs presented? Y
• Key facts: Silicone bulb engages tongue via suction · no mandibular/dental effect · forward tongue displacement maintains velopharyngeal patency · edentulous or MAA-intolerant · often uncomfortable + lower adherence · minimal craniofacial side effects.
• Indication: Second-line for edentulous, severe periodontal disease, MAA intolerance.

5. OSA Diagnosis: AHI Thresholds, PSG Levels, Screening Tools · Tier 1

• Key features / when to use: Screen all snorers + witnessed apnea + sleepy with STOP-BANG (≥5 = high risk) + Epworth (≥10 concerning); AHI = (apnoeas + hypopnoeas)/hours sleep; severity: mild 5-15, moderate 15-30, severe >30; Level 1 PSG reference standard.
• Alternatives / considerations: Level 2/3/4 home testing acceptable if high pretest probability; wearables (Oura, Fitbit, Apple Watch) emerging for screening but not diagnostic.
• Companion investigations / adjuncts: STOP-BANG (snoring, tired, observed apnea, pressure, BMI, age, neck, gender); Epworth (8 situations, 0-3, total ≥10); Level 1 PSG channels (EEG, EOG, EMG, ECG, thermistor, strain gauges, pulse oximetry, snore sensor).
• Histopath presented? N · Labs presented? Y
• Key facts: AHI severity: mild 5-15, moderate 15-30, severe >30 · STOP-BANG 5-8 yes = high risk · Epworth ≥10 concerning · Level 1 PSG reference (12-13 channels, attended); Levels 2-4 home-based · apnoea ≥10 sec; hypopnoea 30-50% ↓ + ≥3-4% SpO₂ drop or arousal · RERA counts toward RDI.
• Labs / sleep-study findings: SpO₂ nadir + arousal index + REM/supine AHI + sleep efficiency + staging · PSG channels (EEG C3A2/A1A2, EOG, EMG, ECG, thermistor, strain gauges, pulse oximetry, snore sensor) · SpO₂ <90% + arousal index >20/hr = moderate-severe.
• Indication: Screen all snorers/sleepy with STOP-BANG + ESS; refer to sleep physician for PSG if high-risk.

Top LOs (verbatim, High-yield preserved):

• “Explain the mechanism of action, indications, and clinical efficacy of mandibular advancement appliances for managing primary snoring and mild-to-moderate OSA. High-yield: anterior mandibular movement ↑ velopharyngeal airspace, AHI reduction outcomes, patient preference over CPAP, clinical indications.”
• “Identify patient characteristics predicting MAA response vs non-response… High-yield: responder (younger, lower BMI, female, retracted maxilla/mandible); non-responder (older, ↑ BMI, larger neck, nasal obstruction).”
• “Describe the side effects and craniofacial changes… High-yield: dry mouth (86%), occlusal changes (posterior open bite + ↓ overjet), TMJ (transient symptoms).”

Mock-exam / past-year flags: OSA = Tier 1 ▶ OFP Q3 (moderate OSA + retrognathia + STOP-BANG + AHI + MAA mechanism + responder profile + side effects + TRD + OSA-bruxism overlap). DIRECT MOCK HIT — upgrade from prior “lecturer hint” status.

L36 L36 Bruxism

Source: L36 Bruxism

1. Sleep vs Awake Bruxism · Tier 1 · PAST YEAR 2024

• Clinical features: Sleep bruxism ~8% adults, ↓ with age; triggers (stress, caffeine, alcohol, smoking, OSA). Awake bruxism: stress-associated, more common during high concentration; 22-30% prevalence, higher in younger. Both varied severity from harmless to risk.
• Differential diagnosis: Sleep vs awake (video-EEG/PSG with masseter EMG; rhythmic/phasic during sleep; awake needs awareness or EMA); temporal association with wakening.
• Relevant investigations: Video-EEG/PSG (Level 1 gold-standard) with surface EMG masseter; self-report questionnaires; smartphone EMA for awake; Epworth + STOP-BANG for SDB overlap; sleep-study review for arousal-bruxism correlation.
• Histopath presented? N · Labs presented? Y (Convention: N · Lecture: Y — sleep studies for SDB) ⚠ DISAGREEMENT
• Clinical signs / key facts: Sleep: rhythmic phasic or non-rhythmic tonic during sleep; not a movement/sleep disorder in healthy individuals (2018 consensus) · awake: repetitive/sustained tooth contact, bracing/thrusting during wakefulness · awake more strongly stress-associated · weak OSA-bruxism correlation; protective for airway patency.
• Management: Identify type; assess protective vs risk vs harmless; sleep study referral if SDB suspected; education + reassurance; lifestyle modifications (stress, caffeine/alcohol/smoking); psychosocial assessment.

2. Clinical Signs of Bruxism · Tier 1

• Clinical features: Tooth wear/bruxofacets (not exclusively bruxism; erosion + abrasion + reflux main causes); masseter hypertrophy (uni/bilateral, usually asymptomatic); tongue scalloping (~30-50% without bruxism); linea alba (more common in general population than bruxers); multiple tooth/restorative fractures = significant for treatment.
• Differential diagnosis: Tooth wear vs other causes (history of parafunction vs erosive beverages/reflux); masseter hypertrophy vs primary masseter enlargement (bilateral symmetric in bruxers); tongue scalloping vs macroglossia (systemic causes: amyloidosis, myxedema, acromegaly); linea alba low specificity.
• Relevant investigations: Clinical exam for bruxofacets/wear; masseter palpation + measurement (compare sides); tongue/buccal inspection; PSG if SDB overlap; dental impressions/casts for baseline; photograph baseline; medication reconciliation.
• Histopath presented? N · Labs presented? N
• Clinical signs / key facts: Bruxism is a spectrum — not a complete diagnosis · single indicators not pathognomonic · none reliable as sole indicators · patients may not realise if they associate term only with grinding (not clenching/bracing/thrusting) · must integrate with history + instrumental.
• Management: Document signs; assess severity (mild wear vs extensive/fractures); harmless vs risk; baseline photo; patient education on parafunction; splint therapy if risk behaviour.

3. Differential Diagnosis: Tardive Dyskinesia + Movement Disorders · Tier 1

• Clinical features: Tardive dyskinesia: dementia + long-term antipsychotics (chlorpromazine, haloperidol, olanzapine, risperidone); oromandibular dystonia ~3-30/100,000; involuntary sustained repetitive/tonic contraction with abnormal jaw posturing; video reveals tongue protrusion at regular intervals; Parkinsonism, akathisia, dystonia = extrapyramidal reactions; onset correlates with medication.
• Differential diagnosis: Bruxism vs tardive dyskinesia (video shows involuntary rhythmic grinding in bruxism vs sustained abnormal posture/dystonic; drug history critical); bruxism vs oromandibular dystonia (dystonia = jaw-opening/closing/deflecting/retruding posturing, not grinding; >60% idiopathic); bruxism vs epilepsy (loss of consciousness + post-ictal + stereotyped motor); bruxism vs TBI/Huntington’s (neurological history + imaging).
• Relevant investigations: Video-EEG monitoring (most accurate); PSG for sleep bruxism; medication reconciliation with start dates; neurological exam (tremor, rigidity, postural instability); brain imaging if dementia/TBI/tumour; neurologist referral if movement disorder.
• Histopath presented? N · Labs presented? N
• Clinical signs / key facts: Case: 55 y/o female fronto-temporal dementia thought chronic bruxism (splint intolerant) → video revealed tongue protrusion + jaw movement at regular intervals = tardive dyskinesia · movement disorder requires neurology referral, not dental management · dystonia typically idiopathic; secondary causes (CNS tumours, infarctions, TBI, long-term dopamine-blocking agents).
• Management: Identify movement disorder via video; refer to neurology; do NOT provide occlusal splint (ineffective for movement disorder); manage underlying psychiatric/neurological condition; educate patient + family.

4. Medication-Induced + Secondary Bruxism · Tier 2

• Clinical features: SSRIs (fluoxetine, paroxetine, sertraline) + antipsychotics (olanzapine, risperidone, clozapine); ADHD meds (methylphenidate, amphetamines); antihistamines (diphenhydramine); TCAs (amitriptyline, doxepin); antiemetics (metoclopramide); recreational (cocaine, amphetamines, ecstasy, methamphetamine); onset temporal correlation with medication start/dose change; secondary also OSA, GERD, hyperthyroidism, anxiety.
• Differential diagnosis: Medication-induced vs primary (temporal relationship key); psychiatric vs primary (timing vs baseline psychiatric history); drug-induced vs substance abuse (detailed drug history); SDB-associated secondary (STOP-BANG/Epworth screening; weak OSA-bruxism correlation despite co-presentation).
• Relevant investigations: Medication reconciliation with precise start/stop dates; psychiatric interview baseline before medication; STOP-BANG + Epworth + Berlin for SDB; PSG if OSA; TSH + free T4 if hyperthyroidism; GERD history/screening.
• Histopath presented? N · Labs presented? Y (Convention: N · Lecture: Y — medication history as “lab equivalent”) ⚠ DISAGREEMENT
• Clinical signs / key facts: Triggers: antidepressants, antipsychotics, ADHD drugs · if significant, dentists should NOT stop these medications but write to psychiatrist re: alternatives · bruxism may be protective in OSA (airway patency); management differs · 2018 consensus: bruxism in healthy individuals is non-pathological — severity assessment drives need.
• Management: Identify temporal correlation; contact psychiatrist for alternative medications; do NOT advise stopping psychiatric meds; assess severity; education + lifestyle modifications + splint if risk behaviour; monitor for resolution after medication change.

5. Occlusal Splint Therapy for Bruxism · Tier 1

• Clinical features: Splint design: hard material (PMMA, PEEK) + flat plane + light even contacts + worn nightly; soft splints/retainers CONTRAINDICATED (↑ EMG “chewing-gum effect” + short-term ↑ sleep bruxism); splints protect dentition but do NOT stop activity; regression to mean + placebo drive success; BoNT bruxism index ↓ at 4 wk but not at 12 wk.
• Differential diagnosis: Hard vs soft (hard > soft for TMD + bruxism via EMG; soft paradoxical activity increase); ARA vs flat-plane stabilisation (ARA reserved for disc displacement with acute pain); BruxApp adjunct (not primary therapy).
• Relevant investigations: Clinical exam for baseline bruxofacets/wear; PSG with bruxism EMG sensors if severity assessment; EMG (surface or intramuscular) for instrumental grading (possible/probable/definite); baseline photos + dental casts; post-splint PSG to confirm protective benefit (not “cure”).
• Histopath presented? N · Labs presented? N
• Clinical signs / key facts: “Don’t just Splint and Split!” — mechanism theory only (foreign-body reflex, condylar loading, cognitive awareness postulated) · protect dentition (protect, not stop activity) · contraindications: soft splints · all splints can cause tooth movement — inform patient · maintenance critical: regular checks + storage in case · cost-benefit: BoNT high-cost (~$1,000/treatment) only 4-wk efficacy, not indicated for simple bruxism · BruxApp reminder system aid.
• Management: Assess severity/need (harmless = observation; risk = intervention); hard flat-plane with light even contacts; educate on protective vs curative role; regular follow-up (monthly initially, then 6-monthly); combine with stress reduction + habit reversal + physio + biofeedback; BoNT reserved for acute flares or specific movement disorders.

Top LOs (verbatim, High-yield preserved):

• “Describe the evolution, epidemiology, risk factors, aetiology, and pathophysiology of sleep and awake bruxism… High-yield: sleep vs awake distinction, non-occlusal aetiologies (stress, medications, substance use, OSA), 2018 consensus redefining bruxism as non-pathological.”
• “Describe the clinical features of bruxism… High-yield: case-anchored presentations (dentist w/ wear/scalloping, SDB pt w/ OSA-bruxism overlap, female w/ isolated muscle hypertrophy); specificity limitations of individual markers.”
• “Explain management principles and decision-making framework: harmless vs risk vs protective… High-yield: severity dictates management; protective bruxism in OSA should not be treated; flat-plane hard-material splints (not soft) for risk behaviour.”

Mock-exam / past-year flags: PAST YEAR 2024 (awake + sleep bruxism) + ▶ OFP Q3 (OSA-bruxism overlap as marked secondary consideration). DIRECT MOCK HIT.

§4 — Disagreements & Edge Cases

1. L1 — Lesion morphology description. Convention pairs clinical photo with histopath interpretation in an OSCE; L1 teaches only clinical description.
2. L7 / L11 — Contact lichenoid reaction + oral lichenoid lesions. Lecture mentions patch testing / drug-allergen history; convention does not routinely use lab testing.
3. L14 — Kaposi’s sarcoma. Convention emphasizes HHV8 serology; lecture emphasizes tissue HHV8 identification.
4. L16 — Medication-induced xerostomia. Convention measures via sialometry; lecture emphasizes clinical Challacombe scoring.
5. L18 — Fibrous dysplasia. Convention requires serum biochem (ALP, Ca, PO4, PTH); lecture only implies.
6. L19 — Metastatic disease to mandible (MOCK CASE 3). Mock stem lists biopsy but does NOT explicitly request histopath/labs; conventionally both required (PSA, ALP, bone scan, biopsy + IHC).
7. L29 — Synovitis / capsulitis. Lecture shows inflammatory pathology but these are rarely biopsied clinically; MRI is practical “lab.”
8. L33 — Myositis. Convention requires histopath + CT; lecture does not detail.
9. L33 — Myospasm. Lecture presents needle EMG as gold standard; convention treats clinically without routine EMG.
10. L34 — Trigeminal neuralgia. Lecture flags HLA-B*1502 screening for Asian patients pre-carbamazepine; not universal convention.
11. L36 — Sleep/awake bruxism. Lecture incorporates sleep studies (PSG/STOP-BANG/Berlin) for SDB comorbidity; not conventional bruxism labs.
12. L36 — Medication-induced bruxism. Lecture treats medication history as “lab equivalent”; not conventional.

§4.5 — Tutorial Clinical Pearls [added 2026-05-15]

Compact high-yield clinical pearls extracted from 16 tutorial-integrated case discussions. Bundled here to avoid bloating per-lecture cram sheets.

OLP & Lichenoid (Tutorials 15, 16)

• Beclamethasone spray = preferred first-line for OLP (2 sprays × 3/day until resolution + 2-3 days extra).
• Dexamethasone mouthwash effective but expensive (~AUD$80/bottle) + ↑ candidiasis risk → ALWAYS combine with Fungilin/Amphotericin lozenge.
• Superimposed candida red flag: sudden worsening AFTER initial steroid response = fungal superinfection (not OLP relapse).
• Triamcinolone (Kenalog) = skin prep, off-label, difficult on wet mucosa → therapeutic guidelines prefer beclamethasone.
• Difflam (benzydamine) for mild symptoms — avoid unnecessary steroid use.
• Refractory OLP algorithm: check compliance → rule out fungal → systemic CS for severe ulceration → investigate lichenoid triggers (replace amalgam one at a time + patch test “Dental Series” via dermatology).
• OLP non-response to steroids ≥6 weeks = RED FLAG for malignant transformation → urgent rebiopsy.
• Solitary RED lesion ≠ OLP (OLP is bilateral + symmetric). Solitary erythematous = erythroplakia until proven otherwise.
• Dysplasia on OLP biopsy EXCLUDES the OLP diagnosis → reclassify as oral epithelial dysplasia + manage as OPMD.
• Field cancerisation rule: if ONE OLP area transforms, biopsy ALL other lichenoid/erythematous areas immediately.
• Surveillance: 3-monthly initially → 6-monthly stable → 1-yearly after 5 y stable; LIFELONG recall.

Leukoplakia & OPMD Surveillance (Tutorials 7, 8, 9, 10)

• Biopsy margin, NOT ulcer centre (centre = necrotic, non-diagnostic).
• Multi-site biopsy if lesion >2 cm or heterogeneous (worst-looking + adjacent normal).
• Atypia in basal third only = mild dysplasia.
• Female + non-smoker = paradoxical higher relative malignant transformation risk vs smokers.
• Lesions <5 y duration = higher risk; after 5 y stability, risk significantly drops.
• Rapid change + new white plaques + interdental bone loss = MAJOR alarm (not OLP).
• Unknown primary SCC in 1-4% of H&N cancers → CT/MRI + comprehensive head/neck exam; likely immune clearance of primary.
• Neck node thresholds: >1 cm concerning; hard fixed lumps warrant urgent follow-up regardless of size.

Cancer & Radiation Management (Tutorials 11, 12, 13)

• ORN dose thresholds: 50 Gy baseline risk; 60 Gy significantly elevated; lifelong risk never decreases.
• Pre-RT extraction window: ideally 2-3 weeks healing before RT starts; must balance with 6-week tumour-to-RT window.
• Post-RT extraction ORN risk: 5-15% vs pre-RT extraction: ~5% (rises closer to RT start).
• Atraumatic extraction + alveolectomy = critical surgical technique to prevent bony spicules predisposing to ORN.
• Aggressive pre-RT clearance for poor-compliance/smoking/alcohol patients (avoid future ORN).
• Neutrafill 5000 ppm fluoride twice daily for life (standard toothpaste insufficient post-RT).
• Denture timing: minimum 6 months post-RT before fitting (count from END of RT).
• Salivary tumour biopsy: incisional mandatory (malignant vs benign dictates entirely different surgical extent).
• Mucocele: 10% recurrence post-excision due to scarring; excisional preferred over incisional to rule out malignancy.
• Mucocele histopath: retention (epithelial lining + no inflammation) vs extravasation (no lining + muciphages — most common).

Candidiasis & Infections (Tutorials 3, 4)

• Amphotericin lozenges > nystatin (sugar-free, longer oral contact, stimulates saliva).
• Amphotericin > miconazole (avoids warfarin interaction, safe in liver disease).
• Treatment duration ≥3 weeks (7-14 d insufficient — high recurrence).
• “Candidiasis is a disease of the diseased” — ALWAYS investigate systemic cause.
• Iron deficiency in fit male = urgent red flag → colonoscopy + endoscopy to exclude GI malignancy.
• Standard candidiasis screen: FBC + iron studies (ferritin) + B12 + folate + fasting glucose.
• Smear (active hyphae = active infection) > swab (only confirms organism presence; 50% are carriers).
• Herpes mgmt: acyclovir early + chlorhexidine (green) mouthwash × 2 weeks to prevent 2° bacterial; FBC if adult onset.

Traumatic Ulcers in High-Risk Patients (Tutorials 5, 6)

• High-risk patient (post-cancer / immunocompromised / >2 wk non-healing) = biopsy on FIRST visit (do NOT wait).
• Benign-looking ulcer that fails 50% improvement by 3 months despite compliance → rebiopsy (rule out false-negative, secondary infection, undiagnosed diabetes).
• Post-radiation healing extremely slow — 12-month observation appropriate; 6-week recall intervals.
• Antifungal in xerostomia: amphotericin lozenges FAIL in severe dry mouth → miconazole gel preferred (with GP consult re: warfarin/statin interactions).
• Denture rule: NEVER wear at night; relieve sharp areas.

§5 — Cross-references

• [[MOC Oral Medicine]] · [[MOC Oral Pathology]]
• [[Most Common Cases]] — mock exam + past-year + lecturer hints
• [[OFP LOs]] — L27–L36 with inline High-yield annotations
• [[Lecture LOs]] — L1–L19
• [[L0 Introduction and Project]] — OSCE format definition

New mock OSCE cases (8 cases — read 2026-05-15)

Oral Med Mock Q1:

• [[Oral Med Mock Q1 Case 1 - Exophytic Tongue Lesion_integrated]]
• [[Oral Med Mock Q1 Case 2 - Recurrent Ulceration and Oral Burning_integrated]]
• [[Oral Med Mock Q1 Case 3 - Mandibular Pain and Systemic History_integrated]]
• [[Oral Med Mock Q1 Case 4 - Asymptomatic Pigmented Lesion_integrated]]
• [[Oral Med Mock Q1 Case 5 - Asymptomatic Lip Lesion_integrated]]

OFP Mock Formative:

• [[OFP Mock Formative Q1 - Post-Traumatic Trigeminal Neuropathic Pain_integrated]]
• [[OFP Mock Formative Q2 - TMJ Disc Displacement and Clicking_integrated]]
• [[OFP Mock Formative Q3 - Obstructive Sleep Apnoea_integrated]]

Tutorial integrated files (clinical pearls — read 2026-05-15)

Infections (L5): [[3. Infections_integrated]] · [[4. Infections_integrated]] · Injuries (L6): [[5. Injuries_integrated]] · [[6. Injuries_integrated]] · OPMDs (L9–L12): [[1. Benign Epithelial Pathosis_integrated]] · [[2. Benign epithelial Pathosis_integrated]] · [[7. OPMDs_integrated]] · [[8. OPMDs_integrated]] · [[9. Epithelial Pathosis II_integrated]] · [[10. Epithelial Pathosis II_integrated]] · Cancer Mgmt (L13): [[11. Dental care of Cancer Patients_integrated]] · [[12. Dental Care of Cancer Patients_integrated]] · Salivary (L15): [[13. Salivary Gland Diseases case 1_integrated]] · [[14. Salivary Gland diseases case 2_integrated]] · Immune (L7–L8): [[15. Allergies and Immune Mediated Disease_integrated]] · [[16. Allergies and Immune mediated disease_integrated]]

All 27 source lectures (L9 added 2026-05-15)

[[L1 Oral Soft Tissue and Lesion Evaluations]] · [[L2 Surgery in Oral Medicine]] · [[L3 Investigations]] · [[L4 Imaging of Hard and Soft Tissues]] · [[L5 Viral, Bacterial and Fungal Infections of the Oral Cavity]] · [[L6 Physical and Chemical Injuries]] · [[L7 Allergies and Immune Mediated Disease I - OLP]] · [[L8 Allergies and Immune disease II]] · [[L9 Benign Epithelial Pathosis]] · [[L10 OPMDs and Oral Cancer]] · [[L11 OPMDs and Oral Cancer II]] · [[L12 OPMDs Part IIIk]] · [[L13 Dental Management of Oral Cancer Patients]] · [[L14 Soft Tissue Tumors]] · [[L15 Non neoplastic and neoplastic salivary gland diseases]] · [[L16 Dry Mouth]] · [[L17 Bone Disease 1]] · [[L18 Bone Disease 2]] · [[L19 Bone Disease 3]] · [[L27 Defining Orofacial Pain]] · [[L28 TMD]] · [[L29 Intracapsular disorders of TMD]] · [[L30 Botox]] · [[L31 Occlusal Splint Therapy]] · [[L32 Non-Odontogenic Toothache]] · [[L33 Temporomandibular disorders; Extracapsular disorders]] · [[L34 Neuropathic Orofacial Pain including Burning Mouth Syndrome]] · [[L35 Oral Appliance Therapy for Snoring and OSA]] · [[L36 Bruxism]]